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The Cys-loop receptor superfamily includes the GABAA, GABAC, glycine, and serotonin
receptors as well as the nicotinic acetylcholine receptors (nAChRs). Cys-loop receptors 
are important drug targets for Parkinson’s disease, Alzheimer’s disease, and nicotine 
addiction. They are also targets of general anesthetics. Understanding the mechanisms 
of allosteric modulation for Cys-loop receptors has implications for the design of novel 
therapeutics for the treatment of pain, inflammation, and neurological disease. I employed 
a combination of computational and experimental approaches to understand allosteric 
modulation of these receptors. Four major contributions resulted from my graduate 
research: 
1) NMR structures of the transmembrane (TM) domains of the α7 and α4β2 
nAChRs as well as the α1 glycine receptor were resolved to provide a scaffold for 
rationalizing drug-binding sites and drug action. While all structures revealed the typical 
four-helix bundle, differences were observed which could affect drug binding and 
allosteric modulation.  
2) Computational and experimental results showed that the general volatile 
anesthetic halothane bound to both α7 and α4β2 nAChRs, despite different sensitivities 
of these receptors to halothane. NMR data also revealed that volatile anesthetics 
halothane and isoflurane bound to the EC end of the β2 TM domain, but only at the IC 
end of the α7 TM domain.  
 
 iv 
3) We not only revealed the drug binding sites but also determined that the binding 
site at the EC end of the TM domain is functionally relevant.  
4) Several factors critical to allosteric modulation in Cys-loop receptors were 
identified. Applying the perturbation-based Markovian transmission model to GLIC, we 
identified signaling pathways of agonist-induced channel gating. Using NMR, we 
identified a link between protein dynamics changes and allosteric modulation. Molecular 
dynamics simulations suggested that asymmetric binding of the anesthetic propofol to 
GLIC facilitated the transition from an open- to a closed-channel structure. The study 
provides evidence that ligand-induced asymmetry facilitates conformational transitions. 
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CHAPTER 1  
INTRODUCTION 
1.1. BACKGROUND 
Cys-loop receptors mediate the fast synaptic transmission in the central and peripheral 
nervous systems. They are pentameric ligand-gated ion channels (pLGICs) formed from 
five identical or homologous subunits arranged symmetrically or pseudo-symmetrically 
around a central channel axis. Each subunit contains an extracellular  domain (ECD), a 
transmembrane domain (TMD) comprised of four transmembrane (TM) helices (TM1 to 
TM4), and a large flexible intracellular domain (ICD) connecting TM3 and TM4 1. In the 
typical physiological response, neurotransmitters bind to the orthosteric sites located in 
the ECD and trigger the opening of the channel gate located in TM2 to allow the flow of 
ions (Figure 1.1.1). However, channel activity can also be modulated by a variety of 
ligands, including general anesthetics, binding to other allosteric sites on these receptors. 
The diverse responses to allosteric modulation of channel activities contribute to the 
pharmacological diversity of the Cys-loop receptor superfamily. 
 2 
 
Figure 1.1.1. Structural topology of the Cys-loop receptor. (a) Top view of the Cys-loop receptor 
showing the quaternary arrangement of the five subunits around the central channel axis and side. (b) Side 
view of the Cys-loop receptor highlighting the extracellular (EC), transmembrane (TM) and intracellular (IC) 
domains. The four TM helices are labeled 1 through 4 corresponding to TM1 through TM4, respectively. 
The 4 Å resolution structure of the muscle-type nAChR (PDB ID: 2BG9) was used as the structural 
template 1. The orthosteric binding sites are highlighted in red.  
 
The Cys-loop receptor superfamily includes the γ-aminobutyric acid type A and 
type C (GABAA and GABAC), glycine, serotonin (5HT3) and the nicotinic acetylcholine 
(nACh) receptors. The GABA and glycine receptors are anionic or inhibitory channels that 
are selective for chloride and are potentiated by general anesthetics at clinically relevant 
concentrations. In contrast, nicotinic acetylcholine receptors (nAChRs) are cation 
selective or excitatory channels and are generally inhibited by anesthetics 2. The diverse 
responses of Cys-loop receptors to allosteric modulators, particularly anesthetics, provide 
an intriguing base for research into the mechanisms of allosteric modulation. Diverse 
allosteric responses to anesthetics can even be found among the neuronal nAChRs, a 
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subset of the Cys-loop receptor superfamily. The neuronal nAChRs are comprised of α 
(α2–α10) and β (β2–β4) subunits. Among these subunit subtypes, the α7 subunit can 
exist as a functional homopentamer 3, while other subunits require combinations of α and 
β subunits to form functional pentamers 4, as is the case for the α4β2 nAChR. The α7 and 
α4β2 nAChRs exhibit highly distinct sensitivities to volatile anesthetics. Despite ~60% 
sequence homology, the α4β2 nAChR is hypersensitive to volatile anesthetics at clinically 
relevant concentrations, while the α7 nAChR is insensitive to volatile anesthetics at 
clinically relevant concentrations 5,6. Differences in anesthetic modulation for such 
homologous subunits provide the platform to probe what makes one subunit more 
susceptible to allosteric modulation by anesthetics than the other. Functional α7β2 
pentamers have been identified which offer the opportunity to compare effects of 
anesthetics between homopentameric α7 nAChRs and heteropentameric α7β2 
nAChRs 7. 
The functional diversity of receptor responses to allosteric modulation provides a 
great opportunity and challenge to determine the molecular mechanisms of allosteric 
modulation. Due to the complexity of these receptors, combined with intrinsic difficulties 
of working with membrane proteins, the molecular mechanisms of allosteric modulation 
of Cys-loop receptors have not been well understood. While the goal of fully 
understanding these mechanisms is too large to be covered in this thesis, the research 
presented here has made substantial contributions towards this goal. My thesis work 
provides insights into the action of allosteric modulators acting on Cys-loop receptors. To 
this end, I have employed a combination of computational and experimental approaches 
to determine the specific anesthetic binding sites within nAChRs, which binding sites are 
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functionally relevant, and the mechanism by which ligand binding affects the functional 
response. 
1.2. MOTIVATION 
Cys-loop receptors are important pharmacological targets for therapeutic drugs. In 
particular, the α7 and α4β2 nAChRs are found in high abundance in the brain 8,9. Their 
roles in the central nervous system make them likely candidates for therapeutics targeting 
neurological diseases, including Parkinson’s disease 10, Alzheimer’s disease 11, and 
nicotine addiction 12,13. The α7 nAChR is also a target for therapeutics involved with 
angiogenesis and inflammation 14,15. Cys-loop receptors are also targets of general 
anesthetics. The nAChRs have been implicated in anesthetic action associated with 
memory 16, nociception 17, and the autonomic response 18. The GABAA receptor has been 
implicated in sedation, amnesia, and muscle relaxation, while the glycine receptor has 
been implicated in immobility 19-21. Understanding the mechanisms of allosteric 
modulation for Cys-loop receptors therefore has implications for the design of novel 
therapeutics for the treatment of pain, inflammation, and neurological disease. 
1.3. GOALS AND ACCOMPLISHMENTS 
1.3.1. Open Questions 
While previous studies have determined the location of the neurotransmitter-binding site 
within Cys-loop receptors 22-25, the sites of anesthetic interaction within Cys-loop 
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receptors remain unclear. This is primarily due to the small size and low affinity of 
anesthetics, which makes specific protein-anesthetic interactions difficult to identify. The 
small size and low affinity of anesthetics also makes them more likely to bind to many 
non-specific locations. In order to determine how ligand binding affects channel function, 
one must determine the ligand binding sites and which binding sites are functionally 
relevant. Moreover, even though a functionally relevant site of ligand binding has been 
identified, as in the case of neurotransmitter binding, it is still challenging to determine the 
precise mechanism of allosteric action. In this thesis, my work has sought to provide 
insights into the action of allosteric modulators acting on Cys-loop receptors. To this end, 
I have employed and combination of computational and experimental approaches to 
address the following three questions:   
1) What are the specific binding locations of general anesthetics within the 
structures of nAChRs?  
2) Which binding sites are responsible for the functional response?  
3) How does ligand binding at functionally relevant sites elicit the functional 
response?  
1.3.2. Summary of Achievements 
Four major contributions resulted from this thesis work: 1) resolved solution NMR 
structures for the α1 glycine receptor TMD, as well as the α4β2 and α7 nAChR TM 
domains that provide scaffolds for determining ligand-binding sites; 2) determined the 
sites of anesthetic binding within the α4, β2, and α7 nAChR subunits; 3) identified which 
site is most likely functionally relevant; and 4) finally, identified factors critical to the 
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allosteric modulation in Cys-loop receptors. Each of these contributions is summarized 
below and covered in detail in the subsequent chapters.  
 
Structures of Cys-loop Receptor TM Domains (Chapter 2) 
The Cys-loop receptor structure was first determined for the muscle-type nAChR found 
in Torpedo marmorata by cryo-electron microscopy (cryo-EM) at 4 Å resolution 1. More 
recently, high-resolution crystal structures have been obtained from homologous 
receptors found in the bacteria Erwinia chrysanthemi (ELIC) 26 and Gloeobacter violaceus 
(GLIC) 27,28 as well as the glutamate-gated chloride channel (GluCl) found in 
Caenorhabditis elegans 29 determined at 3.3 Å, 2.9 Å, and 3.3 Å, respectively. While the 
EC domain has been well-characterized by crystal structures of acetylcholine binding 
proteins (AChBPs) 24,30,31, the ECD of the mouse α1 subunit 32, and the α7/AChBP 
chimera 33, structures for the TMD have remained sparse, primarily due to difficulties 
inherent in working with membrane proteins. Crystal structures of full-length receptors 
solved from bacterial homologues and the glutamate chloride receptor, as well as the low-
resolution cryo-EM structure of the muscle type nAChR from Torpedo marmorata, have 
provided valuable information into the structure of the TM domains for Cys-loop receptors. 
In the past, full-length structures for mammalian Cys-loop receptor TM domains 
were unavailable, despite their importance as drug targets 34,35. In this section of the thesis 
the NMR determined structures for full-length TM domains of the human α7, α4, and β2 
nAChRs in lauryldimethylamine-oxide (LDAO) 36,37 as well as the human glycine receptor 
α1 subunit in lyso-1-palmitoylphosphotidylglycerol (LPPG) 38 are discussed. While all 
structures revealed the typical four-helix bundle, subtle differences in cavity sizes and 
helical tilting have been observed among the solved structures, which could affect drug 
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binding and allosteric modulation of the channel 37,39,40. This finding underscores the 
importance of full structure determination even when structures for homologous proteins 
exist. Furthermore, the NMR structure of human α1 glycine receptor revealed a novel kink 
in the TM3 helix, which is likely involved in the function of the glycine and GABAA 
receptors 38. Structure determination of the full-length TM domains for human Cys-loop 
receptors are therefore an important contribution for the purpose of designing specific 
allosteric modulators. 
 
Anesthetic Binding Sites (Chapter 3) 
To determine sites of anesthetic interaction within Cys-loop receptors we employed both 
computational and experimental methods. Early work on the muscle-type nAChR using 
photo-affinity labeling suggested multiple binding sites for the volatile anesthetic 
halothane in the ECD and at the EC/TM interface 41. Molecular docking and molecular 
dynamics (MD) simulation on the α4β2 nAChR performed previously in the lab 
demonstrated halothane-binding sites in the ECD and at the EC/TM interface similar to 
the previous study 42,43. In subsequent work on the α7 nAChR, similar results were 
observed with the addition of a novel site observed at the intracellular (IC) end of the 
TMD 44. The site at the EC/TM interface was later confirmed by solution NMR for the β2 
nAChR for the volatile anesthetics halothane and isoflurane and the intravenous 
anesthetic ketamine 39,40, showing an intra-subunit site located at the extracellular (EC) 
end of the TMD. While not observed in the previous photo-affinity labeling experiments 
on the muscle-type nAChR, the computationally predicted site observed at the IC end of 
the TMD for the α7 nAChR was observed using NMR for the anesthetics halothane, 
isoflurane, and ketamine in the α7 nAChR 37,39,40. 
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Functionally Relevant Anesthetic Binding (Chapter 4) 
Ligand binding does not necessitate a resultant functional effect. Therefore, it is 
necessary to ascertain which binding sites are necessary to produce the functional effect. 
MD simulations of the α7 nAChR compared to simulations of the α4β2 nAChR suggested 
that the β2 subunit was responsible for the difference in anesthetic sensitivity between α7 
and α4β2 44. From this result, we predicted that the α7β2 nAChR would be sensitive to 
volatile anesthetics. In a subsequent study we experimentally confirmed our 
computational prediction. NMR data revealed that isoflurane bound to the EC end of the 
β2 TMD, but not the α7 TMD. Mutations to cavity lining residues in TM2 confirmed the 
result. Furthermore, significant dynamics changes were observed for the pore-lining 
residues, only in the β2 TMD, suggesting that only the drug binding that can affect the 
channel dynamics will produce a functional effect 40.  
Our work has also covered potential sites of action for the intravenous anesthetic 
ketamine on the α7 nAChR. In contrast to volatile anesthetics, ketamine is a more 
effective inhibitor of the α7 nAChR than the α4β2 nAChR 45,46. NMR studies on the α7 
TMD demonstrated that the site of ketamine binding was similar to that of isoflurane or 
halothane binding in the α7 TMD. However, only ketamine binding affected the channel 
gate residue (L9’). While functional measurements confirmed that the α7 TMD could be 
inhibited by ketamine, we cannot rule out the possibility of ketamine inhibition via a site in 
the ECD, as suggested by our work with GLIC 47. The crystal structure of the GLIC-
ketamine complex showed ketamine binding to a site in the ECD of GLIC just below the 
C-loop. Functional investigation using site-directed cysteine mutagenesis confirmed the 
functional relevance of the site to GLIC inhibition. In this work it was suggested that 
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ketamine binding was facilitated by charged residues surrounding the observed ketamine 
binding site, a feature shared with α7, but not α4β2 47. 
 
Mechanisms of Allosteric Modulation (Chapter 5) 
Perhaps the most challenging question to address is the molecular mechanism by which 
allosteric ligand binding to the receptor affects the conductance of ions through the 
channel pore. While this work does not fully provide the answer to this question, the work 
contributes toward achieving this goal. The contributions are three-fold. We 
computationally identified likely molecular pathways involved in agonist-induced channel 
gating. Using NMR, we identified protein dynamics changes linked to allosteric 
modulation of the channel. Finally, our results from molecular dynamics suggested that 
asymmetry of ligand binding may be important for conformational transitions in proteins.  
Molecular pathways of agonist binding were determined by applying the 
perturbation-based Markovian transmission (PMT) model to the Cys-loop receptor 
homologue GLIC. The PMT model is a course-grained model developed by Lu and Liang 
48 that builds on prior work by Chennubhotla and Bahar treating allosteric propagation as 
a Markov process 49. The PMT model was used in conjunction with Yen’s algorithm 50 to 
determine the most likely paths of allosteric transmission through the receptor. Among 
the top ten paths from nine different perturbations we achieved a consensus of two 
primary paths between the ECD and the channel gate residue. The first was an intra-
subunit pathway consistent with the conformational wave theory for channel gating 51,52. 
The second path, however, was a novel inter-subunit pathway between TM domains of 
adjacent subunits 53. 
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Previous studies have demonstrated that mutations affecting anesthetic 
modulation often concurrently affect the intrinsic gating dynamics of the channel 54-56, 
suggesting that the propensity of the channel to allosteric modulations is intrinsically 
related to the channel gating dynamics. Our structural studies on the hGlyR-α1 TMD 
revealed a dynamic segment between the EC ends of TM2 and TM3, which could be 
related to functional effects of observed for both agonist binding and the binding of other 
allosteric modulators 38. The study suggested that allosteric modulation of the receptor 
was related to the dynamics of this site. This notion was supported by other studies 
demonstrating the importance of dynamics at the EC end of TM2 to channel gating 57,58. 
Our NMR studies on the neuronal nAChRs also underscored the importance of dynamics 
to channel gating. Only the anesthetic binding that could significantly change the channel 
dynamics could be correlated to functional consequences. Particularly, it was observed 
that isoflurane binding at the EC end of the TMD could substantially reduce dynamics for 
nearby residues in TM2 40.  
Finally, our work has suggested that the symmetry of ligand binding may also play 
an important role in ligand-induced conformational transitions. Previous functional 
experiments have shown that ligand binding to only three of five symmetric agonist 
binding sites in homomeric Cys-loop receptors produces the maximum current response 
59-61. Our MD simulations suggest that asymmetric binding of the anesthetic propofol to 
GLIC can facilitate the transition from an open-channel structure to a closed-channel 
structure 62. In the study, systems with propofol asymmetrically bound to one, two, or 
three sites could produce a greater conformational heterogeneity of TM2 tilting angles 
associated with more rapid channel dehydration as compared to symmetric systems with 
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zero or five propofol molecules bound. The results indicate that ligand-induced 
asymmetry may be necessary to facilitate conformational transitions from one channel 
state to another, and therefore play an important role in the molecular mechanisms of 
allosteric modulation.  
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CHAPTER 2  
STRUCTURES OF CYS-LOOP RECEPTOR 
TRANSMEMBRANE DOMAINS  
2.1. NMR STRUCTURES OF NEURONAL NACHRS 
This section has been published in Biochim Biophys Acta 1818 (5): 1261-1268 and 
Biochim Biophys Acta (in press, 2014).  
2.1.1. Background and Significance 
The α7 and α4β2 nAChRs are two of the most abundant nAChR subtypes in the brain 3,8. 
Both nAChRs have been recognized for the important roles they play in learning, memory, 
and cognition 16,63,64. Consequently, they are likely candidates for therapeutics targeting 
a variety of neurological diseases, including Parkinson’s disease 10, Alzheimer’s 
disease 11,65, schizophrenia 65, and nicotine addiction 12,13. The α7 nAChR is also a target 
for therapeutic modulation of angiogenesis and inflammation 14,15. Despite the importance 
of the α7 and α4β2 nAChRs as targets for therapeutic modulation, experimental structural 
characterization of these receptors has remained sparse 66-68. 
Structural characterization of the TM domains for individual Cys-loop receptors is 
necessary to identify drug-binding sites, design novel therapeutics, and discover the 
molecular mechanisms of drug action 69,70. The TMD contains the channel gate and 
therefore is the critical region for controlling the flow of ions across the membrane 71. 
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Positive and negative allosteric modulators acting on the nAChR TM domains have been 
implicated as useful therapeutics for neurological diseases 72-74. The TMD also provides 
binding sites for both intravenous and inhalational general anesthetics. The intravenous 
anesthetic etomidate binds to the TMD of the Torpedo nAChR 75. The inhalational 
anesthetic halothane has shown evidence of binding to nAChR TM domains both 
experimentally in the Torpedo nAChR 41 and computationally in the α4β2 and α7 nAChRs 
42-44. High-resolution structural information of nAChR TM domains is important both for 
characterizing mechanisms of action for existing drugs and for indentifying plausible 
binding sites for new drugs.  
In this section, we present the NMR structures for the TM domains of the α7, α4, 
and β2 nAChR subunits using LDAO micelles as a membrane mimetic. In LDAO micelles, 
both α4β2 and α7 nAChR TM domains spontaneously form pentameric assemblies. 
Reconstituting the α4β2 nAChR into lipid vesicles, we demonstrated that the α4β2 
assemblies retained their functional capability to transporting Na+ ions. Further functional 
assays performed by injecting the α7 nAChR TM domain into Xenopus laevis oocytes 
revealed that the α7 nAChR not only could conduct ions but also could be modulated by 
ivermectin and ketamine. Together the functional assays suggest that the α7 and α4β2 
TM domains retain their pharmacologically relevant features. High-resolution structures 
of the individual α7, α4, and β2 TM domains, as well as the assembled pentameric 
structural model for the α4β2 nAChR TM domain, provide valuable templates for 
rationalizing mechanisms of channel function and drug action. 
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2.1.2. Methods 
Sample Preparations 
Proteins were expressed in Escherichia coli Rosetta 2(DE3) pLysS (Novagen) at 15 °C 
for ~3 days using the Marley protocol 76. The ECD at the N-terminus was replaced with a 
TEV protease recognition site and a histidine tag. A short synthetic linker ‘GGGEG’ 
replaced the ICD for the α7 TMD. For α4 and β2 TM domains the synthetic linker 
‘GGGGG’ replaced the ICD. Each α7, α4, or β2 TM domain contains 137 residues with 
an approximate molecular weight of 15 kDa. Glutamate mutations at the N- and C-termini, 
designed to lower the pI, were necessary to secure protein stability for NMR 
measurements. Mutation of three hydrophobic residues to serine within the TM2-TM3 
linker of α7, α4, or β2 was also instrumental to prevent protein destabilization. Direct 
exposure of hydrophobic residues to the aqueous phase in the absence of the ECD 
resulted in protein aggregation and precipitation in a short time period. Amino acid 
sequences showing mutations of the α7, α4, and β2 TM domains are shown in Figure 
2.1.1. The expressed proteins were purified by Ni-NTA (GE Healthcare) chromatography 
before and after overnight cleavage of the his-tagged region at 4 ºC. The purification 
buffer contained 50 mM Tris, 150 mM NaCl, and 0.5% LDAO, and proteins were eluted 
with imidazole. Each NMR sample had 0.25-0.3 mM protein, 1-2% (40-80 mM) LDAO, 5 
mM phosphate acetate pH 4.7, 10 mM NaCl, and 20 mM 2-mercaptoethanol to prevent 
disulfide bond formation. 5% D2O was added to the NMR samples for deuterium lock in 
NMR measurements. The α4 and β2 nAChRs natively form α4β2 heteropentamers. 
Therefore in the case of the α4 and β2 nAChR TM domains, we prepared four types of 
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samples: (1) pure α4; (2) pure β2; (3) α4:β2=2:3; and (4) α4:β2=3:2. The α7 nAChR 
natively forms homopentamers so only pure α7 NMR samples were prepared. 
 
Figure 2.1.1. Sequence comparison for α4, β2, and α7 nAChRs and their respective NMR constructs, 
α4’, β2’, and α7’. Mutation of a few residues gave much more stable NMR samples. Glutamate mutations 
(highlighted in red), primarily at the N- and C-termini, lowered the isoelectric point and prevented protein 
precipitation at pH 4.7. Three serine mutations (highlighted in green) were introduced to the TM2-TM3 linker 
to increase sample stability in the absence of the ECD. The sequence numbering corresponds to that of 
the α7 nAChR.  
 
NMR spectroscopy 
NMR spectra were acquired at 45 ºC on Bruker Avance 600, 700, 800, and 900 MHz 
spectrometers equipped with a triple-resonance inverse-detection cryoprobe, TCI (Bruker 
Instruments, Billerica, MA). Spectral windows of 11 or 13 ppm (1024 data points) in the 
1H dimension and 22 or 24 ppm (128 data points) in 15N dimension with a relaxation delay 
of 1 s (or 1.5 s at 900 MHz) were used for collecting 1H-15N TROSY-HSQC spectra. 1H-
13C HSQC spectra were acquired as 1024 points in the 1H dimension and 256 increments 
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in the 13C dimension with spectral windows of 11 ppm (1H) and 64 ppm (13C). For α7 
chemical shift assignment, a suite of NMR experiments were performed: HNCA 
(1024×28×72) and HN(CO)CA (1024×28×54), both with spectral windows of 1H-12 ppm, 
15N-20.5 ppm, 13C-19 ppm; HNCO (1024×32×40) with spectral widths of 1H-11 ppm, 15N-
22 ppm, and 13C-10 ppm; 15N-edited NOESY (1024×36×104) with spectral windows of 
1H-11 ppm and 15N-22 ppm, and a mixing time of 120 ms. For α4 and β2 chemical shift 
assignment, the NMR experiments performed included: HNCA and HN(CO)CA (1024  
36  80) with a spectral window of 18 ppm in the 13C dimension, HNCO (1024  36  40) 
with a 13C spectral width of 10 ppm, 15N-edited NOESY (1024  36  160) with a mixing 
time of 120 ms at 900 MHz and 150 ms at 700 MHz, and 13C-edited NOESY (1024  36 
 192) with a mixing time of 150 ms. In addition, CBCA(CO)NH (1024  32  80) with a 
13C spectral window of  60 ppm was acquired. In order to evaluate the temperature 
dependence of individual residue chemical shifts, α4 and β2 1H-15N TROSY-HSQC 
spectra were collected at 40, 43, 45, and 48 ºC. α7 1H-15N TROSY-HSQC spectra were 
collected at 35, 40, and 45 C The residues with temperature coefficients < 4.5 ppb/K 
were considered to have hydrogen binding 77. The observed 1H chemical shifts were 
referenced to the DSS resonance at 0 ppm and the 15N and 13C chemical shifts were 
indirectly referenced 78.  
 
Size exclusion chromatography–multi-angle light scattering analysis  
The molar masses of the protein-detergent complexes were determined using size 
exclusion chromatography (Superdex 200 10/300, GE Healthcare) coupled with multi-
angle light scattering (HELEOS, Wyatt Technology), UV (Agilent 1100 Series; Agilent 
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Technology), and differential refractive index (Optilab rEX; Wyatt Technology) detection. 
The measurements were performed on the samples that had been used for NMR in 10 
mM sodium acetate pH 4.6, 100 mM NaCl, 0.05% LDAO at a flow rate of 0.5 mL/min at 
room temperature. HELEOS calibration constants were determined in the 
same buffer using chicken egg lysozyme (Affymetrix) as the standard. Light scattering 
data was analyzed and the molar mass of the protein-detergent complex was determined 
using ASTRA software (Wyatt Technology) 79. The conjugate analysis module of ASTRA 
was used to differentiate contributions of the protein and detergent to the molecular 
weight of each complex. The specific refractive index (dn/dc) values of 0.185 and 0.148 
were used for the protein and LDAO detergent, respectively 80. The UV extinction 
coefficients of α7, α4 and β2 were calculated from their sequences. A measured 
UV extinction coefficient of 0.06 for a 1% solution at 280 nm was used for LDAO. 
 
Functional measurements for α7 in Xenopus laevis oocytes 
The purified α7 TMD in LDAO detergent was reconstituted into asolectin vesicles by 
adsorption of detergent using Bio-Beads SM-2 non-polar polystyrene adsorbent (Biorad) 
in the presence of a 100:1 molar ratio of asolectin to protein following the manufacturer’s 
instructions. The prepared vesicles (50 nl) containing 100 ng of α7 TM domain were 
injected into Xenopus laevis oocytes (stages 5–6). Oocytes were maintained in modified 
Barth’s solution containing 88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 15 mM HEPES, 
0.3 mM Ca(NO3)2, 0.41 mM CaCl2, 0.82 mM MgSO4, 10 μg/mL sodium penicillin, 10 
μg/mL streptomycin sulphate, and 100 μg/mL gentamycin sulphate, pH 6.7 at 18 °C. After 
1-3 days, channel function was measured by two-electrode voltage clamp experiments 81. 
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Oocytes in a 20-μl oocyte recording chamber (Automate Scientific) were clamped at -60 
mV with an OC-725C Amplifier (Warner Instruments) and currents were elicited using 
ivermectin as an agonist. The recording solutions contained 130 mM NaCl, 0.1 mM CaCl2, 
10 mM HEPES, pH 7.0 with the indicated concentrations of ivermectin and ketamine. 
Data were collected and processed using Clampex 10 software (Molecular Devices). 
 
 The Na+ flux assay for functional measurements of α4β2  
The Na+ flux assay, as measured by the reduction of Sodium GreenTM dye (Invitrogen, 
Carlsbad, CA) fluorescence due to Na+ leaving the vesicles through open channels, is an 
effective way to macroscopically assess activity of the α4β2 TM channels. We prepared 
25 mM vesicles with ~500 μM α4β2. The vesicles contained egg phosphatidylcholine 
(PC)/phosphatidylglycerol (PG) in a 3:1 molar ratio and lipid biotinyl-cap-PE (1 mol %). 
Lipids dissolved in chloroform were mixed with α4β2 and dried to a thin film by nitrogen 
gas. Residual organic solvent was removed by vacuum overnight. The lipid-protein 
mixture was hydrated overnight at 42°C with a buffer solution containing 20 mM Tris, 100 
mM NaCl, and 3 μM Sodium GreenTM at pH 7.5. The vesicles were obtained by multiple 
subsequent cycles of freeze/thaw and sonication. Sodium GreenTM dye outside the 
vesicles was removed by extensive dialysis. 
The Na+ flux assay was performed using an Olympus IX81 microscope (Olympus 
America, Center Valley, PA), equipped with a Sutter Lambda xenon exciter light source, 
various excitation and emission filters, and an ORCA-ER digital camera. For each 
measurement, vesicles containing α4β2 were added onto the streptavidin coated glass 
slide. The image acquisition started before vesicles were washed with a buffer solution 
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(50mM CaCl2 20mM Tris at pH 7.5) to dilute the extra-vesicle Na+ concentration. The 
resulting Na+ concentration gradient drove Na+ out of the vesicles when channels were 
formed. Consequently the fluorescence intensity resulting from Sodium GreenTM trapped 
inside vesicles was reduced. Decay of the Sodium GreenTM fluorescence intensity within 
each cluster of vesicles was recorded using the program In-vivo and analyzed by 
MetaMorph (Molecular Devices, Sunnyvale, CA). 
 
Data processing, analysis and structure calculations  
NMR data were processed using NMRPipe 4.1 and NMRDraw 1.8 82, and analyzed using 
Sparky 3.10 83. 1H, 15N, and 13C chemical shift assignments for the α7, α4, and β2 nAChR 
TM domains were performed manually using the acquired NMR spectra. Initial NOE 
cross-peak assignment was carried out manually and then more cross-peaks were 
assigned using CYANA 2.1 84. For α7, α4, and β2 subunits, a total of 100 monomer 
structures were calculated using CYANA 3.0 based on NOE and hydrogen-bonding 
restraints, as well as Talos dihedral angle restraints derived from the chemical shifts 85. 
Restraints for α4, β2, and α7 are shown in Table 2.1.1, Table 2.1.2, and Table 2.1.3, 
respectively. Of these 100 structures, the 25 with the lowest target function underwent 
further refinement using Cyana 3.0. A final bundle of 20 structures with the lowest target 
function was analyzed using VMD 86 and Molmol 87.  
The α4 and β2 structures with the smallest root mean square deviations (RMSD) 
from their respective average structures were used for building pentameric models. The 
MATLAB® programming environment was used to input structure coordinates, perform 
coordinate transformations, and save a pentamer model in PDB format. Individual 
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structures of α4 and β2 were first oriented such that each helical axis of TM2 was parallel 
to the Z-axis. The helical axis of TM2 was determined using only the backbone atoms of 
residues from 245 to 266 for α4 or 239 to 260 for β2. The structures were then duplicated 
to form (α4)2(β2)3 and (α4)3(β2)2 pentamers, where the center of the backbone atoms for 
each of the five TM2 helices was located on the vertices of a five-fold symmetric 
pentagon. Orientations of the α4 and β2 subunits were adjusted to satisfy the NMR 
chemical shift perturbation data, in which interacting residues between α4 and β2 were 
indicated. The pore lining residues (T248, S252, and V259) for the α4 subunit were also 
set to be consistent with experimental results from the substituted cysteine accessibility 
method 88. We constructed two pentameric models of α4β2 with 2:3 and 3:2 ratios for α4 
to β2. It is plausible that α4β2 in our sample preparation was in both stoichiometries 89,90. 
The pentameric structural models were subjected to 2000 steps of steepest descent 
minimization in NAMD 2.6 91 with a 100 kcal/mol restraint on backbone atoms. The pore 
radius profiles were obtained using the HOLE program 92 with a step size of 0.2 Å along 
the pore axis. 
2.1.3. Structures of the α4 and β2 nAChR TM Domains 
Structures of the TM domains for subunits α4 and β2 (Figure 2.1.2) were determined 
based on constraints generated from NMR experiments. (Figure 2.1.3, Table 2.1.1, and 
Table 2.1.2). The backbone RMSD of the helical regions among the 20 lowest energy 
structures for α4 or β2 is less than 1 Å. Because of their high sequence homology (~88%), 
the α4 and β2 TM domains share considerable structure similarity (Figure 2.1.2c), and 
the backbone RMSD of their helical regions is ~1.5 Å.  
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Figure 2.1.2. NMR structures of the α4 and β2 nAChR TM domains. Bundles of the 20 lowest-energy 
NMR structures for (a) α4 and (b) β2 nAChR TM domains. The color scheme varies from red in (a) or blue 
in (b) for TM1 to green for TM4. (c) Overlay of the representative structures of α4 (red) with β2 (blue).  
 
Figure 2.1.3. Summary of NMR restraints for structural calculations of the (a) α4 and (b) β2 TM 
domains. Structural restraints include hydrogen binding, NOE connectivity, and Cα chemical shift index. 
Residues with amide proton temperature coefficients < 4.5 ppb/K were considered to be involved in 
hydrogen bonding and are marked with (●). Sequential, midrange, and long-range NOE connectivities are 
linked by lines with widths proportional to the observed NOE intensities. The helical regions of the calculated 
protein structure are indicated below the sequence.  
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Table 2.1.1. Statistics for the 20 calculated structures of the human α4 nAChR TMD. 
NMR structure Statistics 
Number of distance restraints 1070 
   Intraresidue (|i − j| = 0) 362 
   Short range (|i − j| = 1) 421 
   Medium range (1 < |i − j| ≤ 4) 259 
   Long-range, inter-helical (|i − j| ≥ 5) 28 
Number of dihedral angle restraints 180 
   (Residues 8-16, 18-30, 35, 37-59, 70-92, 109-129)  
Number of hydrogen bond restraints 148x2 
   (Residues 9-30, 36-59, 72-94, 109-130)  
Number of upper limit restraints violations > 0.5 Å 0 
Number of dihedral angle restraints violations > 5° 0 
Backbone RMSD (Residues 9-30, 36-59, 72-94, 109-130) 0.87 ± 0.16 Å 
Heavy atom RMSD (Residues 9-30, 36-59, 72-94, 109-130) 1.15 ± 0.18 Å 
Ramachandran plot  
   Residues in most favored regions 87.6 % 
   Residues in additionally allowed regions 9.7 % 
   Residues in generously allowed regions 2.2 % 
   Residues in disallowed regions 0.5 % 
 
Table 2.1.2. Statistics for the 20 calculated structures of the human β2 nAChR TMD. 
NMR structure Statistics 
Number of distance restraints 766 
   Intraresidue (|i − j| = 0) 328 
   Short range (|i − j| = 1) 289 
   Medium range (1 < |i − j| ≤ 4) 114 
   Long-range, inter-helical (|i − j| ≥ 5) 35 
Number of dihedral angle restraints 184 
   (Residues 8-16, 18-30, 35, 37-58, 70-92, 109-131, 133)  
Number of hydrogen bond restraints 146x2 
   (Residues 9-31, 36-59, 70-92, 110-130)  
Number of upper limit restraints violations > 0.5 Å 0 
Number of dihedral angle restraints violations > 5° 0 
Backbone RMSD (Residues 7-30, 36-58, 70-92, 109-130) 0.95 ± 0.28 Å 
Heavy atom RMSD (Residues 7-30, 36-58, 70-92, 109-130) 1.36 ± 0.26 Å 
Ramachandran plot  
   Residues in most favored regions 87.9 % 
   Residues in additionally allowed regions 10.2 % 
   Residues in generously allowed regions 1.7 % 
   Residues in disallowed regions 0.2 % 
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We compared the α4 and β2 NMR structures with the structures of GLIC, GluCl, 
and the α1 and β1 Torpedo nAChR. The helical length of the pore-lining TM2 in α4 and 
β2 resembles that in the GLIC and GluCl structures 27-29, but is shorter than that in the 
Torpedo nAChR structural model 1. The c-terminus of the TM2 helix in α4, β2, GLIC and 
GluCl ends a few residues before the conserved proline in the TM2-TM3 linker. The same 
helical termination at the c-terminus of TM2 was also found previously in different 
membrane mimetic environments 66,93. However, in the Torpedo nAChR structural mode, 
the TM2 helix ends three residues after this conserved proline. Another interesting 
observation is on the TM3-TM4 linkers of these proteins. Only two or six residues link 
TM3 and TM4 in GLIC or GluCl, respectively. On the other hand, the TM3-TM4 linker in 
the Torpedo or the α4β2 nAChR is large often containing over a hundred residues. To 
make the protein size manageable for NMR, we removed the majority of the TM3-TM4 
linker in α4 and β2, keeping only 18 residues (13 original loop residues plus an additional 
5 consecutive glycine residues). The drastic variations in the number of the TM3-TM4 
linker residues among these proteins do not profoundly alter the four helical bundle motifs 
of the TM domains. The structural resilience to modification of the intracellular region is 
in accord with observations that the GABAA and 5HT3 receptors were functional after the 
deletion of their IC domains 94. 
2.1.4. Structure of the α7 nAChR TM domain 
A bundle of the 20 lowest target function structures of the α7 TMD (PDB ID: 2MAW), as 
shown in Figure 2.1.4a, were determined based on short-, medium-, and long-range 
NOEs, dihedral angle constraints, and hydrogen bonding constraints (Figure 2.1.5). The 
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average pair-wise RMSDs in the helical regions are 1.24 ± 0.32 Å for the backbone and 
1.64 ± 0.30 Å for all heavy atoms. Detailed statistics of structural calculations are provided 
in Table 2.1.3.  
 
Figure 2.1.4. NMR structures of the α7 nAChR TMD. (a) A bundle of the 20 lowest-energy structures of 
the α7 TMD (PDB ID: 2MAW). The structures are colored from red for TM1 to blue for TM4. The backbone 
atom RMSD for the helical regions is 1.24 ± 0.32 Å. (b) Overlay of representative structures of α7 (blue) 
and α4 (yellow; PDB ID: 2LLY). The backbone atom RMSD for the helical regions between α7 and α4 is 
2.9 Å. (c) Overlay of representative structures of α7 (blue) and β2 (green; PDB ID: 2LM2). The backbone 
atom RMSD for the helical regions between α7 and β2 is 2.1 Å. 
 
The tertiary structure of the α7 TMD resembles those determined previously for the α4β2 
(PDB IDs: 2LLY; 2LM2) nAChR 36 and other homologous pLGICs 26-29. However, small 
structural differences can be observed among the nAChR TM domains. The angles 
between TM2 and TM4 helices are 3.9 ± 0.5 in α7, but 8.8 ± 0.9 and 10.5 ± 1.1 in α4 
and β2, respectively. The angles between TM1 and TM3 helices are 3.8 ± 0.7 in α7, but 
5.3 ± 0.6 and 5.7 ± 0.7 in α4 and β2, respectively. Structural alignment of α7 onto α4 or 
β2 (Figure 2.1.4b and c) shows that the α7 structure is more compact at the EC end of 
the TMD, where α7 has an intra-subunit cavity with a volume of 122 ± 10 Å3. In contrast, 
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α4 and β2 have larger cavities in the same region with volumes of 232 ± 6 Å3 and 179 ± 
12 Å3, respectively. The structural differences at the IC end of the TMD seem to be 
reversed. The intra-subunit cavities at the IC end of the TM domains have volumes of 209 
± 8 Å3, 139 ± 11 Å3, and 131 ± 10 Å3 for α7, α4, and β2, respectively. 
 
Table 2.1.3. Statistics for the 20 calculated structures of the human α7 nAChR TMD. 
NMR structure Statistics 
Number of distance restraints 614 
   Intraresidue (|i − j| = 0) 239 
   Short range (|i − j| = 1) 223 
   Medium range (1 < |i − j| ≤ 4) 109 
   Long-range, inter-helical (|i − j| ≥ 5) 43 
Number of dihedral angle restraints 196 
   (Residues 4-15, 17-29, 34, 36-58, 69-93, 107-130)  
Number of hydrogen bond restraints 1522 
   (Residues 4-8,10-22, 24-25, 35-41, 43-47, 49-54, 69-89, 107-119, 121-125)  
Number of upper limit restraints violations > 0.5 Å 0 
Number of dihedral angle restraints violations > 5° 0 
Backbone RMSD (Residues 5-29, 36-58, 69-93, 107-130) 1.24 ± 0.32 Å 
Heavy atom RMSD (Residues 5-29, 36-58, 69-93, 107-130) 1.64 ± 0.30 Å 
Ramachandran plot  
   Residues in most favored regions 86.2 % 
   Residues in additionally allowed regions 13.6 % 
   Residues in generously allowed regions 0.1 % 
   Residues in disallowed regions 0.1 % 
 
 
Figure 2.1.5. Summary of NMR restraints for structural calculations of the α7 nAChR TMD. Structural 
restraints include hydrogen binding, NOE connectivity, and Cα chemical shift index. Residues with 
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temperature coefficients for amide proton chemical shifts smaller than 4.5 ppb/K were considered to be 
involved in hydrogen bonding and are marked with (●) below the protein sequence. Sequential, midrange, 
and long-range NOE connectivities are demonstrated by lines. The Cα chemical shift index is shown below 
the long-range NOE connectivities. The helical regions of the calculated α7 structure are indicated below 
the sequence. To convert the residue numbering used in the NMR study to the numbering for the full-length 
α7 nAChR, add 202 for residues labeled 1 to 102 and add 337 for residues labeled 103 to 137. 
2.1.5. Pentameric Structure Model of the α4β2 TMD 
To determine whether the TM domains of α4 and β2 interact with each other and their 
oligomerization state in LDAO micelles, we performed NMR and SEC-MALS 
measurements on mixtures of α4 and β2.  
For better resolution, only one subunit type in the α4β2 mixture was 15N - or 13C-
labeled for each NMR spectrum. In other words, only one set of residues in the mixture, 
either from α4 or β2, was observed in the NMR spectrum. If α4 and β2 did not interact 
with each other, the NMR spectrum of the mixture would be the same as the spectrum of 
α4 or β2 alone. On the other hand, differences between the NMR spectra of a single 
subunit type and the α4β2 mixture are indicative of interactions between two different 
subunits. As shown in the spectral overlay of α4 and the α4β2 mixture in Figure 2.1.6a, 
several residues of the α4 subunit were perturbed by the addition of the unlabeled β2. 
Similarly, β2 was perturbed in the NMR spectra when it was mixed with the unlabeled α4. 
Fully annotated spectra for α4 in the presence of β2 or β2 in the presence of α4 are 
provided in the online supporting material of the published manuscript 36. These NMR 
data suggested that the α4 and β2 TM domains interacted with each other and formed 
oligomers in LDAO micelles. The oligomeric state of the α4 and β2 TM domains in the 
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NMR samples was determined using size exclusion chromatography coupled with SEC-
MALS. As shown in Figure 2.1.6b, the average molar mass of the α4β2 oligomers across 
the elution peak is 74.6 kDa, which is virtually the same as the expected molar mass of 
75 kDa for a pentamer of the α4 and β2 TM domains. These results suggest that the TMD 
alone is sufficient for pentameric assemblies to spontaneously form in a membrane 
mimetic environment. 
 
Figure 2.1.6. NMR and SEC-MALS data supporting pentameric assembly of the α4β2 nAChR TMD in 
LDAO. (a) Overlay of 1H-15N TROSY-HSQC spectra of α4 in the absence (black) and presence (green) of 
β2. Peaks circled in red showed changes in α4 chemical shift after the addition of β2, signifying interactions 
between α4 and β2. A limited number of residues experiencing changes in chemical shift suggested that 
the presence of β2 did not significantly alter the α4 structure. (b) SEC-MALS analysis indicated the 
formation of the α4β2 pentameric assembly. The molar mass (red) of the α4β2 assembly in the nAChR 
α4β2-detergent complex was obtained using conjugate analysis and is shown across the elution peak 
(black) from size exclusion chromatography. The average molar mass of the α4β2 assembly is 74.6 kDa. 
The dotted line indicates the expected molar mass of 75 kDa. 
 
Changes in the α4 and β2 NMR spectra due to a perturbation from their interacting 
partners are relatively small and limited to only a few residues (Figure 2.1.6a). This is 
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understandable for at least two reasons. First, the pure or mixed subunits are in the same 
oligomeric state. Second, the α4 and β2 TM domains contain a high percentage of 
identical residues. Because of these reasons, when the adjacent subunit was changed 
from the same type to a different type in the pentameric assemblies, the structure of the 
α4 or β2 subunit did not change considerably. Thus, we built the α4β2 pentameric models 
using the NMR subunit structures (Figure 2.1.2). The NMR chemical shift perturbation 
data were used to guide spatial arrangement of interacting residues between α4 and β2 
for building the model. For example, α4-L239 in the TM1 helix and β2-L294 in the TM3 
helix were both affected by the presence of the complementary subunit in the chemical 
shift perturbation experiments. They are likely close to each other in space. Similar inter-
subunit pairs were identified at different locations along the membrane normal (Figure 
2.1.7). They were used for assembling pentameric models.  
The α4β2 nAChR was originally found to exist in the (α4)2(β2)3 stoichiometry 95,96, 
but later was also found to form (α4)3(β2)2 89,90. Thus, we constructed models for both 
stoichiometries (Figure 2.1.8). The pore lining residues, T2’, S6’, L9’, V13’, L17’, and α4-
E20’ or β2-K20’, agree with those determined previously using the substituted cysteine 
accessibility method (SCAM) 88,97. The pore radius profiles in Figure 2.1.9 show funnel 
shaped channels for (α4)2(β2)3 and (α4)3(β2)2, opening widely at the extracellular end 
and narrowing gradually toward the intracellular end. The funnel shaped pore profile with 
a widely opened extracellular end was also observed in the GLIC and GluCl structures 27-
29. The (α4)2(β2)3 model is in an apparently open-channel conformation and its minimal 
pore radius at T2’ (2.9 Å) is greater than that in GLIC (~2.5 Å). Although pore profiles 
resulting from backbones are nearly the same for both models, the pore radius at L9’ is 
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smaller in the (α4)3(β2)2 model. The sidechain of α4-L9’ protruded into the pore lumen 
slightly more than the sidechain of β2-L9’.  
 
Figure 2.1.7. Top views of interacting residues between α4 (red) and β2 (blue) highlighted in (a) 
(α4)3(β2)2 and (b) (α4)2(β2)3 pentamer models. Interacting residues were identified by NMR chemical shift 
perturbation experiments. β2-L256 contacts α4-L263 closely. It is also adjacent to α4-N221. At another 
interface of the β2 and α4 subunits, β2-L216 contacts α4-T265 and α4-M286. β2-L294 and β2-W439 
interact directly with α4-L239 and α4-F298, respectively. These interactions extended the perturbation 
effect to α4-F237, α4-T296 and α4-V299 and caused changes in chemical shifts of these residues. 
 
Figure 2.1.8. Top views of the α4β2 pentamer models: (a) (α4)2(β2)3 and (b) (α4)3(β2)2. Cartoon 
presentations for α4 and 2 subunits are colored orange and gray, respectively. Residues of TM2 are shown 
in surface representation and colored according to residue types, acidic in red, basic in blue, polar in green, 
and non-polar in white. 
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Figure 2.1.9. Pore-radius profiles for the (α4)2(β2)3 (black) and (α4)3(β2)2 (gray) models. The dashed 
and solid lines represent profiles determined by the backbone atoms or including the side chains, 
respectively. Positions of the pore lining residues are highlighted. Pore profiles were generated using the 
HOLE program 92. 
 
The α4β2 nAChR structural models allow us to visualize findings observed in 
previous experiments. Changing the stoichiometry of α4 and β2 altered Ca2+ permeability 
in α4β2 nAChR. Increasing the proportion of negative charges in (α4)3(β2)2 was found to 
be associated with increasing permeability to Ca2+ 98. Indeed, as shown in Figure 2.1.8, 
positively charged β2-K20’ and negatively charged α4-E20’ are located at the 
extracellular pore entrance. A larger proportion of α4-E20’ in (α4)3(β2)2 provides a benefit 
by attracting Ca2+ to the pore entrance. Electrostatic interaction between β2-K20’ and α4-
E20’ may also help to stabilize pentameric assemblies 99. Results from previous 
photoaffinity labeling experiments on the α4β2 nAChR are well represented in, and 
explained by, our structural models. 3-trifluoromethyl-3-(m-[125I]iodophenyl) diazirine 
([125I]TID), a hydrophobic probe 100, was photolabeled onto the α4β2 nAChR for mapping 
the protein/lipid interface 101. We highlighted the residues labeled by [125I]TID in our α4β2 
models (Figure 2.1.10), including homologous residues α4-C582 and β2-C445 in TM4, 
α4-C226 and α4-C231 in TM1, and β2-C220 that is homologous to α4-C226 101. Our 
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structures show exposure of α4-C582 and β2-C445 in TM4 and α4-C231 in TM1 to lipids. 
More interestingly, our structures show that α4-C582 and β2-C445 of TM4 face towards 
α4-C226 and β2-C220 of TM1, respectively. They form a [125I]TID binding pocket along 
with surrounding lipids. Although α4-C226 and β2-C220 are less exposed to lipids, their 
labeling by [125I]TID could be facilitated by α4-C582 and β2-C445 in the same pockets. 
However, if the Torpedo nAChR model 1 is used for explaining the photolabeling data, 
α4-C582 and β2-C445 seem to have no association with α4-C226 and β2-C220, 
respectively (Figure 2.1.10). 
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Figure 2.1.10. The NMR structures of the TM domains of (a) α4 and (b) β2 nAChRs showing residues 
photolabeled by [125I]TID 101. α4 and β2 are shown in ribbon and colored from green (TM1) to red (TM4) 
in (a), and from green (TM1) to blue (TM4) in (b). Residues photolabeled by [125I]TID in α4 (C226, C231, 
and C582) and β2 (C220 and C445) are shown in a surface presentation. For comparison, the α1 (gray) 
and β1 (silver) subunits of the Torpedo nAChR structure were aligned with α4 and β2, respectively, and 
shown in cartoon presentation. Residues homologous to the [125I]TID labeled residues are shown in yellow 
sticks. The NMR structures and the Torpedo nAChR structure show different positions of α4-C582 and β2-
C445. In our NMR structures, α4-C582 and β2-C445 oriented towards α4-C226 and β2-C220, respectively, 
suggesting the likelihood of a [125I]TID binding pocket involving α4-C226 and α4-C582 or β2-C220 and β2-
C445. The Torpedo nAChR model, however, suggested no association between α4-C226 and α4-C582 or 
β2-C220 and β2-C445 for [125I]TID binding. 
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2.1.6. Functional Measurements of the α4β2 Assembly 
 
Figure 2.1.11. Fluorescence images of the Na+ flux assay on vesicles in the (a) presence and (b) 
absence of the α4β2 nAChR TMD. Membrane-impermeable Sodium Green™ fluorescent dyes were 
enclosed inside the vesicles to probe intra-vesicle Na+ concentrations. The fluorescence intensity of the 
vesicles with α4β2 channels in (a) decreased significantly within a short period of time after washing away 
extra-vesicle sodium, indicating Na+ efflux through the channels. However, fluorescence intensity of the 
control vesicles without α4β2 in (b) remained nearly constant before and after washing away extra-vesicle 
Na+ during the same time period. 
 
NMR chemical shift perturbation experiments in combination with the SEC-MALS 
analysis provided evidence for the formation of the α4β2 pentameric assembly. To assess 
whether the α4β2 TM domains formed ion-conducting channels, we performed a Na+ flux 
assay. Significant reduction of Sodium Green™ dye fluorescence was observed in 
vesicles immediately after dilution of the extra-vesicle salt concentration only if the 
vesicles contained the α4β2 assembly (Figure 2.1.11a). During the same measurement 
time, however, fluorescence remained almost the same in vesicles lacking α4β2 (Figure 
2.1.11b), confirming that the observed fluorescence reduction in Figure 2.1.11 was not 
due to fluorescence bleaching. Efflux of Na+ from the vesicles containing α4β2 indicates 
that the α4β2 TM domains are capable of transporting Na+ across a membrane. The data 
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in Figure 2.1.11 suggest that the open conformation of the α4β2 assembly is 
thermodynamically accessible at room temperature, though it cannot determine how 
rapidly the closed and open conformations spontaneously exchange.  
2.1.7. Functional Measurements of the α7 nAChR TM domains 
 
Figure 2.1.12. Representative traces of Xenopus laevis oocytes injected with vesicles containing 
the purified α7 nAChR TMD. (a) Current response at 10 and 30 μM ivermectin. (b) Inhibition of ivermectin 
(30 μM)-elicited current by 100-μM ketamine.  Bars over the trace indicate length of application of the 
indicated compounds. Scale bars indicate 0.5 min and 0.1 μA. 
 
The α7 TMD spontaneously formed ion-conducting channels when injected into 
Xenopus laevis oocytes as reconstituted asolectin vesicles (Figure 2.1.12).  Although the 
α7 TMD does not possess the orthosteric agonist-binding site of native human α7 
nAChRs, the channel current could be elicited by ivermectin, a known positive allosteric 
modulator acting through the TMD 102,103. Ketamine inhibited ivermectin-induced current 
(Figure 2.1.12b), consistent with the effect of ketamine on native human α7 nAChR 
45,46,104. No ivermectin-elicited current was observed in control oocytes injected with the 
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asolectin vesicles not containing the α7 TMD. These data demonstrate that the α7 TMD 
retains pharmacological responses observed for the full-length α7 nAChR. 
2.1.8. Conclusions 
In this section we discussed the NMR derived structures of the α7, α4, and β2 nAChR TM 
domains in LDAO micelles. These structures are valuable for understanding the biological 
and pharmacological properties of both α7 and α4β2 nAChRs, particularly for 
characterizing binding sites and mechanisms of action for new and existing drugs. SEC-
MALS and the Na+ flux assay demonstrated that the α4β2 TM domains spontaneously 
form pentamers permeable to Na+. We also found that the α7 nAChR TMD injected into 
Xenopus laevis oocytes retained pharmacological properties of the native α7 nAChR 
TMD, namely potentiation by ivermectin and inhibition by ketamine. Our data suggests 
that the presented NMR structures are biologically relevant and offer valuable frameworks 
for rationalizing drug binding and modulation for the α7 and α4β2 nAChRs. 
2.2. NMR STRUCTURE OF THE GLYCINE RECEPTOR TM DOMAIN 
This section has been published as a full article in Structure 21 (10): 1-8.  
2.2.1. Background and Significance 
The glycine receptor is an anion-selective channel and a major inhibitory receptor in the 
human adult spinal cord and brain stem. Anionic Cys-loop receptors include both the 
glycine and GABAA receptors. The GABAA receptor has been implicated in sedation, 
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amnesia, and muscle relaxation, while the glycine receptor has been implicated in 
immobility 19-21. Prior to the publication of the structure discussed here, no structure was 
available for a mammalian anionic Cys-loop receptor TMD. The NMR structures of the 
human glycine receptor α1 subunit (hGlyR-α1) TMD offer a valuable complement to 
existing crystal structures of Cys-loop receptors 1,29,81 and their homologues 27,28. The 
structures reveal features previously unobserved in crystal structures or the NMR 
structures of cationic Cys-loop receptors 36, which may be functionally distinct to anionic 
Cys-loop receptors.  
The functional state of a crystal structure is often inferred from electrophysiology 
measurements under comparable conditions. However, crystallization conditions may 
bias the crystal structures into conformations that contradict electrophysiology results. 
The crystal structure of the mutation-stabilized open-channel ELIC is nearly identical to 
that of the closed ELIC 105. Propofol inhibits GLIC current, but the crystal structure of the 
GLIC-propofol complex shows the same open channel conformation as that observed in 
GLIC 106. Such complications highlight the limitation of crystal structures in revealing 
functional states of Cys-loop receptors and the need for complementary structural 
approaches.  
In this section we present the NMR structures for the full-length hGlyR-α1 TMD 
determined in LPPG. Electron microscopy (EM) and functional measurements show that 
the TMD forms pentameric and spontaneously Cl–-conducting channels. The NMR data 
revealed structural and dynamic features of the hGlyR-α1 TMD that may be shared by 
other anion-selective Cys-loop receptors. The functional relevance of the TMD structures 
was validated by a recent study 107 showing that the hGlyR-α1 TMD in a chimera with the 
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GLIC ECD functions as an anion-selective channel and mirrors the pharmacological 
profile of the native hGlyR-α1. 
2.2.2. Methods 
Protein expression and sample preparation 
The protein was expressed using the Novagen pET-31b(+) system (Novagen, Milwaukee, 
WI) in E. coli BL21(DE3)pLysS competent cells (Novagen). M9 minimum medium was 
used for protein expression with (15NH4)2SO4 and [U-13C] glucose as the sole source of 
nitrogen and carbon for 15N-labeling and 15N ,13C-double labeling. To assist in chemical 
shift assignment, specific 15N labeling of alanine, phenylalanine, leucine, isoleucine, and 
valine were performed using a previously reported method 108. The fusion protein was 
purified on staggered His-Bind chromatography columns (Novagen). Cleavage of the 
hGlyR-α1 TMD from the fusion protein was achieved using the standard protocol 109. Final 
purification for the hGlyR-α1 TMD was carried out using reverse-phase HPLC with a C4 
column (Vydac, Hesperia, CA). NMR samples were prepared as described previously 
110,111. Aliquots of the hGlyR-α1 TMD (4 mM) dissolved in trifluoroethanol (TFE) were 
titrated into a 200 mM solution of LPPG micelles (10 mM sodium phosphate buffer, pH 
5.8) to a protein-to-LPPG ratio of ~1:200. Distilled H2O was added to reach the water-to-
TFE ratio of 16:1 by volume. The sample was vigorously mixed, rapidly frozen in liquid 
N2, and lyophilized overnight at –80°C to remove all solvents, particularly TFE. The 
lyophilized sample was rehydrated in deionized H2O with 5% D2O for NMR field lock. 
NMR samples for structure determination typically had a protein concentration of ~500 
μM with a protein-to-LPPG ratio of ~1:200 (pH 5.8).  
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For site-directed paramagnetic spin labeling, the wild-type hGlyR-α1 TMD (with 
one cysteine, C290) and two single-cysteine mutants (C290S/S296C and C290S/S308C) 
were prepared as described in the literature with minor modifications 112. Cysteine was 
reduced using DTT at a 10-fold molar excess for 30 minutes at room temperature. Excess 
DTT was removed by dialysis overnight in 10 mM sodium phosphate buffer at pH 5.8. 
MTSL was added from a concentrated stock in acetonitrile to a MTSL-to-protein molar 
ratio of 5:1 and incubated overnight at room temperature before removing the free MTSL 
by dialysis in a 10 mM sodium phosphate buffer. 
For functional measurements, large unilamellar vesicles (LUV) were prepared 
using the same method reported previously 113. Briefly, PC and PG in a 3:1 molar ratio 
were dissolved and mixed in chloroform. The mixture was divided equally into three 
portions for use in: control samples without the protein, samples with the protein, and 
samples with the same amount of protein and picrotoxin (Tocris Bioscience, Ellisville, 
MO). The mixtures were dried into thin films under a stream of N2 gas and left under 
vacuum overnight to completely remove the organic solvents. The dried films were 
rehydrated with one volume of 5 mM Tris-HCl buffer at pH 7.2 (buffer A) and four volumes 
of 0.5 M KCl in buffer A. After vigorous vortexing and brief sonication, the samples were 
subjected to two cycles of freeze and thaw alternating between –80C and room 
temperature, respectively. Immediately before the magnetization-inversion transfer (MIT) 
experiments, the vesicles were expanded by adding buffer A to reach a final total lipid 
concentration of 25 mM, a KCl concentration of 200 mM, a protein concentration of 26 
μM and a picrotoxin concentration of 1 mM. 
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For EM measurements, serial dilutions, using a buffer containing 10 mM HEPES 
and 50 mM KNO3, were made from a stock solution in the same buffer with a protein 
concentration of 54 μM and a protein-to-LPPG ratio of 1:50. Five μl of diluted samples 
were deposited onto a glow-discharged carbon foil grid, blotted with filter paper, and 
stained with 2% uranyl acetate. 
 
NMR spectroscopy 
For backbone chemical shift assignment, the following spectra were collected: HNCO 
(1024x40x64) with 13C spectral width of 12ppm, HNCA and HN(CO)CA (1024x40x80) 
with 13C spectral widths of 32 ppm, and HNCACB and CBCA(CO)NH (1024x40x80) with 
13C spectral widths of 75ppm. HCCH-TOCSY was collected for side chain assignment. 
To obtain the distance restraints, 15N- and 13C-edited NOESY (1024x60x248) were 
acquired with spectral windows of 27 ppm and 80 ppm for the 15N and 13C dimensions, 
respectively. Mixing times were 150 ms for both 15N- and 13C-edited 3D NOESY. Unless 
otherwise specified, spectral windows for 1H and 15N dimensions were 12 ppm and 26 
ppm, respectively. 15N-edited 3D NOESY spectra were acquired for the samples with 
selectively 15N-labeled Ala, Phe, Leu, Ile, or Val. Longitudinal (R1) and transverse (R2) 15N 
relaxation rate constants and 15N-{1H} heteronuclear NOE were measured at 40°C on a 
Bruker Avance 700 MHz spectrometer. R1 was determined using 9 delay values: 10, 100, 
200, 400, 600, 800, 1000, 1500 and 2800 ms. The R2 experiment also used 9 delay 
values: 16, 32, 64, 96, 128, 160, 240, 320 and 480 ms. For the steady-state 15N-{1H} NOE 
measurement, a train of 120 high-power pulses separated by 5 ms for the duration of 3 s 
was used for proton saturation and data was collected with and without proton saturation 
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in an interleaved fashion. Temperature effects on chemical shift were measured using a 
series of 1H-15N HSQC experiments collected at 35, 40, 45, and 50°C on a Bruker 900 
MHz spectrometer. DSS was used as an internal reference for 1H chemical shift, with 15N 
and 13C chemical shifts indirectly referenced 78. Topspin and NMRPipe 82 were used to 
process NMR data. Sparky was used for resonance assignment 83.  
The MIT experiments 113,114 were performed at 30C using a 4 mm MAS probe on 
a Bruker Avance 600 MHz spectrometer. In the absence of the chloride shift reagent, only 
one peak was observed and manually set to 0 ppm. In the presence of ~20 mM Co(gly)3−, 
the extra-vesicle resonance (35Clout) was separated from the intra-vesicle resonance 
(35Clin) by ~25 ppm. A pair of hard 90 pulses, separated by the reciprocal of twice the 
chemical shift difference, was used to selectively invert the 35Clout resonance while 
returning the 35Clin magnetization back to the Z direction. The inversion-recovery time, t, 
varied from 10 μs to 0.5 ms, followed by a third 90 read pulse. Typically, 14 inversion-
recovery times were used in each MIT experiment. The recycle delay was set to at least 
10 times the T1 value of the 35Cl signals. The Mnova NMR program (Mestrelab Research, 
Escondido, CA) was used to measure the MIT peak intensities by spectral deconvolution. 
Influx and efflux rates were calculated using a two-site exchange mode. Details are 
described below.  
 
NMR spectroscopy for measuring Cl− flux across the hGlyR-α1 TM channels 
A two-site exchange model was used to derive the unidirectional flux rate constants from 
the MIT experiments. With the approximation that the longitudinal relaxation time, T1, is 
similar for the intra- and extra-vesicle magnetizations, it has been shown 113 that the time 
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dependence of the uninverted magnetization, I, and inverted magnetization, S, on the 
inversion recovery time are given by: 
  
 ( 2.1 ) 
  
 ( 2.2 ) 
 
where I0 and S0 are the spectral intensities of a fully relaxed spectrum, and ki and ke are 
influx and efflux rate constant. The thermal equilibrium condition is satisfied by kiS0 = keI0. 
T1 was measured using the conventional inversion-recovery method. The ki and ke values 
can be determined by non-linear least square fitting of the MIT data using Equation ( 2.1 
) and Equation ( 2.2 ). 
 
Structure calculations 
The upper and lower bound distance restraints were derived from NOESY and PRE data. 
Backbone dihedral angles were predicted from chemical shift values using the semi-
empirical method implemented in TALOS 85. Hydrogen bonding restraints were generated 
for those residues whose H-D exchange was in the slow category (absolute temperature 
slope < 4.5 ppb/K) 77 and in addition whose CSI and NOE restraints indicated a helical 
secondary structure. Restraints used in structure calculations are summarized in Table 
2.2.1. The 76 backbone dihedral angle restraints were derived from the available 
chemical shift data of Cα, Cβ, C, N, H, and Hα. The long-range distance restraints for 
accurate tertiary structure determination were derived from PRE experiments 112, in 
addition to the unambiguous inter-domain NOESY cross peaks. We made three separate 
spin labeling positions along the length of the TM3 domain at C290, S296C, and S308C. 
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A simultaneous C290S mutation was made in the latter two cases, so that only one spin 
labeling position is present in each mutant. Distance restraints from PRE were generated 
using the established method 112.  
 
Electron microscopy 
The uranyl acetate stained samples were examined at 200 kV with a TF20 electron 
microscope (FEI, Hillsboro, OR). Images were recorded on a 4Kx4K Gatan CCD camera 
(Gatan, Inc., Warrendale, PA) at a nominal magnification of 50,000x and underfocus 
values ranging from 1.5 to 3.0 μm. The CCD images were processed using EMAN image 
analysis software 115. Specifically, the particles were boxed manually with 72 x 72 pixels 
(2.14 Å/pixel), normalized, and then combined into one raw image stack file. A total of 
526 individual particle images were initially chosen. These raw images were band pass-
filtered and iteratively aligned to each other. About 210 good particle images were 
selected. The aligned raw projection images were classified and averaged within each 
class 115. 
2.2.3. The hGlyR-α1 TMD Forms Spontaneously Open Cl− Channels 
A protein encompassing the entire sequence (Figure 2.2.1) of the hGlyR-α1 TMD was 
expressed and reconstituted in LPPG lipid micelles for structure determination using EM 
and high-resolution NMR. Unlike the GlyR ECD that assembles randomly into dimers and 
higher-order oligomers 116, the full-length hGlyR-α1 TMD spontaneously assembles into 
pentameric structures in LPPG lipid micelles. The negatively stained EM images (Figure 
2.2.2) show face-on projections of pentamers. A small population of tetramers is also 
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discernible, in accordance with the tetrameric sub-conductance state measureable in the 
authentic GlyR from mouse spinal cord neurons 117. Circular averaging of all face-on 
pentamer images yielded a ring diameter of ~45 Å for the peak intensities (Figure 2.2.3). 
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Figure 2.2.1. Sequence alignment of the hGlyR-α1 TMD and homologous proteins. The sequence of 
the construct under study (hGlyR-α1 TM) aligned with the TM domains of the native human GlyR-α1 subunit 
(GlyR-α1), the glutamate chloride channel from C. elegans (GluCl), four representative members in the 
Cys-loop receptor superfamily (GABAA α1 subunit, nAChR α1 and α4 subunits, and 5HT3 α subunit), and 
two bacterial homologues (ELIC and GLIC). An artificial loop between TM3 and TM4 and a 6-His tag at the 
C-terminal are shaded in light purple. Solid lines below six sequences mark the experimentally determined 
TM helices. Residues believed to be part of the ion selectivity filter are highlighted in red rectangle boxes. 
Sequence alignment was performed using Clustal X version 2.0 118. 
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Figure 2.2.2. Electron microscopy analyses of the hGlyR-α1 TMD oligomeric complexes. (a) A raw 
electron micrograph of negatively stained hGlyR-α1 TMD oligomers in LPPG (scale bar, 50 nm). 
Representative particles are indicated with red circles. (b) Selected 2D class averages of hGlyR-α1 TMD 
oligomers from 210 particle images. Class averages show doughnut-shaped particles with a central channel 
and several oligomeric states, including pentamer and tetramer. (c) Representative raw particle images 
corresponding to the pentameric (0-3) and tetrameric (5-7) configurations. An average of the raw particles 
from panel 0-3 is shown in panel 4. Panel 8 and 9 show side views of the particles.  
 
Figure 2.2.3. Radial intensity profiling of circular averaged pentameric particles in negatively 
stained EM images. (a) Radial averaging of pentameric particles. (b) Density line profile of the box region 
in (A). Peak to peak distance is ~45 Å. 
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We also reconstituted the same expressed protein into LUVs made of L-α PC and 
PG lipids. Function of the hGlyR-α1 channel for Cl− transport was measured by NMR MIT 
experiments  113,114 using Co(Gly)3− as a Cl− shift reagent 119 to separate intra- and extra-
vesicle 35Cl resonances. We found that the channels are not only spontaneously open in 
the absence of the agonist-binding ECD, but also Cl− permeable (Figure 2.2.4a). At a 
nominal channel density of ~20-2000 per vesicle, the unidirectional Cl− efflux and influx 
rates 113 are 1350 ± 460 and 560 ± 290 s−1, respectively. Moreover, the Cl− transport 
across the TM channels can be completely blocked in the presence of 1 mM picrotoxin 
(Figure 2.2.4b), indicating that the quaternary association of the TMD is preserved to form 
a functional channel with a pore geometry resembling that of the authentic open channel.  
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Figure 2.2.4. Channel functional measurements. (a) Stack plots of 35Cl NMR spectra in Cl− flux 
measurements across LUVs by NMR MIT experiments. Left: control vesicles without the protein; Right: 
vesicles having the hGlyR-α1 TMD channels. The Cl− shift reagent Co(Gly)3− separates extra-vesicle Cl− 
signal from the intra-vesicle signal (marked by the asterisk *). The intensity of the intra-vesicle signal (*) 
changes as a function of the inversion-recovery time (t) due to the exchange of intra- and extra-vesicle Cl−. 
(b) The rates of Cl− influx (ki) and efflux (ke) are determined by fitting the intensity changes as a function of 
t with a two-site exchange model (solid line). ○, LUV without protein; ●, LUV with protein; ▼, LUV with the 
same amount of protein and with 1 mM picrotoxin. Error bars show the standard error of the mean. 
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2.2.4. NMR structure of the hGlyR-α1 TMD 
 
Figure 2.2.5. NMR structures of the hGlyR-α1 TMD. (a) The bundle of 15 lowest target function monomer 
structures of the hGlyR-α1 TMD (PDB ID: 2M6B). The TM1, TM2, TM3, and TM4 helices are indicated in 
red, light green, green, and blue, respectively. (b) Top view of the bundle of 15 lowest target function 
pentameric structures of the hGlyR-α1 TMD (PDB ID: 2M6I). Pore lining residues are highlighted based on 
residue type: green–polar, gray–nonpolar, and blue–basic. (c) Side view of the bundle of 15 lowest target 
function pentameric structures of the hGlyR-α1 TMD. For clarity, only two subunits are shown. Pore lining 
residues are labeled and colored based on their residue type. (d) The pore profile calculated using the 
HOLE program 92. 
 
A bundle of 15 monomer structures of the hGlyR-α1 TMD with the lowest target 
function from the CYANA calculation (Figure 2.2.5) exhibits a typical four-helix-bundle 
fold, which has been observed in the TMD structures of the α4β2 nAChR 36 and other 
known structures of pLGICs 26,27,47,120. The tertiary (Figure 2.2.5a) and quaternary (Figure 
2.2.5b) packing of the TM helices were determined from the long-range intra-subunit and 
inter-helical NOE connectivity (Figure 2.2.6), PRE restraints 112, and diameter restraints 
derived from the EM images. The orientation of the TM2 helix relative to the membrane 
normal was determined using the residual dipole coupling (RDC) data from the TM2-TM3 
helical segments in low-q bicelles as reported previously 121. See 5.3.6.Appendix A for 
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details on structure calculation methods. The NMR structure statistics for the bundles of 
15 monomers (PDB ID: 2M6B) and 15 pentamers (PDB ID: 2M6I) are summarized in 
Table 2.2.1. The pair-wise RMSD among the 15 lowest target-function pentamer 
structures are 0.50 Å and 0.91 Å for the backbone and all heavy atoms, respectively, in 
the four membrane-spanning helices.  
Several structural features of the hGlyR-α1 TMD are worth noting. First, the pore-
lining TM2 has a stable α-helix involving residues from P250 (–2’) to S267 (15’). Residues 
from 16’ to 18’ show an unwound helix exhibiting a slightly larger helical pitch (Figure 
2.2.5a). The residues after 18’ in TM2 are non-helical. In contrast, structures of several 
pLGICs, including the α4β2 nAChR determined by NMR 36, show a longer TM2 α-helix 
that typically contains 23 residues (–2’ to 20’).  
Second, unlike a straight helix observed in other pLGICs, the TM3 helix of hGlyR-
α1 has a kink at A288 (Figure 2.2.5a). The kink changes the helix axis direction by ~33°. 
It is also notable that the fourth residue upstream from the kink is a conserved aspartate 
(D284). Aspartate is known to frequently locate at the i-4 position of TM helical bends 122.  
Third, while most of the pore-lining residues in the hGlyR-α1 TMD structure (Figure 
2.2.5c) agree well with homologous residues in the previously published pLGIC 
structures, one distinction is that the well-conserved L261 (9’) in our open-channel 
structures does not directly face the lumen of the pore, but T262 (10’) does.  
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Table 2.2.1. Statistics for the 15 calculated structures of the hGlyR-α1 TMD in LPPG micelles.  
NMR Distance & Dihedral Restraints Monomer Pentamer 
   
Distance restraints   
    Total NOE 1014 1014 x 5 
    Intra-residue 321 321 x 5 
    Inter-residue 693 693 x 5 
      Sequential (|i-j| = 1) 348 348 x 5 
      Medium-range (|i-j| ≤ 4) 324 324 x 5 
      Long-range (|i-j| > 4) 21 21 x 5 
    Hydrogen bonds 106 106 x 5 
Total dihedral angle restraints 152 154 x 5 
    Phi 76 77 x 5 
    Psi 76 77 x 5 
PRE restraints 219 226 x 5 
    Upper 107 114 x 5 
    Lower 112 112 x 5 
Inter-subunit distance restraints from EM and RDCa   
   Total constraints  600 
     Upper  300 
     Lower  300 
   
Structure Statistics   
   
Violations (mean and s.d.)   
    Upper distance restraints (Å)  0.0075 ± 0.0008 0.0157 ± 0.0010 
    Lower distance restraints (Å)  0.0016 ± 0.0010 0.0102 ± 0.0012 
    Dihedral angle restraints (º) 0.130  ± 0.010 0.338  ± 0.028 
    Max. dihedral angle violation (º)     1.29 3.32 
    Max. distance restraint violation (Å)  0.24 0.63 
Average pairwise RMSDb (Å)   
    Heavy     1.04 ± 0.11c 
2.27 ± 0.25d 
0.91 ± 0.14c 
1.50 ± 0.36d 
    Backbone   0.67 ± 0.13c 
1.66 ± 0.18d 
0.50 ± 0.17c 
0.95 ± 0.30d 
Ramachandran Plot   
    Residues in most favored regions 88.6% 86.3% 
    Residues in allowed regions 11.3% 13.0% 
    Residues in disallowed regions 0.1% 0.7% 
PDB ID 2M6B 2M6I 
a RDC values used to generate pentamer restraints were obtained from the previous study 121. 
b The rmsd to the average coordinates was calculated from 15 structures. 
c Calculated over the helical TM regions (residues 220-241, 250-270, 289-305, 398-421)  
d Calculated over residues 215-425  
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Figure 2.2.6. NOE connectivity and Cα chemical shift index for the hGlyR-α1 TMD in LPPG micelles. 
The line thickness of the NOE connectivity is proportional to the cross-peak intensities. The helical regions 
observed in the NMR structure (black coils) are shown underneath the sequence. The filled circles below 
the sequence mark the residues where backbone hydrogen-bond restraints were imposed on the basis of 
the temperature dependence of the exchangeable amide protons. The two ends of a segment from TM2 to 
TM3 that is highly dynamic are marked with stars below the sequence.  
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Finally, the open channel pore of hGlyR-α1 has a cone shape with the smallest 
diameter of 6.2 Å at a hydrophobic girdle defined by P250 (–2’) and A251 (–1’) side chains 
situated at the cytoplasmic side of the membrane (Figure 2.2.5d). The positively charged 
R252(0’) side chains are tangential to the circumference of the pore. The constriction size 
of the hGlyR-α1 open pore is close to the estimated 6.2 Å for glycine and GABAA 
receptors based on the studies of ion permeability 123.  
2.2.5. Dynamics of the hGlyR-α1 TMD 
The dynamic characteristics of the TM2 and TM3 helices near the TM2-3 loop are 
observed not only in the bundle of structures (Figure 2.2.5a), but also directly in the high 
resolution NMR spectra, where two sets of NMR peaks are identifiable for several 
residues near the TM2 C-terminus, including S268(16’), G269(17’), and S270(18’) (Figure 
2.2.7a). The data suggest that at least two conformations coexist in this region and they 
undergo slow exchange on the μs timescale used for NMR data acquisition. It should be 
noted that a similar minor conformation was also observed in an extended TM2 segment 
of GlyR 124 and in the TM2-TM3 construct in lipid bicelles 121. The NMR structures 
determined in the present study are associated with the major peaks. The structure in the 
minor conformation could not be determined because of insufficient NOESY connectivity.  
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Figure 2.2.7. Conformational dynamics around the TM2-TM3 linker. (a) A representative 1H-15N HSQC 
spectrum of the hGlyR-α1 TMD in LPPG micelles at 40°C. Several residues at the C-terminus of TM2 show 
two sets of peaks, as exemplified in the insert for S268(16’), G269(17’), and S270(18’), indicating that two 
conformations coexist in this region and undergo slow conformational exchange. (b) The 15 lowest target 
function structures of the hGlyR-α1 TMD (ribbons) are aligned with the crystal structure of GluCl (cartoon, 
PDB ID: 3RHW). TM3 of the hGlyR-α1 TMD is highlighted in green. Ivermectin (orange sticks) observed in 
GluCl partially overlaps with the kink at A288 (black sticks) in the NMR structures of the hGlyR-α1 TMD. 
The residue D284 (purple sticks), located 4 residues upstream of A288, may be responsible for the kink 122. 
(c) The segment showing high dynamics is highlighted in yellow between S267 (green) and A288 (black) 
in the bundle of 15 lowest target function NMR structures.  
2.2.6. Structural Comparison of the hGlyR- α1 TMD with Other Cys-loop 
Receptors 
The NMR-resolved structures of the hGlyR-α1 TMD show a general topological 
agreement with the pLGIC structures determined previously, but several notable 
differences may be functionally important. One distinct difference is the relatively short 
TM2 helix, which is about a half helical turn shorter than TM2 helices of ELIC 26,120, GLIC 
27,28,47 and GluCl 29, but about two helical turns (7 residues) shorter than TM2 helices 
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shown in the cryo-EM structure of nAChR 1. One may wonder if a shorter TM2 helix is 
due to different methodologies, NMR vs. X-ray. Our previously published NMR structures 
of the α4β2 nAChR TMD 36 negate this possibility. Both α4 and β2 show a TM2 helical 
length similar to that observed in ELIC, GLIC, and GluCl. The discrepancy in the TM2 
helical length between hGlyR-α1 and other pLGICs occurs at the C-terminal end of TM2, 
where the helix ends at the 18’ residue (with slight unwinding after 15’) in hGlyR-α1, but 
at 20’ in other pLGICs. Furthermore, the TM2 residues S268(16’), G269(17’), and 
S270(18’) of hGlyR-α1 undergo slow exchange between two distinct conformations that 
have not been observed in the α4β2 nAChR using the same NMR method. These results 
demonstrate the unique structural flexibility at the EC end of the pore in hGlyR-α1. 
Compared to other pLGICs, glycine receptors are uniquely rich with serine residues (15’, 
16’ 18’) near the TM2 C-terminus (Figure 2.2.1). It is known that the OH group of serine 
can weaken the helical backbone hydrogen bonds by constraining the carbonyl oxygen 
through the O···H-O interaction 125. The presence of a cluster of serines near the TM2 C-
terminus may have contributed to the structural flexibility in the region. 
2.2.7. Functional Importance of Observed Structural Dynamics 
It is also notable in the bundle of NMR structures (Figure 2.2.5) that R271(19’) shows 
conformational variation with a smaller population in a more extended helix and a larger 
population in an unwound conformation. Consequently, instead of facing the pore, R19’ 
in some structures is mostly tangent to the pore, where R271(19’) experiences a more 
hydrophobic environment. Indeed, such conformational flexibility was noted previously by 
tethering a rhodamine fluorophore to R271C 126, in which the experiment showed a 
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population shift of the fluorescence probe at 19’ to a more hydrophobic environment upon 
channel opening, suggesting that conformational flexibility at the EC end of the pore is 
related to channel function. Ester substitution is expected to weaken the backbone 
hydrogen bonds and increase the flexibility of the pore-lining TM2 helix. Single-point 
amide-to-ester mutations at 13’, 16’, or 19’ of nAChR increased the receptor’s sensitivity 
to agonist more than tenfold 57. A more recent study using electron paramagnetic 
resonance spectroscopy also observed greater conformational changes at the EC end of 
TM2 upon agonist binding 58.  
The high flexibility of the TM2 C-terminus of hGlyR-α1 is likely coupled with the 
structural flexibility near the N-terminal helix of TM3. A helical kink (I285-A288) divides 
the TM3 domain into two α-helical segments: one from V277 to D284 and the other from 
V289 to V307 (Figure 2.2.5a and Figure 2.2.6). Three points about the kink are worth 
noting. First, statistically speaking, D284 is likely responsible for the kink formation. 
Analysis of nonredundant polypeptide chains revealed kinks in 64% of TM helices and 
aspartate showed notably high frequency at the i-4 position of the TM helical kink 122, 
though it remains unclear why aspartate promotes the helical disruption. Second, D284 
is conserved in both glycine and GABAA receptors. It likely plays a similar structural and 
functional role in all anion-conducting Cys-loop receptors. Mutation of this conserved 
aspartate in the α1 GABAA receptor significantly reduced receptor activity 127. Third, while 
the TM3 helices in the crystal structure of the GluCl and ivermectin complex show no kink 
29, the kink may exist in the absence of ivermectin. When we aligned the TM structures of 
GluCl and hGlyR-α1, it became clear that ivermectin partially overlapped with the kink 
observed in the NMR structure (Figure 2.2.7b), suggesting that ivermectin binding may 
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have stabilized a straight helical conformation and that without ivermectin the flexibility 
would make it much more challenging to obtain high quality GluCl crystals for X-ray 
structure determination.  
S267 and A288 mark the two ends of a dynamic region of the channel in our hGlyR-
α1 TMD structures (Figure 2.2.7c). Intriguingly, mutations S267Y and A288W in the 
hGlyR-α1 TMD were found to substantially reduce general anesthetic and alcohol 
potentiation of GlyR responses 55. Mutations at S267 showed that ethanol modulation 
was correlated with the volume but not the polarity or hydropathicity of the substituting 
side chains, suggesting that S267 itself is not directly involved in alcohol binding 128. 
These functional consequences may result from the reduced conformational flexibility in 
the region due to bulky substitution at the S267 position. In fact, our previous NMR study 
demonstrated that the S267Y mutation increased the α-helix length at the TM2 C-
terminus 111. Mutation of A288 to an amino acid with a different size can also alter 
conformational flexibility in the region with functional consequences. Indeed, A288F and 
A288G have opposite functional impacts, with the former reducing and the latter 
increasing glycine-induced channel activation 54. It is unlikely that glycine binding is 
affected by the mutations because the orthosteric agonist-binding site in the ECD is 
remote from A288. The changes in conformational flexibility due to mutations alter the 
channel’s susceptibility to allosteric activation.  
2.2.8. Conclusions 
In this section we presented the NMR structures of the hGlyR-α1 TMD, the first structures 
for a mammalian anionic Cys-loop receptor TMD.  Using NMR and electron microscopy 
 57 
we demonstrated that the hGlyR-α1 TMD spontaneously forms pentameric Cl− 
conducting channels. While the structures of the hGlyR-α1 TMD share an overall topology 
with previously solved structures of pLGICs, several unique features were observed 
which are potentially relevant to the allosteric modulation of the channel. These features 
include a shorter helix of the pore-lining TM2 with helical unwinding near the C-terminal 
end, a TM3 helical kink at A288, and a highly dynamic segment between S267(15’) of 
TM2 and A288. The NMR structures of the hGlyR-α1 TMD provide valuable structural and 
dynamic templates for rationalizing dynamic modulation of anionic Cys-loop receptors 
and discovering novel therapeutic modulators.  
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CHAPTER 3  
ANESTHETIC BINDING SITES IN NICOTINIC 
ACETYLCHOLINE RECEPTORS 
3.1. ANESTHETIC SITES IDENTIFIED COMPUTATIONALLY  
This section has been published as a full article in J Phys Chem B 114: 7649-7655. 
3.1.1. Background and Significance 
The α7 and α4β2 nAChR subtypes are found in high abundance in the brain 8,9. Despite 
high sequence homology (α7 has 62% and 57% sequence homology with α4 and β2, 
respectively), they exhibit substantial differences in their responses to general volatile 
anesthetics. The α4β2 nAChR is sensitive to inhaled general anesthetics, while α7 is 
considerably less sensitive 5,6. 
The underlying cause for the different functional responses of α7 and α4β2 to 
general anesthetics remains unclear. Discovering the cause may advance the current 
understanding of anesthetic action on the α7 and α4β2 nAChR as well as homologous 
proteins. There are at least three possibilities that can contribute to the differences 
observed on α7 and α4β2. 1) Inhaled anesthetics interact with α4β2, but not with α7. 2) 
Anesthetics interact with both proteins, but in distinctive regions of the proteins and with 
different binding affinities. In this case, anesthetics may bind to functionally relevant 
regions in α4β2, while binding to functionally insensitive regions in α7. 3) Anesthetics act 
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similarly in both proteins, but α7 and α4β2 react differently to the perturbation of 
anesthetics due to their intrinsic structural and dynamic differences.  
Complementary to experimental efforts, computational approaches provide 
meaningful predictions that can be substantiated by experimental evidence. Modeling, 
MD simulations, and normal mode analysis (NMA) have illustrated structural and dynamic 
features for nAChRs and predicted plausible channel gating mechanisms 129-133. 
Computations have also provided insights for anesthetic binding to proteins and 
anesthetic effects on protein structures and dynamics 42,43,134-137.  
In this section, we investigated how the inhaled general anesthetic halothane 
interacted with the α7 nAChR over 20-ns MD simulations on the closed- and open-
channel α7 in the absence and presence of halothane molecules. In this section of the 
thesis we compare the computationally determined binding sites and energies for open- 
and closed-channel α7 with those previously determined for halothane binding in 
α4β2 42,43. Our computational model suggests that halothane binds to the α7 nAChR. The 
halothane binding sites in α7 were distributed in EC and TM domains as well as the 
EC/TM interface, similar to binding locations observed previously in α4β2 42,43.  
3.1.2. Methods 
The open- and closed-channel α7 systems were prepared using the same method 
reported previously 138. Briefly, the sequence of human α7 nAChR (P36544) was obtained 
from the ExPASy Molecular Biology Server (http://us.expasy.org) 139. The closed-channel 
α7 structure was gen erated by homology modeling using the structure of Torpedo 
marmorata nAChR 1 as a template (PDB ID: 2BG9). The resulting closed-channel α7 
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model was energy minimized for 10,000 steps with a 500 kcal/mol/Å2 harmonic restraint 
on its backbone atoms using NAMD 2.6 91 and evaluated subsequently using the 
PROCHECK program 140. The open-channel α7 was generated in the same way as we 
did previously for generating open-channel α4β2 nAChR 138. Elastic-network NMA 141 was 
performed on the closed-channel α7 nAChR using the online elNémo server 142. The 
lowest frequency eigenvectors, corresponding to a twist-to-open motion, were applied to 
the closed-channel α7 model through multiple cycles. In each cycle, heavy atoms of α7 
experienced only small displacements, the model was energy minimized, and the pore 
radius was evaluated using the Hole program 92. The final minimum pore radius at the 
hydrophobic girdle was 4.0 Å, which was close to the experimentally obtained value of 
3.7 Å for the open-channel 143. Two nicotine molecules were docked at the agonist-
binding sites for open-channel α7. The choice of nicotine rather than other agonists was 
based on our comparative studies on α4β2 42,43,138, in which nicotine was used as an 
agonist for the open-channel simulations because of its high affinity to α4β2 and the 
availability of the nicotine-bound AChBP crystal structure 30. The open- and closed-
channel α7 were separately immersed into a previously prepared water and lipids box 
138,144 and energy-minimized for 50,000 steps with a harmonic restraint of 500 kcal/mol/Å2 
on protein backbones. 
All MD simulations were performed using NAMD 2.6 91 and CHARMM27 force-field 
parameters 145. In order to be comparable with the simulations for α4β2 42,43, the constant 
pressure of 1 atm and the constant temperature of 303 K (NPT ensemble) were also 
applied to the α7 simulations. Each open- and closed-channel system first went to a NPT 
equilibration with an initial harmonic restraint of 250 kcal/mol/Å2 applied to the protein Cα 
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atoms. The restraint was gradually removed over a ~2 ns time period. The systems then 
went to unrestrained simulations for multiple ns before taking snapshots of the open- and 
closed-channel α7 for halothane docking. The docking to the α7 snapshots at four 
different time points (3.5, 4.5 5.5 and 6.5 ns) showed similarities (Figure 3.1.1 and Figure 
3.1.2). Halothanes present in the snapshot at 5.5 ns were carried on for additional 20-ns 
simulations. The subsequent 20-ns MD simulations were performed on four individual 
systems: a closed channel without halothane, a closed channel with halothane, an open 
channel without halothane, and an open channel with halothane. Each halothane system 
underwent two additional replica simulations with different random seeds, yielding three 
statistically independent trajectories for each halothane system. The same protocols 
reported previously were used for the MD simulations 42,138. Halothane parameters for 
docking and MD simulations were taken from our previous publication 146.  
The initial halothane sites in α7 were identified using Autodock4 147, through a 
Lamarckian genetic algorithm with a grid spacing of 0.375 Å. Structural snap shots of both 
closed- and open-channel α7 from the four previously mentioned time points were 
collected for halothane docking. We performed 500 independent halothane dockings on 
each of these structures. Based on the binding energies and occupancies from docking 
and similarity to the sites observed in Torpedo marmorata nAChR 41, five and four high 
halothane occupancy sites were determined for the open- and closed-channel α7, 
respectively. One halothane was manually placed at the interface of the EC and TM 
domains in the closed channel for the purpose of comparison with the open channel. 
Thus, five halothane molecules were present in both open- and closed-channel systems 
for MD simulations.  
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Halo-1closed was identified with high occupancy near the agonist-binding site. A 
similar site (close to δ212) was also identified by photoaffinity labeling experiments on the 
Torpedo marmarota nAChR 41. Halo-1open was found in three different snapshots with high 
occupancy and low binding energy. Halo-2 was found with high occupancy across all four 
structures in the closed channel and in 3 snapshots of the open channel. This site is 
consistent with the γ111 site in Torpedo marmarota nAChR 41. Halo-3 and halo-4 
represent the EC/TM interfacial sites found across almost all snapshots for both open- 
and closed-channel α7 (only halo-4 was manually put in the closed-channel for 
comparison). These sites were also consistent with the δ228 site identified in Torpedo 
marmarota 41. Halo-5 was found with high occupancy in all snapshots of the closed 
channel. But in the open channel, halo-5 was only observed in docking on a snapshot 
from 2.5 ns (data not shown) with occupancy of 105 of 500 and a binding energy of -3.35 
kcal/mol. We purposely kept a halothane molecule in this location in the open-channel 
structure at 5.5 ns to test if it behaved similar or different from Halo-5closed. Figure 3.1.1, 
Figure 3.1.2, Table 3.1.1, and Table 3.1.2 show and summarize halothane-docking 
results in the closed and open channels. 
Halothane binding energies (Gbinding) were calculated for each halothane site in 
both open- and closed-channel α7 using the Free Energy Perturbation (FEP) 148,149 
implementation in NAMD-2.6 91. The same calculation protocol used previously for the 
α4β2 systems 42 was adopted in the calculations for α7 systems except that the time step 
was changed from 2 fs to 1 fs. The Gbinding is the result of subtracting the free energy 
of ligand water interactions (GL,W) from that of ligand protein interactions (GP,L). 
VMD 86 was used for visualizing MD trajectories and generating figures. 
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Figure 3.1.1. Halothane docking results for the closed-channel α7 nAChR. Docking was performed on 
structures taken from four different time points of unrestrained MD simulation. Note the similarities of 
halothane docking sites among four snapshot structures. Halothanes present in the snapshot at 5.5 ns are 
carried on for subsequent simulation. Colors of halothane at different sites are the same as that in the main 
text (i.e halo-1 is blue, halo-2 is red, halo-3 is green, and halo-5 is magenta). Halothanes colored in gray 
are those that appear in the docking results but are not included for further simulation. Halothanes are 
numbered the same as that in Table 3.1.1. 
 
Table 3.1.1. Energies and Occupancies for Halothanes in Figure 3.1.1 
a Energies in kcal/mol 
b Occupancies based on 500 runs 
c Halothanes are numbered according to Figure 3.1.1 
 
  3.5 ns  4.5 ns  5.5 ns  6.5ns 
IDc  Energya Occupancyb   Energy
a Occupancyb  Energya Occupancyb  Energy
a Occupancyb 
1  -3.67 280  -3.46 230  -3.62 148  -3.50 206 
2   -3.66 101  -3.43 12  -3.57 37  -3.43 278 
3   -3.65 1  -3.33 13  -3.4 154  -3.33 1 
4   -3.55 66  -3.33 19  -3.29 126  -3.27 6 
5   -3.52 11  -3.32 106  -3.28 10  -3.27 1 
6   -3.49 1  -3.32 116  -3.23 1  -3.22 5 
7   -3.48 4  -3.31 3  -3.22 24  -3.22 2 
8   -3.42 33  -3.13 1     -3.20 1 
9   -3.23 2          
10   -3.23 1          
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Figure 3.1.2. Halothane docking results for the open-channel α7 nAChR. Docking was performed on 
structures taken from four different time points of unrestrained MD simulation. Note the similarities of 
halothane docking sites among four snapshot structures. Halothanes present in the snapshot at 5.5 ns are 
carried on for subsequent simulation. Colors of halothane at different sites are the same as that in the main 
text (i.e halo-1 is blue, halo-2 is red, halo-3 is green). The two green halothanes represent equivalent sites 
in different subunits. Halothanes colored in gray are those that appear in the docking results but are not 
included for further simulation. Halothanes are numbered the same as that in Table 3.1.2. 
 
Table 3.1.2. Energies and Occupancies for Halothanes in Figure 3.1.2 
  3.5 ns  4.5 ns  5.5 ns  6.5ns 
IDc  Energya Occupancyb  Energy
a Occupancyb  Energya Occupancyb  Energy
a Occupancyb 
1  -3.57 307  -3.4 88  -3.59 28  -3.50 206 
2  -3.44 8  -3.37 259  -3.59 406  -3.43 278 
3  -3.39 65  -3.34 37  -3.47 5  -3.33 1 
4  -3.37 19  -3.34 9  -3.37 15  -3.27 6 
5  -3.37 39  -3.32 22  -3.35 4  -3.27 1 
6  -3.36 29  -3.3 15  -3.31 32  -3.22 5 
7  -3.27 1  -3.26 66  -3.23 10  -3.22 2 
8  -3.25 1  -3.26 1     -3.20 1 
9  -3.25 1  -3.18 3       
10  -3.22 29          
11  -3.22 1          
a Energies in kcal/mol 
b Occupancies based on 500 runs 
c Halothanes are numbered according to Figure 3.1.2 
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3.1.3. Closed and Open-channel α7 Models  
 
Figure 3.1.3. The closed- (a) and open- (b) channel structures of α7 at the end of 20-ns simulations. 
For clarity, the lipids and water molecules in the simulation systems are not shown. Five halothane-binding 
sites, labeled 1-5 for each system, at the beginning and end of the simulations are highlighted with 
transparent and solid halothane molecules in VDW format, respectively. EC and TM domains are labeled 
and the EC/TM interface is marked with a dash line. 
 
The closed- and open-channel α7 models (Figure 3.1.3) were generated through 
the same strategy as used for previously constructing α4β2 nAChRs 138. Subunit packing 
and channel integrity were maintained over the course of 20-ns of simulation. RMSD of 
backbone atoms reached plateaus gradually in both conformations and stabilized in the 
last 7 ns of the simulations. At the end of the simulations, the pore radius at the 
hydrophobic girdle was ~4.0 Å and ~2.2 Å for the open channel and closed channel, 
respectively (Figure 3.1.4). The constricting residues for the closed channel were L256 
and to a lesser extent V252, in agreement with Law’s α7 model 130. Interestingly, the 
narrowest pore region (~3.0 Å radius) in our open-channel model occurred at residue 
T245, which is close to the IC end of the channel. In the narrow pore region, the hydroxyl 
group of T245 could interact effectively with an ion to facilitate partial desolvation of the 
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ion, and thus assist ion permeation through the pore. The pore profile with a wide-open 
EC entrance and a much narrower IC exit (presumably for Na+) for the open-channel of 
α7 is quite similar to that found in the X-ray structure of GLIC 27.  
 
Figure 3.1.4. Pore radius profiles for the closed- (blue) and open- (red) channel  α7 conformations 
at the end of 20-ns simulations. Plotted are the averages (solid) and standard deviations (dashed) of the 
pore radii calculated from 100 snapshots from the last 1 ns of simulation. The locations of pore lining 
residues are labeled. 
3.1.4. Halothane in α7  
Although previous experiments suggested that halothane had no functional impact on the 
α7 nAChR 5,6, we found multiple halothane binding sites in both the closed- and open-
channel α7 nAChR (Figure 3.1.3). Most halothane molecules did not move significantly 
away from their initial positions during the simulations. The binding energies of halothane 
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molecules at their final sites of the first 20-ns simulations were calculated using the FEP 
method and summarized in Table 3.1.3.  
 
Table 3.1.3. Binding energies and disassociation constants of halothane in closed- and open-channel α7 
calculated using FEP based on the first simulation 148,149.  
Site ID Binding Energy (kcal/mol) Kd (mM) 
 open Closed open Closed 
halo-1 -6.3 -3.1 2.9 x 10-2 5.8 
halo-2 -3.7 -2.7 2.1 11.3 
halo-3 -5.3 -7.0 1.5 x 10-1 8.9 x 10-3 
halo-4 -2.9 -6.8 8.1 1.2 x 10-2 
halo-5 -7.3 -8.7 5.4 x 10-3 5.3 x 10-4 
 
Several features are noteworthy. First, halothane-binding sites sampled all 
representative regions of the α7 nAChR, including the EC and TM domains and the 
EC/TM interface. Second, most binding sites were at comparable locations in the closed- 
and open-channel α7 nAChR. Third, halothane binding energies varied significantly 
among individual sites. Halo-5, surrounded primarily by non-polar residues at the 
intracellular end of the TM domains, showed the lowest binding energy in both channel 
conformations. Halo-3 and halo-4 at the EC/TM interface exhibited lower binding energies 
in the closed channel than in the open channel. However, halo-1 and halo-2 in the ECD 
had lower binding energies in the open channel. Collectively, the variation in binding 
energies reflected differences in local binding environments.  
Despite the existence of multiple halothane sites in α7, the pattern of halothane-
binding sites in α7 did not show the five-fold symmetry that one might expect from a 
homopentamer, such as the α7 nAChR. This is understandable if one considers 
asymmetric motion in α7 129,131,150. Asymmetric anesthetic bindings in a highly symmetric 
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protein assembly were also observed in high-resolution X-ray structures of apoferritin 
complexed with anesthetics 135,151, in which subtle motion-induced changes at potential 
binding sites might differentiate one equivalent site from another.  
3.1.5. Comparison of halothane binding between α7 and α4β2  
Multiple halothane sites in the α4β2 nAChR were identified by our previous computational 
studies 42,43. The existence of halothane binding sites in α4β2 was in good agreement 
with the finding that the channel function of the α4β2 nAChR could be inhibited by 
halothane 5,6. In the case of the α7 nAChR, on which halothane showed no obvious impact 
in electrophysiology measurements 5,6, one might expect no significant halothane binding. 
However, our data suggested multiple binding sites in α7. Moreover, halothane binding 
energies in α7 were comparable with those in α4β2. One potential explanation for the 
discrepancy is that the halothane sites exclusive to α4β2 may hold primary responsibility 
for producing functional inhibition. It is, therefore, noteworthy that α4β2 had halothane 
binding sites in the TM domains toward the EC end, either between the α4 and β2 
subunits or within a β2 subunit, with Kd values less than 0.2 mM 42,43, while equivalent 
sites did not exist in α7. 
3.1.6. Conclusions 
Our study revealed several important points regarding anesthetic binding to the α7 
nAChR. First, lack of sensitive functional responses of the α7 nAChR to halothane in 
previous experiments is unlikely due to lack of halothane interaction with α7. Multiple 
halothane binding sites were observed in both closed- and open-channel α7. Some of the 
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sites have fairly high binding affinities. Second, the binding sites and affinities of 
halothane in α7 are dependent on the protein conformation. Overall halothane affinity was 
higher in the closed-channel α7, similar to previous observations of α4β2 42,43. Finally, 
while many of the sites observed in α7 and α4β2 overlapped, sites were observed at the 
EC end of the TMD in α4β2, which were not present in α7.  
3.2. HALOTHANE AND KETAMINE BINDING SITES IN 42 DERIVED BY NMR  
This section has been published as a full article in Biochim Biophys Acta 1828 (9): 398-
404.  
3.2.1. Background and Significance 
Cys-loop receptors, including nAChRs, are important targets of general anesthetics 
152,153. Among the many nAChR subtypes, the α4β2 nAChR is one of the most abundant 
subtypes in the brain 8. It is involved in memory 16, nociception 17, and the autonomic 
response 18. It is highly sensitive to a variety of general anesthetics. Its current is inhibited 
by both volatile and intravenous general anesthetics at clinically relevant concentrations 
5,6,154.  
To reveal the underlying mechanism of anesthetic inhibition of a channel protein, 
an essential task is to identify where anesthetics bind to the protein. Mutagenesis has 
been widely used to determine residues showing different functional responses to 
anesthetics before and after mutations 55,155,156. Such an approach is useful, but it is 
difficult to differentiate direct binding from allosteric action. Photoaffinity labeling has 
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emerged as a powerful tool for identifying specific protein residues participating in 
anesthetic binding 41,153,157-160. Analogues of halothane 41, etomidate 75,159,161, and a 
neurosteroid 157 have been used in photoaffinity labeling studies of the Torpedo nAChR 
or the GABAA receptor. Multiple anesthetic binding sites were identified in the TM 
domains and other regions of these receptors. Despite considerable progress in 
developing new anesthetic analogues for photolabeling 162-164, the choices of anesthetics 
for photolabeling are still limited. In addition, large hydrophobic patches within the TMD 
often hinder amino acid sequencing and have made it difficult to determine specific 
photolabeled residues in some channel proteins. X-ray crystallography can offer high-
resolution structural information for anesthetic binding. A critical issue is whether a high 
quality crystal is attainable for the protein of interest. Structural determination of 
eukaryotic Cys-loop receptors remains a great challenge, but recent successes on 
structures of prokaryotic homologues are encouraging 26-29. Crystal structures of the 
ligand-bound ELIC 120,165 and the anesthetic desflurane- or propofol-bound GLIC 106, shed 
light on molecular recognition of general anesthetics in Cys-loop receptors. NMR 
spectroscopy is yet another powerful technique for structure determination of ion 
channels 36,66,111,166 and probing protein-ligand interactions at the atomic level. Using 
NMR, we have identified specific sites of anesthetic interaction with the TM domains of 
several proteins 93,113,167-171.  
In this study, we used NMR spectroscopy to examine the plausible binding sites of 
the volatile general anesthetic halothane and the intravenous general anesthetic 
ketamine within the TM domains of the α4β2 nAChR. We previously determined the 
structures of the entire TM domains of the α4 and β2 nAChRs in LDAO detergent micelles 
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by solution NMR 36. The high-resolution structure of the α4β2 TMD discussed in Section 
2.1 provides an excellent platform for investigating anesthetic binding sites that may be 
responsible for anesthetic inhibition of the α4β2 nAChR. The knowledge of anesthetic 
binding sites within the nAChR TM domains is essential for solving the mystery of 
anesthetic modulations of the α4β2 nAChR and other Cys-loop receptors. 
3.2.2. Methods 
 Sample Preparations 
Expression and purification of the human α4 and β2 nAChR TM domains as well as the 
NMR sample preparation were reported in detail recently 36. The same protein expression 
and purification protocols were used for the current study. Each NMR sample contained 
0.25-0.3 mM protein, 1-2 % (40-80 mM) LDAO detergent, 5 mM sodium acetate pH 4.7, 
10 mM NaCl, and 20 mM 2-mercaptoethanol to prevent disulfide bond formation. 5% D2O 
was added to the samples for deuterium lock in NMR measurements. To keep adequate 
NMR spectral resolution, two types of the NMR samples were prepared for investigating 
anesthetic binding. One is β2(α4), in which β2 is 15N-labeled (NMR observable) and mixed 
with the unlabeled α4 (invisible in 15N NMR) in a 3:2 molar ratio. Another type is α4(β2) 
that has α4 15N-labeled and mixed with unlabeled β2 in a 3:2 molar ratio. In these 
individually labeled α4β2 samples, α4 and β2 retained their assembling interfaces and 
gained better NMR spectral resolution. The anesthetics ketamine or halothane were 
titrated to the samples using a micropipette or a gas-tight microsyringe, respectively. The 
ketamine concentration in the NMR samples was calculated based on the concentration 
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of a stock solution. The halothane concentration was quantified based on 19F NMR using 
the method reported previously 170.  
 
NMR data acquisition, processing, and analysis  
NMR spectra were acquired on Bruker Avance 600, 700, or 800 MHz spectrometers at 
45 ºC. Each spectrometer was equipped with a triple-resonance inverse-detection 
cryoprobe, TCI (Bruker Instruments, Billerica, MA). 1H-15N TROSY-HSQC spectra were 
acquired for each sample before and after adding anesthetics. Concentrations of 
halothane and ketamined used for the NMR experiments were up to 8 and 0.3 mM, 
respectively. Spectral windows of 13 ppm (1024 data points) in the 1H dimension and 22 
or 24 ppm (128 data points) in 15N dimension were used. One second relaxation delay 
was used. The specific α4 and β2 residues affected by anesthetic binding were identified 
based on chemical shift changes induced by anesthetics. Since halothane has a distinct 
proton resonance that is suitable for saturation transfer used to determine halothane 
binding sites, we also performed 2D saturation transfer experiments using a modified 
HSQC pulse sequence 168 on the β2(α4) and α4(β2) samples containing ~2.0 mM 
halothane that has a distinct proton resonance. The spectra were acquired in an 
interleaved fashion with on- and off-1H resonance frequencies of 6.48 ppm (the halothane 
proton) and 15 ppm (blank), respectively. The selective saturation was achieved using an 
IBURP2 pulse train (50 ms Gaus1.1000-shaped or rectangular pulses with an interpulse 
delay of 4 μs). A total saturation time was one sec and a relaxation delay was 1.5 sec. 
The 1D saturation transfer difference experiments 172 were performed to confirm that the 
saturation parameters used in 2D experiments were chosen properly. The 1H chemical 
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shifts were referenced to the DSS resonance at 0 ppm and the 15N chemical shifts were 
indirectly referenced 78. 
NMR data were processed using NMRPipe 4.1 and NMRDraw 1.8 82, and analyzed 
using Sparky 3.10 83. Each processed spectrum had 4096  512 data points. 1H and 15N 
chemical shift assignments for the α4 and β2 TM domains after addition of anesthetics 
were referenced to the previous assignments for the same proteins without drugs 36. The 
published pentameric models of α4β2 and the MATLAB® programming environment were 
used to analyze interactions between anesthetics and α4β2. Chemical shifts and peak 
intensities in the NMR spectra were measured using Sparky 3.10 83.  
 
Visualization of anesthetics in the α4β2 nAChR 
To assist visualizing anesthetics in the NMR identified binding sites, we performed 
targeted docking of halothane or ketamine to our previously reported α4β2 model. The 
targeted docking kept only those sites consistent with the NMR results. Docking was 
performed with Autodock4 147 using a Lamarckian genetic algorithm with a grid spacing 
of 0.402 Å. For each intra-subunit site suggested by the NMR data, 250 independent 
anesthetic dockings were performed within a cube covering ~9000 Å3 located at either 
the EC or IC end of the TMD. For each inter-subunit site, 500 independent anesthetic 
dockings were performed within a ~21x 21 x 42 Å rectangular prism covering the length 
of the inter-subunit interface. 
 74 
3.2.3. Multiple halothane interaction sites in the α4β2 nAChR 
Halothane bound to inter- and intra-subunit cavities of the α4β2 TM domains. As exhibited 
in the 1H-15N HSQC spectra in Figure 3.2.1, the majority of residues were not affected 
when 2mM halothane was added to either the α4(β2) or the β2(α4) samples. However, 
some residues had obvious changes in chemical shift. Full assignments of the NMR 
spectra showing halothane effects are provided in the online supporting material of the 
published manuscript 39. Direct interactions between halothane and α4β2 were further 
demonstrated in 2D saturation transfer experiments 173,174 (Figure 3.2.2). After the residues 
showing changes either in chemical shift or saturation transfer were mapped onto the 
structure of α4β2 (Figure 3.2.3), the halothane interaction sites became apparent. The β2 
subunit has two intra-subunit halothane binding sites near the EC and IC ends of the 
TMD. The closeness of hydrogen atoms of halothane to Y212 and V262 (site #1 in Figure 
3.2.3) and to T224 and F231 (site #2) facilitated the observed saturation transfer (Figure 
3.2.2). The α4 subunit also has an intra-subunit halothane site (#3) near the IC end of the 
TMD. Halothane near the EC end of the α4 TMD (#4) more or less resided between intra- 
and inter-subunit site, where residues I268 and N221, L222 of α4 and K260 and V262 of 
β2 line the cavity. It appears that #4 is open for halothane to sample both intra- and inter-
subunit cavities. Another inter-subunit site for halothane (#5) is supported by I450 of β2 
and L283 of α4, where saturation transfer was observed (Figure 3.2.2).  
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Figure 3.2.1. NMR spectra of the α4β2 nAChR TMD in the absence (black) and presence (green) of 
2 mM halothane. (a) α4(β2), where only α4 is 15N-labeled; (b) β2(α4), where only β2 is 15N-labeled.. Peaks 
displaying significant changes in chemical shift are circled. 
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Figure 3.2.2. The 2D saturation transfer experiment showed specific interactions between halothane 
and residues of α4β2. (a) Overlay of the α4(β2) spectra with (green) and without (red) saturation of the 
proton resonance of halothane (2 mM). (b) Overlay of the β2(α4) spectra with (green) and without (black) 
saturation of the proton resonance of halothane (2 mM). The labeled resonance peaks showed significant 
intensity decrease when the proton resonance of halothane was saturated.  
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Figure 3.2.3. Multiple halothane-binding sites in the α4β2 nAChR. The TM domains of α4 and 2 are 
colored in yellow and silver, respectively. Residues of α4 (green) and β2 (orange) are highlighted in the 
surface presentation if they show direct interactions with halothane in the 2D saturation transfer 
experiments or in the stick presentation if they show changes in chemical shift upon halothane binding. The 
docked halothane molecules are numbered and shown in light gray. Note the inter-subunit sites, #4 and 
#5. 
 
Collectively, both α4 and β2 have intra-subunit binding sites for halothane. The 
intra-subunit sites near the EC end and the IC end are homologous to the anesthetic site 
identified in the X-ray structures of GLIC 106 and a neurosteroid photolabeling site in the 
β3 subunit of the GABAA receptor 157, respectively. In addition to the intra-subunit sites, 
our NMR data revealed existence of inter-subunit sites for anesthetic binding. The inter- 
and intra-subunit sites identified at the EC end of the TMD are analogous to sites identified 
in our previous computational studies 42,43. 
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3.2.4. Ketamine interaction sites in the α4β2 nAChR 
Compared to volatile anesthetics, such as halothane, the intravenous anesthetic 
ketamine inhibits the function of the α4β2 nAChR at a lower concentration 45. We added 
only 80 μM ketamine to the α4(β2) or β2(α4) samples and observed notable changes in 
chemical shift for several residues in 1H-15N HSQC spectra (Figure 3.2.4) Full 
assignments of the NMR spectra showing ketamine effects are provided in the online 
supporting material of the published manuscript 39. Severe overlapping of proton signals 
of ketamine and protein prevented a reliable result from saturation transfer difference 
experiments. Thus, the ketamine sites were determined based on chemical shift 
perturbation. Two ketamine-binding sites emerged when the ketamine-perturbed 
residues were mapped onto the NMR structure of α4β2 (Figure 3.2.5). One is reminiscent 
of the intra-subunit halothane site near the EC end of the TMD in β2 (Figure 3.2.3). 
Another is located near the IC end of the TMD between β2 and α4, where ketamine 
contacts I287 of β2 and V234 of α4. Ketamine perturbation to these residues propagated 
to other more remote residues (V283 and K246) and caused changes in their chemical 
shifts.  
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Figure 3.2.4. NMR spectra of the α4β2 nAChR TMD in the absence (black) and presence (green) of 
80 μM ketamine. (a) α4(β2), where only α4 is 15N-labeled; (b) β2(α4), where only β2 is 15N-labeled. Peaks 
displaying significant changes in chemical shift are circled. 
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Figure 3.2.5. Ketamine-binding sites in the α4β2 nAChR. The TM domains of α4 and β2 are colored in 
yellow and silver, respectively. The residues of α4 and β2 showing changes in chemical shift upon ketamine 
binding are highlighted in green and orange sticks, respectively. The docked ketamine molecules are 
numbered and shown in light gray. 
3.2.5. A common general-anesthetic binding site near the EC end of the TMD 
Both the inhalational anesthetic halothane and the intravenous anesthetic ketamine have 
multiple interaction sites in the TM domains of the α4β2 nAChR. This finding is in accord 
with previous computational predictions 42-44,175,176 and experimental 
observations 41,158,159,177 on the α4β2 nAChR and its homologous proteins.  
Among different sites, the intra-subunit binding site near the EC end of the TM 
domain (#1 in Figure 3.2.3 and Figure 3.2.5) has been most substantiated by experiments 
on several homologous proteins. Photo-affinity labeling of [14C] halothane to the Torpedo 
nAChR was identified on residue δ-Y228 41, which is homologous to Y212 of β2 lining  
halothane site #1 (Figure 3.2.3). Fluorescence quenching experiments suggested 
halothane binding to an equivalent site in GLIC 177. Furthermore, crystal structures of 
GLIC in complex with the anesthetics desflurane and propofol revealed the intra-subunit 
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anesthetic binding site 106 that is in remarkable agreement with our NMR identified site 
for halothane or ketamine in the β2 subunit (Figure 3.2.6). It is intriguing to see that in the 
absence of the ECD, the TMD alone presents the same anesthetic binding site as the 
intact homologous proteins. Such a finding indicates that the NMR structures of the α4β2 
TM domains 36 well represent the same domains in the intact protein. Halothane and 
ketamine have very different molecular volumes and shapes. Their binding to the EC end 
of the α4β2 nAChR TMD not only supports the notion that the site is a common anesthetic 
binding site for pLGICs 106, but also demonstrates the flexibility of the cavity to 
accommodate different anesthetics. 
 
Figure 3.2.6. Comparisons of the intra-subunit anesthetic binding sites within the β2 subunit (silver) 
with the crystal structures of the anesthetic-bound GLIC (white, transparent). (a) The NMR 
determined residues showing halothane cross-saturation (orange ball and stick representation) as well as 
changes in chemical shift (orange sticks) are in remarkable agreement with the X-ray determined binding 
position for desflurane (magenta). (b) Likewise, residues showing changes in chemical shift in response to 
ketamine binding agree well with the binding position of propofol (purple) in GLIC. 
3.2.6. Additional anesthetic binding sites 
Inter-subunit halothane binding sites at the interface of α4 and β2 (#4 and #5 in Figure 
3.2.3) are almost at the same height as the intra-subunit halothane site at the upper part 
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of the TMD. Several residues lining these sites were implicated previously as anesthetic-
labeling residues in homologous proteins. L283 at the inter-subunit halothane-binding site 
is homologous to A288 of the α1 glycine receptor, where the site for alcohol and 
anesthetic action was rationalized 55,178. Although the X-ray structures of GLIC bound with 
desflurane or propofol revealed only the intra-subunit anesthetic binding site, the study 
recognized the possibility of anesthetic migration from intra- into inter-subunit cavities 106. 
The NMR identified halothane sites (#4 and #5) in Figure 3.2.3 add compelling evidence 
for anesthetic binding to the inter-subunit cavities. Ketamine, however, did not appear in 
the inter-subunit cavities at the upper part of the TMD. The larger size of ketamine may 
have prevented the molecule from occupying both intra- and inter-subunit cavities.   
Another discrete set of intra- or inter-subunit cavities for anesthetic binding was 
found at the IC end of the TM domains. Halothane or ketamine binding to this region of 
the α4β2 nAChR was observed for the first time, but halothane binding to the homologous 
region in GLIC (W213 and W217) was detected previously using fluorescence quenching 
177. The region at the IC end of the TMD was also observed for cholesterol binding in the 
Torpedo nAChR 179. Neurosteroids modulate GABAA receptors via binding to the TM 
domains of the receptors 155,180. A neurosteroid-binding site at the IC end of the TMD was 
recently indentified 157, highlighting the importance of this region in drug binding and 
modulation of channel function.  
It is worth noting that anesthetic binding is not restricted to the TMD. Anesthetics 
may also bind to cavities in the ECD. A recent crystal structure of GLIC in complex with 
ketamine shows that ketamine binds to an inter-subunit cavity in the ECD and the 
ketamine binding inhibits GLIC current 47. For the α4β2 nAChR TMD, in the absence of 
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the ECD, the channels formed exhibit spontaneous opening and closing 36. The degree 
to which anesthetics increase the channel closing probability and which binding site plays 
the most critical role in channel inhibition need to be investigated in future studies. 
3.2.7. Conclusions 
The study revealed multiple anesthetic binding sites in the TM domains of the α4β2 
nAChR. The identified intra-subunit halothane and ketamine sites near the EC end of the 
TM domains are reminiscent of the previously reported site on homologous proteins 41,106, 
supporting the notion that the site identified is a common anesthetic site. The inter-subunit 
sites near the EC end of the TM domains were observed for halothane but not for 
ketamine. It is noteworthy that both intra- and inter-subunit binding sites at the EC end of 
the TMD were identified in previous computational studies 42,43. The sites near the IC end 
of the TM domains were least documented for anesthetic binding in the literature. The 
finding of halothane and ketamine at these sites in our NMR study adds more weight to 
this region.  
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3.3. HALOTHANE AND KETAMINE BINDING SITES IN 7 DERIVED BY NMR  
This section has been accepted for publication as a full article in Biochim Biophys Acta.  
3.3.1. Background and Significance 
The α7 nAChR is one of the most abundant nAChR subtypes in the brain 3. High 
expression levels of the α7 nAChR have been observed in brain regions involved in 
learning, memory, and cognition 63,64. Therefore, the α7 nAChR is a viable target for 
therapeutics to regulate processes impaired in schizophrenia, Alzheimer's disease, and 
other neurological disorders 65,181.  
Unlike the α4β2 nAChR discussed in the previous section, which is highly sensitive 
to the general volatile anesthetic halothane, the α7 nAChR is insensitive to halothane 5,6. 
Despite this discrepancy in sensitivities, our previous computational study identified 
halothane-binding sites in α7, suggesting that the insensitivity of α7 to halothane is 
unlikely due to the lack of halothane binding 44. For the intravenous anesthetic ketamine 
the scenario is somewhat reversed, where the α7 nAChR is more sensitive to ketamine 
inhibition than the α4β2 nAChR 45,46. 
In this study we determined binding sites for the volatile anesthetic halothane and 
the intravenous anesthetic ketamine in the α7 nAChR TMD using NMR spectroscopy. 
The high-resolution structure of the α7 TMD discussed in the previous chapter was used 
as the platform for investigating anesthetic binding sites within the α7 nAChR TMD. As 
predicted by the previous computational project we identified specific halothane binding 
sites in the α7 TMD. Identification of anesthetic binding sites for both halothane and 
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ketamine provides insights into understanding the mechanism anesthetic modulations for 
nAChRs and other Cys-loop receptors. 
3.3.2. Methods 
 Sample preparations 
The human α7 nAChR TMD for the NMR study contained 137 residues (Figure 2.1.1). 
The same protocol as reported previously 36 was used for the α7 expression and 
purification. The protein was expressed in E. coli Rosetta 2(DE3) pLysS (Novagen) at 15 
°C for three days using the Marley protocol 76. The protein was purified in LDAO using 
his-tag affinity column before and after cleavage of the his-tagged region. Each NMR 
sample contained 0.25-0.3 mM α7, 1-2 % (40-80 mM) LDAO detergent, 5 mM sodium 
acetate at pH 4.7, 10 mM NaCl, and 20 mM 2-mercaptoethanol to prevent disulfide bond 
formation. 5% D2O was added for deuterium lock in NMR experiments. The anesthetics 
ketamine (80-240 μM) or halothane (0.7-5.5 mM) were titrated into the samples using a 
micropipette or a gas-tight microsyringe, respectively. The concentration of the volatile 
anesthetic halothane was quantified based on 19F NMR using the method reported 
previously 170.  
 
NMR spectroscopy 
NMR spectra were acquired on Bruker Avance 600 MHz spectrometers at 45 ºC using 
triple-resonance inverse-detection cryoprobes (Bruker Instruments, Billerica, MA). 1H-15N 
TROSY-HSQC spectra were acquired in the absence and presence of the anesthetics 
halothane or ketamine. Direct contacts of halothane with the α7 TMD were determined 
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by STD spectra 172. 2D saturation transfer spectra 168 were acquired in the presence of 
3.2 mM halothane in an interleaved fashion with on- and off-1H resonance frequencies of 
6.48 ppm (the halothane proton frequency) and 25 ppm (blank), respectively. The 
selective saturation was achieved using an IBURP2 pulse train (50 ms Gaus1.1000-
shaped with an interpulse delay of 4 μs). The total saturation time was 2 s and a recycle 
delay was 3 s. The 1H chemical shifts were referenced to the DSS resonance at 0 ppm 
and the 15N and 13C chemical shifts were referenced indirectly 78. 
NMR data were processed using NMRPipe 4.1 and NMRDraw 1.8 82 and analyzed 
using Sparky 3.10 83. 1H, 15N, and 13C chemical shift assignments were performed 
manually.  
 
Visualization and molecular docking of anesthetics in the α7 nAChR  
To assist with visualizing halothane- and ketamine-binding sites identified by NMR 
experiments, we performed targeted anesthetic docking to the α7 NMR structures. The 
targeted docking kept only those sites consistent with the NMR results. Docking was 
performed with Autodock4 147 using a Lamarckian genetic algorithm with a grid spacing 
of 0.375 Å. For each binding site suggested by NMR, 250 independent anesthetic 
dockings were performed within a cube covering ~6600 Å3 located at the IC end of the 
TMD. Each docking calculation used an initial population size of 500. 
3.3.3. Halothane binding site in the human α7 nAChR TMD  
To identify residues that directly interact with halothane, we performed 2D saturation 
transfer NMR experiments. In these experiments, spectra for the α7 nAChR TMD in the 
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presence of halothane were acquired in an interleaved fashion with 1H saturation 
frequencies at 6.48 ppm (halothane proton) and 25 ppm (blank), respectively. When 
halothane was saturated, residues showing substantial decrease in their peak intensities 
should be in close contact with halothane (Figure 3.3.1a). These residues include F230 
in TM1, K239 in TM2, and F453 and C449 in TM4. The full spectra of the 2D saturation 
transfer experiments are provided in the online supporting material of the manuscript 37. 
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Figure 3.3.1. Halothane binding sites in the α7 nAChR TMD. (a) Overlay of 2D saturation transfer NMR 
spectra of α7 acquired with 1H saturation frequency on (cyan) and off (purple) the proton resonance of 
halothane (3.2 mM). Residues showing considerable decreases in their peak intensities upon saturation of 
the halothane signal are labeled. (b) Overlay of 1H-15N TROSY-HSQC spectra of α7 in the absence (red) 
and the presence (green) of halothane (1.7 mM). Residues showing significant changes in chemical shift 
or relative peak intensity are labeled. (c) Side and (d) top views of the α7 structure highlighting the residues 
affected by halothane in (a) and (b) using purple and blue sticks, respectively. Two halothane molecules 
are shown in silver surface. 
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1H-15N TROSY HSQC spectra of α7 were acquired in the absence and presence 
of halothane (Figure 3.3.1b). Full assignments of the NMR spectra showing halothane 
effects are provided in the online supporting material of the published manuscript 37. After 
the addition of halothane residues C219, V220, S223 of TM1, K239 of TM2, and T289 of 
TM3, were noted to show changes observable in the HSQC spectra. When these residues 
along with those identified in saturation transfer experiments were mapped onto the α7 
structure, halothane binding to an intra-subunit cavity became clear (Figure 3.3.1c). The 
cavity is large enough to host two halothane molecules. This site is similar to one of the 
sites observed in the α4β2 nAChR 39. However, unlike α4β2, α7 does not have halothane 
bound to the EC end of the TMD. The different binding sites may account for high 
functional sensitivity of the α4β2 nAChR and low functional sensitivity of α7 nAChR to 
halothane 5,182.  
3.3.4. Ketamine binding sites in the human α7 nAChR TMD 
Because the ketamine signal overlaps with the α7 signal in the 1H spectra, the saturation 
transfer experiments could not be performed. Thus, we compared the α7 1H–15N TROSY 
HSQC spectra in the absence and presence of ketamine to identify ketamine binding 
sites. Residues showing significant changes in the spectra after the addition of ketamine 
are highlighted (Figure 3.3.2a) and mapped onto the α7 structure (Figure 3.3.2b). Full 
assignments of the NMR spectra showing ketamine effects are provided in the online 
supporting material of the manuscript 37. Most residues affected by ketamine are located 
in the lower half of the TMD, similar to the case for halothane (Figure 3.3.1c). It is 
noteworthy that the binding sites for ketamine and halothane largely overlap, but each 
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drug perturbed different residues within the relatively large cavity near the IC end of the 
α7 TMD. For example, F453, S285, I217, and L248 displayed chemical shift changes 
upon addition of ketamine, yet similar changes for these residues were not observed 
when halothane was added to the sample (Figure 3.3.1b). Conversely, C219, S223, and 
T289 showed chemical shift changes upon the addition of halothane, but not ketamine. 
Only a single ketamine molecule can fit into the cavity because of the larger molecular 
volume of ketamine. In contrast, the cavity can host two halothane molecules 
simultaneously.  
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Figure 3.3.2. Ketamine binding site in the α7 nAChR TMD. (a) Overlay of 1H-15N TROSY-HSQC spectra 
of α7 in the absence (red) and the presence (green) of 80 μM ketamine. Residues involved in ketamine 
binding demonstrated significant changes in chemical shift or peak intensity. They are highlighted in circles 
and labeled with the one-letter amino acid code and the sequence number. (b) Side and (c) top views of 
the α7 structure highlighting the residues (blue sticks) perturbed by ketamine (gray surface) binding. 
3.3.5. Conclusions 
In this section we revealed the sites of binding for anesthetics ketamine and halothane in 
the TMD of the α7 nAChR. In contrast to our previous observations for the α4β2 nAChR 
TM domains, neither anesthetic binding was observed to bind at the EC end of the α7 
nAChR TMD. Rather, anesthetics halothane and ketamine were observed to bind to an 
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intra-subunit cavity located at the IC end of the α7 TMD. This result is consistent with our 
previous computational prediction 44, where halothane was observed to bind at the IC end 
of the α7 TMD, but was not observed to bind at the EC end of the α7 TMD. Our finding 
here provides experimental evidence for anesthetic binding in α7 similar to that observed 
in our computational study 44.  
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CHAPTER 4   
FUNCTIONALLY RELEVANT ANESTHETIC BINDING SITES 
4.1. COMPUTATIONAL DETERMINANTS OF ANESTHETIC SENSITIVITY 
This section has been published as a full article in J Phys Chem B 114: 7649-7655.  
4.1.1. Background and Significance 
The α7 and α4β2 nAChRs show distinct sensitivities to the general volatile anesthetic 
halothane. The α4β2 nAChR is sensitive to halothane, while α7 is insensitive 5,6. The 
underlying cause for these different functional responses has remained unclear. As has 
been discussed, at least three scenarios could produce the differences observed between 
α7 and α4β2. (1) Halothane interacts with α4β2, but not with α7. (2) Halothane interacts 
with both proteins, but in distinct regions. (3) Halothane binds to similar regions in both 
proteins, but α7 and α4β2 react differently to the anesthetic perturbation. As discussed in 
Chapter 2, scenario 1 is unlikely as both computational and experimental results suggest 
that halothane binds to α7. As the previous studies show the presence of both distinct 
and overlapping halothane binding sites between α7 and α4β2, scenarios 2 and 3 are 
both still valid. 
In this section of the thesis, we continued our previous computational study to 
investigate how halothane binding affected the closed- and open-channel α7 nAChR over 
20-ns MD simulations. To determine why α7 is much less sensitive than α4β2 to 
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anesthetic inhibition, the effects of halothane on the α7 structure and dynamics were 
compared with the data from previous MD simulations on α4β2 42,43. The correlated 
motion between EC and TM domains, particularly at the EC/TM interface, was found 
resilient to halothane perturbation in α7 and α4, but not in β2. Because of its unique 
EC/TM interface, the β2 subunits may bring the α4β2 nAChR to react more sensitively to 
halothane disturbance. The importance of the interface of the EC/TM interface to channel 
function was revealed by MD simulations and various experiments 183-185. Dynamic 
susceptibility to halothane perturbation in the β2 subunit has been perceived as a reason 
why α4β2 is functionally more sensitive to halothane than α7. 
4.1.2. Methods 
Setup of MD simulations is described previously in section 3.1.2. Below are details for 
computational analyses of the simulation systems discussed in this section. 
The Gaussian network model (GNM) 186,187 was used to analyze if halothane had 
any effect on the global dynamics of the α7 nAChR. Cα atoms represented residues and 
the interactions were cutoff at 10 Å. The five slowest modes of the GNM calculations on 
the structures after 20-ns MD simulations were included in the data analysis.  
The pore radius profiles were obtained using the HOLE program 92 with a step size 
of 0.25 Å along the pore axis. Average profiles for both open- and closed- channel α7 
were calculated using 100 frames from the last 1-ns simulation. The water profiles within 
the pore at each simulation time point were calculated by counting the number of water 
molecules within 2.5 Å windows along the pore axis. Each reported water profile resulted 
from the average of profiles at 100 time points over the last 1 ns of simulation.  
 95 
The VMD program 86 was used for visualizing MD trajectories, generating figures, 
and calculating RMSD and root mean square fluctuation (RMSF). RMSF was calculated 
on the data sampling the last 7 ns simulations of the α7 systems. For comparison, the 
same data analysis was also performed on the α4β2 data acquired previously 42,43. 
4.1.3. Differences of halothane behavior in α7 and α4β2.  
Multiple halothane sites in the α4β2 nAChR were identified by our previous computational 
studies 42,43. The existence of halothane binding sites in α4β2 is in good agreement with 
the finding that the channel function of the α4β2 nAChR could be inhibited by halothane 
5,6. In the case of the α7 nAChR, on which halothane showed no obvious impact in 
electrophysiology measurements 5,6, one might expect no significant halothane binding. 
However, our data suggested multiple binding sites in α7. Moreover, halothane binding 
energies in α7 were comparable with those in α4β2.  
How can halothane molecules act on α7 differently from α4β2 to induce different 
functional impacts? First, the halothane sites exclusive to α4β2 may hold primary 
responsibility for producing functional inhibition. α4β2 had halothane binding sites in the 
TM domains toward the EC end, either between the α4 and β2 subunits or within a β2 
subunit, with Kd values less than 0.2 mM 42,43, while equivalent sites did not exist in α7. 
Second, it is possible that different functional responses may result from intrinsic 
differences in the structural and dynamic properties of α7 and α4β2 to similar halothane 
bindings. Our previous studies demonstrated that a halothane-binding site similar to halo-
3 or halo-4 in Figure 3.1.3 could elicit considerable structural and dynamic changes in β2, 
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but not in α4 42,43. If α7 is similar to α4 in its structural and dynamic responses to halothane 
binding, insensitive functional response to halothane binding in α7 should be anticipated.  
4.1.4. Distinct response of the EC/TM interfacial structure and dynamics to 
halothane binding between α7 and β2.  
Interactions of the TM2-TM3 linker with the Cys loop and the β1-β2 linker at the EC/TM 
interface are critical for propagating signals of agonist binding in the EC domain to 
channel gating in the TM domains 138,188-192. We found previously that such interactions 
in β2 were much more susceptible to halothane perturbation than those in α4 42,43. In this 
study, we noticed that α7 more closely resembled α4, bearing similar resilience to 
halothane binding at the EC/TM interface.  
Figure 4.1.1 compares representative EC/TM interfacial structures of the α7, α4, 
and β2 subunits in the open-channel conformations in the absence and presence of 
halothane at the end of 20-ns simulations. The interactions between the EC and TM 
domains are dominated by hydrophobic contacts. Although some halothane molecules 
were initially docked at the EC/TM interface in α7 and α4, they moved away during the 
simulations (Figure 4.1.2) and made no strong impact to the interfacial interaction. In 
contrast, the hydrophobic interaction in the same region of the β2 subunit was disrupted 
by polar contacts (Figure 4.1.1c) and salt bridges (R48 and D268 or D140 and K274) 138, 
creating a more amphiphilic environment. A halothane molecule moved between the Cys 
loop and TM2-TM3 linker of the β2 subunit, weakened the interfacial interactions, and 
consequently generated a wide gap between the EC and TM domains (Figure 4.1.1f). 
Our early experiments proved that anesthetics prefer an amphiphilic environment to a 
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hydrophilic region 113,193,194. Thus, it is understandable why we did not observe the same 
halothane binding and subsequent effect in either α7 or α4 as that in β2.  
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Figure 4.1.1. Residue packing at the EC/TM interface of the open-channel conformations of α7 (a 
and d), α4 (b and e), and β2 (c and f) in the absence (a, b, and c) and presence (d, e, and f) of 
halothane (black, VDW). The residues are colored according to their types, white: nonpolar; green: polar; 
red: acidic; blue: basic. The residues in the TM2-TM3 linker are highlighted in grey shadow, the residues in 
the β1β2 loop and the Cys-loop are covered with transparent yellow surface. Nonpolar contacts dominate 
the interaction at the EC/TM interfaces of all three subunits. Unlike α7 and α4, β2 could form salt bridges 
between K274 and D140 or R48 and D268. Halothane at the β2 EC/TM interface introduced a sizeable gap 
that interrupted the correlated motion between the EC and TM domains. 
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Figure 4.1.2. The initial and final sites of halo-3open (a) and halo-4open (b) over a 20-ns simulation. Both 
halothanes are initially (transparent) docked behind the Cys loop, but each moved away from their initial 
locations at the end (solid) of the simulation. Note that halo-3open migrated up into the ECD, while halo-4open 
migrated toward the pore. 
 
The cross-correlation maps in Figure 4.1.3 integrated all GNM modes that 
demonstrated motional dependency between α7 residues in the absence and presence 
of halothane. For comparison, the corresponding maps of β2 were included in Figure 
4.1.3. In the control systems, the Cys loop and the β1-β2 linker were strongly correlated 
with the TM2-TM3 linker in both α7 and β2 subunits, indicating the capacity of these 
contact points within the EC/TM interface to act as the actuation points for propagating 
signal from the agonist binding site to the channel gate. In the presence halothane, the 
correlations between these loops and linkers remained almost the same in α7, but 
diminished in β2. Insensitivity of correlated motion of α7 to halothane was substantiated 
by the results from the other trajectories as well. Such a sensitive response of β2 and an 
insensitive response of α7 to halothane appeared consistent with halothane induced 
functional responses of α7 and α4β2 5,6. 
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Figure 4.1.3. Cross correlation maps for the open-channel α7 (upper right panels) and β2 (lower left 
panels) nAChRs. Cross correlation maps were generated from the 5 lowest frequency modes of GNM 
analysis for the halothane (a) and control (b) systems. The difference (c) between the halothane and control 
systems (a minus b) shows that α7 displays limited changes in the correlated motion, but β2 has a 
substantial decrease (blue) in its correlated motion between the Cys loop and the TM domains. 
 
The data presented in Figure 4.1.1 and Figure 4.1.3 were from the open-channel 
systems. One may wonder what happened to the closed-channel α7. Interestingly, overall 
higher binding affinity of halothane in the closed-channel conformation did not produce a 
profound effect on the structure and correlated motions of the α7 subunit. A similar 
phenomenon was also observed in the closed-channel α4β2, where halothane had higher 
affinity in the closed system and produced less structural and dynamical consequences 
on the α4β2 than that in the open system 42,43. Taken together, these results suggest that 
high binding affinity of anesthetics may not be sufficient to assure functional changes in 
these receptors.  
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4.1.5. Conclusions 
Our study revealed two important points regarding anesthetic action on α7 nAChR. First, 
lack of sensitive functional responses of the α7 nAChR to halothane in previous 
experiments was unlikely due to lack of halothane interaction with α7. Second, halothane 
binding to α7 did not induce profound changes in the structure and dynamics of α7 that 
could be related to the channel function. This is probably the most distinctive difference 
between α7 and α4β2. The favorable interaction between halothane and the amphiphilic 
EC/TM interface of the β2 subunit brings about changes in dynamics at this interface. 
These changes may be the reason why α4β2 is functionally more sensitive to halothane 
than α7.  
It is worth noting that the previous experiments of anesthetic sensitivity on α7 were 
performed on the recombinant homomeric α7 nAChR 6,195, as reflected in our 
homopentameric α7 structural models. But in nature, α7 could also form heteromeric 
functional channels with other types of subunits. The α7 and β2 subunits of nAChR were 
found co-expressed within individual interneurons, signifying a possibility of the α7 and 
β2 co-assembled nAChR 196. Co-expression of the rat α7 and β2 in Xenopus laevis 
oocytes resulted in functional nAChR channels with lower agonist sensitivity to and slower 
desensitization rate than the recombinant homomeric α7 nAChR 7. Based on what has 
been found in our computational study, we predict that halothane will inhibit the function 
of the α7β2 nAChR, as it does to the α4β2 nAChR. 
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4.2. FUNCTIONALLY RELEVANT SITE FOR VOLATILE ANESTHETIC 
ISOFLURANE BINDING 
This section has been published as a full article in J Biol. Chem. (2013).  
4.2.1. Background and Significance 
Neuronal nAChRs are composed of α (α2 – α10) and β (β2 – β4) subunits and assemble 
to form either homo- or hetero-pLGICs. The α7 subunit mainly forms homo-pLGICs, but 
it can also assemble with β2 or β3 subunits to form hetero-pLGICs 7,197,198. nAChRs have 
been implicated in general anesthesia and play roles in memory 16, nociception 17, and 
the autonomic response 18. Different subtypes of nAChRs show distinct sensitivities to 
general anesthetics 5,6,199, even though they share high sequence homology. For 
instance, the α7 nAChR is insensitive to volatile anesthetics at clinically relevant 
concentrations, while the α4β2 nAChR is hypersensitive 5,6.  
Previously, we investigated potential causes for different sensitivities of the α4β2 
and α7 nAChRs to volatile general anesthetics using MD simulations 42-44. While multiple 
anesthetic binding sites were observed in α7, α4, and β2 subunits, anesthetic binding to 
a site at the interface between EC and TM domains of β2 produced a profound change 
in protein dynamics that was likely to affect channel function. On the basis of the 
simulation results, we proposed that the susceptibility to anesthetic perturbation in β2, but 
not in α7, underlies the functional sensitivity of α4β2 and insensitivity of α7 to volatile 
anesthetics 44. We also predicted that unlike α7, α7β2 would be sensitive to volatile 
anesthetics due to the involvement of β2 44.   
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In the present study, we revealed different functional responses of the α7β2 and 
α7 nAChRs, expressed in neurons and Xenopus laevis oocytes, to the anesthetic 
isoflurane. We also determined the binding sites and dynamic effects of isoflurane on 
both the α7 and β2 nAChR TM domains using NMR, validated the functional relevance 
of the identified isoflurane site via point mutations and subsequent functional 
measurements, and rationalized potential causes underlying the insensitivity of the α7 
channel and the hyper-sensitivity of the α7β2 channel to isoflurane. The study provides 
compelling evidence that isoflurane binds to both α7 and β2, but at different locations. 
More importantly, isoflurane binding induced pronounced dynamics changes in β2, 
particularly for the channel gate residue L249(9’). In contrast, isoflurane binding to α7 did 
not generate the same dynamics changes. The study conveys a message that only those 
sites being able to modulate protein dynamics upon anesthetic binding will produce 
functional effects. 
4.2.2. Methods 
Electrophysiology measurements  
Neuron dissociation and patch clamp whole-cell current recordings were performed as 
reported previously 197. Briefly, several 400-μm coronal slices from postnatal Wistar rats 
(2-3 weeks old) containing the ventral diagonal band (VDB) or the ventral tegmental area 
(VTA) were cut in cold (2-4°C) artificial cerebrospinal fluid (ACSF). The slices were 
incubated for at least one hour in oxygenated ACSF at room temperature (22 ± 1°C). 
Thereafter, the slices were treated with pronase (1 mg/6 mL) at 31°C for 30 min. The 
medial septum/diagonal band or VTA region was micropunched out from the slices using 
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a well-polished needle. Each punched piece was then dissociated mechanically using 
several fire-polished micro-Pasteur pipettes in a 35-mm culture dish filled with well-
oxygenated, standard external solution (150 mM NaCl, 5 mM KCl, 1 mM MgCl2, 2 mM 
CaCl2, 10 mM glucose, and 10 mM HEPES; pH 7.4 with Tris-base). The separated single 
cells usually adhered to the bottom of the dish within 30 min. Human α7-nAChR was 
expressed heterologously in transfected SH-EP1 human epithelial cells as described in 
details previously 200.  
Functional measurements were performed using perforated patch whole-cell 
recordings coupled with a two-barrel drug application system 197. After the formation of 
whole-cell configuration, an access resistance less than 30 MΩ was acceptable for 
voltage-clamp recordings. The series resistance was not compensated in the experiments 
using dissociated neurons. Data were filtered at 2 kHz, acquired at 11 kHz, and digitized 
on-line (Digidata 1322 series A/D board; Axon Instruments, Foster City, CA). All 
experiments were done at room temperature (22 ± 1°C). Clampex 9.2 (Axon Instruments) 
was used for data acquisition, and Prism 3.0 (Prismsoft Inc.) was used for graphics and 
statistical calculation. For statistical analysis of multiple groups of data, one-way or 
multivariate ANOVA followed by appropriate test was applied. p < 0.05 was considered 
significant, and data were represented as mean ± SE. 
To ascertain the different sensitivity of α7β2 and α7 to isoflurane observed in 
neurons, we also used Xenopus laevis oocytes for channel expression and functional 
measurements. The plasmids encoding human α7 and β2 nAChRs for oocyte expression 
were gifts from Prof. Lindstrom’s lab at the University of Pennsylvania and Prof. Henry 
Lester’s lab at the California Institute of Technology, respectively. To reconcile the 
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structural and functional data, we constructed two mutants (α7-M22’V and α7β2-V22’M) 
for functional measurements in oocytes. The mutations were introduced by QuikChange 
Lightning Site-Directed Mutagenesis Kit (Agilent) and confirmed by DNA sequencing. 
cRNAs were synthesized for α7 and α7-M261V(M22’V) with the mMessage mMachine 
SP6 kit (Ambion), and for β2 and β2-V22’M with the mMessage mMachine T7 kit 
(Ambion). The cRNAs were purified with Rneasy Kit (Qiagen). 
Channel functions of Xenopus laevis oocytes (stage 5-6) expressing native and 
mutant nAChRs were measured by two-electrode voltage clamp experiments. For making 
α7β2, the RNAs of α7 and β2 were injected to each oocyte in a 1:1 ratio with a total of 25 
ng. The injected oocytes were maintained at 18˚C in a modified Barth’s solution 120. After 
expressed for 24 to 36 hrs, the oocyte in a 20-μL recording chamber (Automate Scientific) 
and the ND96 buffer 81 was clamped with an OC-725C Amplifier (Warner Instruments) to 
a holding potential of -60 mV, and currents elicited by acetylcholine and modulated by 50-
μM isoflurane were recorded. The collected data were processed using Clampex 10 
software (Molecular Devices).  
 
NMR experiments  
NMR samples of the TM domains of the α7 and β2 human nAChRs were prepared using 
the protocols as reported in detail previously 36. Each NMR sample at pH 4.7 contained 
0.25-0.3 mM protein, 40-60 mM LDAO detergent, 5 mM sodium acetate, 10 mM NaCl, 20 
mM 2-mercaptoethanol to prevent disulfide bond formation, and 5% D2O for deuterium 
lock in NMR measurements. The anesthetic isoflurane was titrated into the samples using 
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a gas-tight microsyringe. The isoflurane concentration was quantified based on 19F NMR 
using the method reported previously 170.  
All NMR spectra were acquired on a Bruker Avance 600 MHz spectrometer, which 
was equipped with a triple-resonance inverse-detection TCI cryoprobe (Bruker 
Instruments, Billerica, MA). 1H-15N TROSY-HSQC spectra were acquired with one-
second relaxation delay for each sample before and after adding isoflurane. Spectral 
windows were typically 13 ppm (1024 data points) in the 1H dimension and 22 ppm (128 
data points) in 15N dimension. The 1H chemical shifts were referenced to the DSS 
resonance at 0 ppm and the 15N chemical shifts were indirectly referenced 78. 
The collected NMR data were processed using NMRPipe 4.1 and NMRDraw 1.8 
82, and analyzed using Sparky 3.10 83. Each processed spectrum had 4096  512 data 
points. 1H and 15N chemical shift assignments for the α7 and β2 TM domains in the 
presence of isoflurane were referenced to the previous assignments for the same proteins 
without drugs 36. Chemical shifts and peak intensities in the NMR spectra were measured 
using Sparky 3.10 83.  
 
Visualization of isoflurane binding and calculation of cavity volumes and angles 
between TM2 and TM4  
To assist visualizing isoflurane-binding sites identified by NMR experiments, we 
performed docking of isoflurane to NMR structures of the α7 and β2 TM domains. The 
targeted docking kept only those sites consistent with the NMR results. Docking was 
performed with Autodock4 147 using a Lamarckian genetic algorithm with a grid spacing 
of 0.375 Å. For each intra-subunit binding site suggested by the NMR data, 250 
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independent anesthetic dockings were performed within a cube covering ~6600 Å3 using 
an initial population size of 500.   
The sizes of inter-subunit cavities for isoflurane binding were calculated using the 
POVME algorithm 201. A grid encompassing the cavity in each of the 20 NMR structures 
of α7 or β2 was generated with 0.5-Å grid spacing. The algorithm output the grid points 
defining the cavity, which represent a subset of the total cavity points. Using MATLAB®, 
we determined the frequency that each point was observed in the bundle of twenty NMR 
structures for α7 or β2. Points shown from at least five structures were used for 
highlighting the cavity in Figure 4.2.3. Reported cavity volumes are the mean ± standard 
error of the volumes calculated for the 20 NMR structures.  
The VMD program 86 was used for visualizing molecular structures and generating 
figures. 
The angles between TM2 and TM4 helices near the EC end of the TM domain 
were calculated for each of 20 structures for β2 or α7. Vectors were fit to backbone atoms 
of TM2 (residues from K260 to L249 in β2 and from E259 to L248 in α7) and TM4 
(residues from L454 to F443 in β2 and from M466 to V455 in α7). Angles were calculated 
using the cross product of the two vectors. The values reported are the mean difference 
between the β2 and α7 angles ± the pooled standard error SEP,  
 where , n1 and n2 represent the two sample 
sizes, and s1 and s2 represent the two standard deviations. 
  
  
SEp = Sp
1
n1
+
1
n2   
  
Sp =
(n1 -1)s1
2 + (n2 -1)s2
2
n1 + n2 - 2
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4.2.3. The α7β2 nAChR is much more sensitive to isoflurane inhibition than the 
α7 nAChR  
Previous pharmacological, cell biological and single cell RT-PCR studies confirmed the 
expression, localization, and assembly of α7β2 nAChRs in VDB neurons 197. We used the 
same dissociated VDB neurons to test functional responses of α7β2 nAChRs to the 
volatile anesthetic isoflurane. As shown in Figure 4.2.1, the inward currents were 
generated by application of 10 mM choline, an agonist for α7-containing nAChRs, in 
acutely dissociated neurons from mouse VDB at a holding potential of −60 mV. The peak 
currents were significantly reduced by 10 μM isoflurane after 2 min of isoflurane pre-
incubation. Isoflurane pre-incubation reduced the maximal choline-induced activation by 
37 ± 8%. The EC50 and Hill coefficient had no significant changes (p = 0.58) in the 
absence (3.8 ± 0.3 mM; 1.35 ± 0.32) and presence (4.1 ± 0.5 mM; 1.23 ± 0.18) of 10 μM 
isoflurane, suggesting that isoflurane inhibition occurs in a non-competitive manner 
(Figure 4.2.1a). Isoflurane inhibition of α7β2-nAChR-mediated whole-cell current in 
acutely dissociated neurons from mouse VDB was concentration dependent with an IC50 
of 11.7 ± 1.6 μM (Figure 4.2.1b), less than 0.1 MAC (Minimum Alveolar Concentration) in 
human 154,202. We measured isoflurane inhibition by using a repeated application protocol, 
in which choline was applied at 2 min-intervals in the continuous presence of 10 μM 
isoflurane. Isoflurane progressively inhibited α7β2 currents. Reversibility of isoflurane 
inhibition was demonstrated by the current recovery after 4 min of isoflurane washout. In 
contrast to α7β2, the homomeric α7 expressed either in neurons dissociated from ventral 
tegmental area (VTA) 203 or in the SH-EP1 cells 200 are not sensitive to 10 μM isoflurane 
(Figure 4.2.1c and d). This is consistent with an IC50 of ~600 μM (~2 MAC) for the human 
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α7 nAChR reported previously 204. Different sensitivities to isoflurane inhibition were also 
observed in the recombinant α7β2 and α7 nAChRs expressed in Xenopus laevis oocytes. 
Representative current traces obtained from oocytes (Figure 4.2.1e and f) echo the 
message conveyed by the results from the dissociated neurons (Figure 4.2.1a-d). In 
addition, we found that a swap of residue 22’ between α7 and β2 had a dramtic impact 
on isoflurane inhibition (Figure 4.2.1g and h). While α7 is insensitive to isoflurane 
inhibition, the mutant α7-M261(22’)V showed 39±7% (n=6) isoflurane inhibition, similar to 
that (46±3%, n=4) observed on α7β2. Conversely, the mutant α7β2-V262(22’)M, similar 
to α7, showed a lower sensitivity to isoflurane inhibition (12±2%, n=4). Altogether, these 
data suggest an indispensible role of β2 and importance of its residue V262(22’) in 
isoflurane inhibition.  
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Figure 4.2.1. Isoflurane inhibited function of the α7β2 but not α7 nAChRs. (a) The α7β2 nAChRs 
expressed in VDB neurons were non-competitively inhibited by 2 minutes pre-incubation with 10 μM 
isoflurane. EC50 of choline and Hill coefficients show no significant differences in the absence and presence 
of isoflurane. (b) Isoflurane inhibited α7β2 with an IC50 of 11.7 ± 1.6 μM. Fractional currents were obtained 
from the mean peak currents elicited by 10 mM choline (~EC70). The error bars are standard errors (n=6). 
(c) Representative whole-cell current traces for α7β2 expressed in VDB neurons, native α7 in VTA neurons 
and heterologously human α7 nAChRs in the SH-EP1 cells. The vertical and horizontal scales represent 
50 pA and 250 ms, respectively. (d) Normalized mean (± SE) peak current responses of α7β2 and α7 
expressed in various cells to the prolonged choline stimulation in the presence of 10 μM isoflurane (n=6). 
Isoflurane inhibited choline-induced currents in α7β2, but not in α7. (e)-(h): Representative current traces 
for (e) α7β2, (f) α7, (g) the α7-M22’V mutant, and (h) the α7β2-V22’M mutant expressed in Xenopus 
oocytes. The currents were elicited by acetylcholine at the EC20, modulated by isoflurane (50 μM), recorded 
by two-electrode voltage clamp at – 60mV. The vertical and horizontal scales represent 25 nA and 1 min, 
respectively. 
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4.2.4. β2 and α7 have different isoflurane binding sites in their TM domains.  
We investigated the binding sites of isoflurane in the TM domains of β2 and α7 nAChRs 
using high resolution NMR. As shown in the 1H-15N TROSY HSQC spectra (Figure 4.2.2a 
and b), the presence of 1.3 or 1.6 mM isoflurane perturbed a number of residues in β2 or 
α7 nAChRs, respectively. The residues with either more than 40% intensity change or a 
combined chemical shift change 205 greater than 15 ppb (β2) and 10 ppb (α7) were 
mapped onto NMR structures of the β2 or α7 TM domains (Figure 4.2.2c and d). Intra-
subunit pockets for isoflurane binding were found in the NMR structures of β2 and α7, but 
at different sites: the one in α7 is close to the intracellular end of the TM domain; the one 
in β2 is at the EC end of the TMD, which is also the site for halothane and ketamine 
binding 39. Moreover, this anesthetic site in β2 is homologous to the previously identified 
anesthetic site in GLIC 106, ELIC 206, and the Torpedo nAChR 41. The isoflurane site in α7 
is homologous to a halothane binding site at the IC end of the β2 TMD identified by NMR, 
and coincides with one of the halothane sites in α7 predicted by our previous MD 
simulations 44. 
Some residues, including the channel gate residue L249(L9’) in β2, showed 
significant changes upon the addition of isoflurane, but are structurally remote from the 
cluster of residues defining the binding pocket. Their changes likely result from allosteric 
effects rather than direct contact with isoflurane. It is also worth noting that several pore-
lining residues in β2, but not α7, showed greatly reduced intensity upon the addition of 
isoflurane, indicative of motional changes for these residues. 
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Figure 4.2.2. Isoflurane binding to the TM domains of β2 and α7. 1H-15N TROSY-HSQC spectra of (a) 
β2 and (b) α7 in the presence (green) and absence (black) of 1.3 or 1.6 mM isoflurane, respectively. 
Residues showing significant changes in chemical shift or peak intensity are labeled and highlighted in red. 
Residues labeled in blue are pore-lining residues. (c) The bundle of 20 NMR structures of the β2 TMD 
mapped with residues highlighted in red in (a). (d) The bundle of 20 NMR structures of the α7 TMD mapped 
with residues highlighted in red in (b). Residues are colored based on residue type: green – polar, white – 
nonpolar, and blue – basic. Docked isoflurane is shown in magenta surface. 
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4.2.5. A smaller intra-subunit pocket excludes isoflurane binding to the EC end of 
the α7 TMD.  
 
Figure 4.2.3. The intra-subunit cavity at the EC end of the TMD in β2, but not in α7, can accommodate 
isoflurane binding. (a) Alignment of 20 NMR structures with the lowest target function for β2 (blue) and 
α7 (yellow), and the cavities of β2 (blue) and α7 (red), outlined by grid points present in at least five of the 
20 structures. Residues highlighted with the side chain bundles (shown in stick representation) in (b) β2 
and (c) α7 have primary responsibility for the different cavity volumes. Note that in β2, the cavity can 
accommodate isoflurane (purple surface), but the cavity in α7 (dotted outline) cannot do the same. (d) The 
top view of the lowest target function structures of β2 (blue) and α7 (yellow) shows different orientations of 
TM helices. 
 
To determine why isoflurane binds to the EC end of the TMD in β2 but not in α7, 
we examined the pocket in this region based on NMR structures of the β2 and α7 TM 
domains. Mostly hydrophobic residues and a few hydrophilic residues from four TM 
helices line the intra-subunit pocket near the EC end of the TM helices in both β2 and α7. 
The average cavity volumes are 179 ± 12 Å3 and 122 ± 10 Å3 for β2 and α7, respectively 
(Figure 4.2.3). The differences in cavity volume primarily result from tighter packing of 
four helices in the region of α7 and greater side chain volume of several cavity-lining 
residues in α7, such as α7-M261(22’) vs. β2-V262(22’), α7-I271 vs. β2-V272, and α7-
F275 vs. β2-L276. The differences in isoflurane inhibition made by these residues were 
V262(22’)
I258(18’)
L276
F275
M261(22’)
V257(18’)
V272 I271
TM2
TM3 TM4
TM1
a b c d
TM2
TM4
TM1
TM3
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evident in functional measurements of the mutants α7-M261(22’)V and α7β2-V262(22’)M 
(Figure 4.2.1g and h). Helical tilting differences (6.7 ± 1.3), measured by angles between 
TM2 and TM4 (Figure 4.2.3d), also contribute to different cavity volumes at the EC end 
of the TMD between β2 and α7. Both the inward helical tilting of α7 and the more bulky 
M22’ side chain in α7 contribute to a smaller cavity. Furthermore, orientations of side 
chains also affect the cavity volumes. For the residues in TM3, both side chains of β2-
V272 and β2-L276 are oriented away from the cavity, while the equivalent residues α7-
I271 and α7-F275 are oriented towards the cavity. A smaller cavity in the EC end of the 
TMD in α7 has reduced the probability of isoflurane binding to the region, considering that 
isoflurane has a volume of 144 Å3 207. 
4.2.6. Isoflurane modulates the dynamics of α7 and β2 differently.  
One of the most striking differences between α7 and β2 is that upon isoflurane binding, 
α7 retained a single signal for each residue in the NMR spectra, but β2 showed classic 
examples of two-site chemical exchange 208,209 for several residues, including the channel 
gate residue L249(9’) and V262(22’) lining the isoflurane-binding pocket in β2. As shown 
in Figure 4.2.4, in the absence of isoflurane (black), each of these β2 residues showed a 
single peak in the NMR spectrum. After adding 1.3 mM isoflurane (red), an additional 
peak became observable for L248 and T265 (denoted as L248’ and T265’, respectively). 
When the isoflurane concentration was increased to 3 mM (cyan), L249 and V262 also 
showed additional peaks. The combined chemical shift change between each pair of 
peaks (A-B or A’-B), ΔωH+N = [(ΔωH2 +ΔωN2)]1/2, is 32, 27, 37, 32 Hz for L248, L249, V262, 
and T265 of β2, respectively. Based on the consensus from many previous studies 208-
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210, the occurrence of two distinct peaks for a residue indicates a slow exchange with 
kex<< 2πΔωH+N ~ 200s-1.  
Conformational exchange among β2 residues also shows some differences. For 
residues L248 and T265, peak A remained at 20 Hz line width and the same resonance 
frequency in the absence and presence of isoflurane, indicating a possibility that slow 
conformational exchange with an extremely low population for the second conformation 
(peak B) already existed in the absence of isoflurane. Isoflurane shifted the equilibria 
between the two conformations. Indeed, the population of conformation B, pB = 1-pA, 
increased from 0 to ~0.3 and more than ~0.5 when isoflurane was increased from 0 to 
1.3 and 3 mM. Overall, L248 and T265 fit well to the scheme of slow exchange between 
two conformations 208-210. In the case of L249 and V262, however, a single peak with a 
broader line width in the 1H dimension was observed in the presence of 0 mM (L249, 21 
Hz; V262, 17 Hz) and 1.3 mM isoflurane (L249, 19 Hz; V262, 16 Hz), but two narrower 
peaks (L249, 16 and 12 Hz; V262, 14 and 12 Hz) were observed in the presence of 3 mM 
isoflurane. The results suggest that L249 and V262 were likely in an intermediate 
exchange regime 208,209 before exposed to 3 mM isoflurane. In addition to slower 
exchange between A’ and B conformations, the increased isoflurane concentration also 
shifted peak A’ from peak A by 14 and 11 Hz for L249 and V262, respectively (Figure 
4.2.4). This is not unexpected, considering that multiple conformers with subtle 
differences can co-exist in a functional state 211,212. 
The sensitivity of β2 and insensitivity of α7 to the dynamics modulation by 
isoflurane are in good agreement with their distinctly different functional responses to 
isoflurane inhibition. 
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Figure 4.2.4. Different dynamics responses of β2 and α7 to isoflurane modulation. Overlay of NMR 
spectra for individual residues in (a)-(d) 2 and (e)-(h) α7 in the presence of isoflurane: 0 mM (black), 1.3 
mM for β2 and 1.6 mM for α7 (red), 3.0 mM for β2 and 3.3 mM for α7 (cyan).  Note that none of the α7 
residues show an additional conformation over the isoflurane concentration range used in the experiments. 
The peaks representing the different conformations for β2 are labeled A, A’, and B. 
4.2.7. Discussion 
Our functional data substantiate the previous prediction 44 that, unlike the α7 nAChR, the 
α7β2 nAChR is sensitive to anesthetic inhibition. The result highlights the role of β2 in 
functional modulation by volatile anesthetics and supports our hypothesis that β2 is 
primarily responsible for the difference of anesthetic susceptibility between α4β2 and 
α7 44. More importantly, the result conveys the message that two or three subunits 
susceptible to anesthetics, such as β2 in α7β2, are sufficient to produce functional effects. 
The message is consistent with the notion obtained from MD simulations of anesthetic 
propofol action in GLIC 62.  
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Why is β2 more susceptible to volatile anesthetics than α7? This key question has 
been addressed by our NMR experiments from three aspects. First, β2 and α7 show some 
structural differences in their TM domains, even though they share a common scaffold. 
The most notable difference lies in the size of an intra-subunit cavity near the EC end of 
the TMD that is large enough in β2, but not in α7, to accommodate isoflurane binding. 
Second, the structural difference leads to different binding locations for isoflurane, which 
binds to the cavity at the EC end of the TMD in β2 but to a pocket located at the IC end 
of the TMD in α7. Finally, differences in their structures and isoflurane-binding sites may 
have contributed to different dynamics responses of β2 and α7 to isoflurane binding. Only 
in β2 were isoflurane-induced changes in conformational populations and motion on the 
μs-ms timescale observed. The combined effects from structures, anesthetic binding 
sites, and dynamics modulations may have contributed to the functional differences 
between β2 and α7. 
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Figure 4.2.5. Sequence alignments for TM domains of human α7 and β2 nAChRs. Sequences of the 
constructs used for NMR samples, α7’ and β2’, are aligned with their respective native sequences. Note 
that only a few terminal and loop residues were changed to increase the stability of NMR samples. The 
labeled sequence numbers are for the α7 nAChR. The pore lining residues are labeled using the 
conventional prime numbering. Residues in the box were mutated in the study. 
 
The sequence identity between β2 and α7 is high, ~50% for the TM domain and 
close to 65% for the pore-lining TM2 helix. Their sequence homology is even higher 
(Figure 4.2.5). Our results demonstrate that variation in a small number of residues is 
sufficient to make differences in protein structures, drug binding sites, and functional 
responses to drug binding. The functional significance of such small changes in structure 
highlights the necessity of solving individual protein structures, even for highly 
homologous proteins. In the case of β2 and α7, the homologous cavity-lining residues β2-
V22’ and α7-M22’ make a notable difference for their respective cavities, isoflurane 
binding, and isoflurane inhibition. Indeed, a single α7-M22’V mutation markedly increase 
the channel sensitivity to isoflurane and the α7β2-V22’M mutation had a reverse effect. 
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This result is consistent with the diminished sensitivity to volatile anesthetics observed 
previously for the I22’M mutation in the α3 containing nAChR 195. A larger volume and 
extended side-chain conformation of M22’ can effectively reduce the cavity volume and 
obstruct drug binding. Moreover, methionine may also stabilize the TM2 helix and make 
it more resilient to structural and dynamic perturbation introduced by anesthetic binding. 
Previous studies using unnatural amino acid substitutions have shown that residues with 
un-branched side chains, such as methionine and alanine, have a more stabilizing effect 
on α helices than branched amino acids, such as valine and isoleucine 213. Similarly, β2-
S19’ and α7-A19’ could also make dynamics differences to the TM2 helix. Alanine is a 
natural helix promoter 214, while serine and threonine often disrupt α-helices due to 
backbone to side chain hydrogen bonds 125,215. Our previous NMR study noted 
heightened conformational dynamics at the EC end of TM2 for the glycine receptor, which 
is uniquely rich with serines in this region compared to other pLGICs 38. Contributions to 
the anesthetic binding site from two pairs of residues in TM3, β2-L276/α7-F275 and β2-
V272/α7-I271, should also not be under estimated. Mutation on the homologous residue 
in GLIC was found to significantly affect the channel’s susceptibility to the anesthetics 
desflurane and propofol 106.  
The anesthetic binding site at the EC end of the TMD, as revealed for isoflurane in 
β2, is probably a common site in pLGICs for anesthetics. Using NMR, we found that 
anesthetics halothane and ketamine bound to the same site in β2 39. The site is also 
consistent with one of the halothane sites identified by photo-affinity labeling in the 
Torpedo nAChR 41 and by fluorescence quenching in GLIC 177. The anesthetics 
desflurane and propofol were found in the homologous site in the crystal structures of 
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GLIC bound with these anestethics 106. Functional and mutation studies on the α7/α3 
nAChR chimeras also underscored the importance of the cavity to inhibition by the volatile 
anesthetic halothane 195. In contrast, anesthetic binding to the IC end of the TMD, as 
observed for isoflurane in α7 in this study, is less effective to perturb channel function. 
Isoflurane inhibits α7 only at concentrations higher than those used clinically 204.  
Our results provide evidence that functional insensitivity of α7 to volatile 
anesthetics is not due to lack of anesthetic binding, at least in the case of isoflurane. The 
hypersensitivity of α7β2 and insensitivity of α7 suggest that the EC end of the TMD plays 
a critical role for channel gating in pLGICs. Increasing the rigidity of residues at the EC 
end of the TMD can make the channel less responsive to activation signals. Many 
previous studies support this notion. Increasing helical flexibility at the EC end of TM2 of 
the nAChR was found to increase the receptors’ sensitivity to agonist more than tenfold 57. 
Disulfide bond trapping experiments on the GABAA receptor 216 and EPR experiments on 
GLIC 58 also support heightened dynamics at the EC end of TM2 during channel gating. 
Our previous work on the glycine receptor suggested that increasing or decreasing the 
conformational dynamics at the EC end of TM2 could respectively increase or decrease 
the channel’s susceptibility to allosteric modulation 38. Thus, it is conceivable that 
changing dynamics of the EC end of the TMD, either via drug binding or point mutations, 
is a common mechanism to modulate functions of pLGICs.  
4.2.8. Conclusions 
The general volatile anesthetic isoflurane binds to an intra-subunit cavity at the EC end 
of the TMD, similar to the binding site observed for halothane. Mutagenesis and functional 
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measurements confirmed that this site is the functionally relevant site for isoflurane, and 
likely other general volatile anesthetics. Our study not only highlights the importance of 
the anesthetic binding site, but also emphasizes the role of channel dynamics in 
anesthetic action. Although β2 and α7 have high sequence homology, the dynamics and 
subtle structural differences are sufficient to affect anesthetic binding as well as functional 
consequences. Anesthetic binding is necessary but not sufficient to produce a functional 
consequence. Only the binding that modulates dynamics of pore-lining residues, such as 
that at the EC end of the β2 TMD, can impact function.  
4.3. FUNCTIONALLY RELEVANT SITES FOR INTRAVENOUS ANESTHETIC 
KETAMINE BINDING 
This section is based on manuscripts published in Structure 20(9): 1463-1469 and 
recently accepted for publication in Biochim Biophys Acta.  
4.3.1. Background and Significance 
In previous sections, it was determined that general volatile anesthetics, such as 
halothane or isoflurane, bound to an intra-subunit cavity at the EC end of the β2 TMD, 
but only bound to a cavity located at the IC end of the TMD in α7. Subsequent functional 
experiments validated that functional insensitivity of α7 to volatile general anesthetics 
resulted from the lack of anesthetic binding to the EC end of the TMD, suggesting that 
the site observed in β2 is the functionally relevant site for volatile general anesthetics. But 
what about the functionally relevant site for the intravenous general anesthetic ketamine? 
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With respect to inhibition by ketamine the α7 nAChR is more sensitive than the α4β2 
nAChR 45,46. The IC50 values of ketamine for the α7 and α4β2 nAChRs are ~20 μM and 
50-72 μM 45,46, respectively. 
In this section of the thesis we rationalize the potentially relevant sites for 
anesthetic ketamine binding within the α7 nAChR TMD. Our results indicate two 
potentially relevant anesthetic binding sites for ketamine in the α7 nAChR: one in the 
TMD, and the other in the ECD. NMR data indicate that ketamine binds to an intra-subunit 
binding site located at the IC end of the α7 TMD. Functional measurements showed that 
the α7 nAChR TMD used in the NMR experiments was inhibited by ketamine. We also 
observed that ketamine, but not halothane, binding to the α7 nAChR TMD could perturb 
the channel gate residue L248(9’), affirming our previous conclusion that only those sites 
that can affect channel dynamics will produce functional effects. Crystal structures of 
GLIC, a bacterial homologue of the α7 nAChR, co-crystallized with ketamine show 
ketamine binding in the ECD. Functional measurements showed that ketamine could 
inhibit GLIC and that the crystallographically determined binding site was functionally 
relevant.  
4.3.2. Ketamine action site in the α7 nAChR TMD 
In the previous section we noted that isoflurane bound to an intra-subunit site at the EC 
end of β2 but not α7. Rather isoflurane binding was noted at the IC end of the α7 TMD. 
These results were consistent for halothane binding, where halothane could bind at the 
EC end of the TMD in β2 (Figure 3.2.4), but was only found to bind to an intra-subunit 
cavity towards the IC end of the TMD in α7 (Figure 3.3.1). As the β2, not the α7, subunit 
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is sensitive to volatile anesthetics it was deduced that the anesthetic binding site at the 
EC, not the IC, end of the TMD was the functionally relevant binding site for general 
volatile anesthetics.  
In the case of the intravenous anesthetic ketamine binding to the α7 nAChR, 
ketamine binding was observed to occupy the intra-subunit cavity at the IC end of the α7 
nAChR TMD as halothane (Figure 3.3.2). However, while α7 is insensitive to halothane, 
it is sensitive to ketamine. Indeed, our functional experiments on the α7 TMD show that 
ketamine could inhibit the α7 nAChR TMD alone, even in the absence of the ECD (Figure 
2.1.12). It is possible that with its larger molecular size, ketamine can accomplish what 
halothane and other volatile anesthetics cannot. While ketamine and halothane share the 
same binding cavity, the residues they affect in that cavity are different. Residues F453, 
S285, I217, and L248 displayed chemical shift changes upon addition of ketamine, but 
not halothane (Figure 3.3.1B). In contrast, residues C219, S223, and T289 showed 
chemical shift changes upon the addition of halothane, but not ketamine. Differences in 
affected residues could result in differences in functional effects. Supporting evidence for 
such a possibility includes that ketamine, but not halothane, changed the chemical shift 
of the pore-lining residue L248 (L9’) (Figure 3.3.2). L9’ is a key residue in the channel 
gate. Its chemical shift change signifies perturbation to the channel gate, which will most 
likely generate a functional consequence. This finding provides further support for our 
hypothesis in the previous section that only the anesthetic binding that can affect the 
channel gate will produce a functional result. 
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4.3.3. Ketamine action site in the α7 nAChR ECD 
While the NMR data discussed above suggest that the functionally relevant site for 
ketamine inhibition of the α7 nAChR is located in the TMD, it is worth noting the possibility 
of an additional site located in the ECD. Such a site has been suggested by our X-ray 
crystallographic studies on GLIC, a bacterial homologue of the α7 nAChR.   
The ECD of GLIC shows a similar architecture to the EC domains of nAChRs 
determined by cryo-EM 1 and X-ray crystallography 32. Furthermore, ketamine can inhibit 
the function of GLIC at concentrations similar to those observed for the α7 and α4β2 
nAChRs 45-47. Co-crystallization of GLIC with ketamine, shows ketamine binding to an 
amphiphilic inter-subunit cavity located in the ECD (Figure 4.3.1). In this cavity, ketamine 
forms favorable electrostatic interactions with hydrophilic residues, in addition to VDW 
interactions with some hydrophobic residues. On one side of the cavity, the chloro group 
of ketamine points to the positively charged amine of K183 of β10 and the phenyl ring 
faces F174 and L176 of loop C. On another side of the cavity, the aminium of ketamine 
makes electrostatic interactions with side chains of N152, D153, and D154 of the β8-β9 
loop (loop F). The carbonyl group of ketamine can potentially form a hydrogen bond with 
the hydroxyl group of Y23 on β1. K183 of the principal side carries a positive charge on 
its side chain whereas the side chains of D153 and D154 of the complementary side are 
likely negatively charged. Thus, electrostatic interactions contribute significantly to 
stabilizing ketamine binding (Figure 4.3.1).  
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Figure 4.3.1. Amphiphilic ketamine-binding cavity in the GLIC ECD. a) The labeled polar and 
hydrophobic residues are within 3.0 Å of ketamine and those unlabeled hydrophobic residues (colored in 
white) are within 4 Å of ketamine. b) Electrostatic potentials mapped to the molecular surfaces for ketamine 
(transparent) and residues within 3.0 Å of ketamine (solid). Potentials were calculated using the APBS 
plugin in VMD. The scale of the potential is from +15 kT/e (blue) to -15 kT/e (red). c) Structure of protonated 
ketamine. 
 
From the modeled structures of the α7 and α4β2 nAChRs 44,138, it is notable that 
both proteins have a pocket similar to the ketamine pocket in GLIC, where several acidic 
residues are on one side of the pocket (Figure 4.3.2). Similar to the electrostatic 
stabilization observed in the GLIC-ketamine crystal structure, these negatively charged 
residues could attract ketamine and stabilize the ketamine binding in the nAChRs. A 
greater number of negatively charged residues in the pocket of α7 than α4β2 nAChRs 
seem to be consistent with the observation that the α7 nAChR is more sensitive to 
ketamine inhibition than the α4β2 nAChR 45. 
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Figure 4.3.2. Interfacial cavities in nAChRs homologous to the ketamine-binding cavity in GLIC. (a) 
α7; (b) α4 (white)-β2 (gray); (c) β2 (gray)-α4 (white). Basic and acidic residues are colored in blue and red, 
respectively. A greater number of acidic residues in the pocket of the α7 nAChR may benefit the binding of 
the positively charged ketamine. Functional measurements indeed showed that inhibition of ketamine was 
more effective on α7 than on α4β2 nAChRs 45. 
 
The ketamine-binding site observed in GLIC partially overlaps with the extended 
interaction surface of antagonists in Cys-loop receptors 31,217, suggesting that ketamine 
inhibition may occur via a similar mechanism as competitive antagonists inhibit functions 
of nAChRs. Additionally, the functional relevance of the identified ketamine site in GLIC 
was validated in electrophysiology measurements by mutating N152 in the binding pocket 
to cysteine and subsequently labeling the site with 8-(chloromercuri)-2-
dibenzofuransulfonic acid (CBFS) to mimic anesthetic binding 47. While these results 
validate the functional relevance of this site for GLIC are they valid for the nAChRs. In 
functional measurements on the α7 nAChR, labeling of α7-S188C (the residue 
homologuous to N152C in GLIC) using an analogue of the α7-specific antagonist 
methyllycaconitine (MLA) demonstrated that this site could be responsible for α7 inhibition 
by MLA 218. Both GLIC and α7 show similar inter-subunit binding cavities, containing a 
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number of acidic residues that could stabilize binding of positively charged ketamine. 
Furthermore, functional measurements demonstrated that covalent labeling at 
homologous sites in GLIC and α7 lining this inter-subunit cavity could result in functional 
inhibition. Taken together, these data suggest that ketamine binding to the α7 EC domain 
likely contributes to functional inhibition of the α7 nAChR.  
4.3.4. Conclusions 
Functional measurements show that ketamine can inhibit ivermectin-elicited currents of 
the α7 nAChR TMD injected into Xenopus laevis oocytes. Our NMR results on the same 
α7 TMD show ketamine binding to an intra-subunit cavity at the IC end of the TMD. Since 
this was the only site observed for ketamine binding to the α7 TMD, it is likely the site 
responsible for ketamine inhibition of the α7 TMD. NMR results also demonstrated that 
ketamine, but not halothane, could perturb the channel gate residue L9’, consistent with 
the sensitivity or insensitivity of α7 to ketamine or halothane, respectively. The finding 
supports our hypothesis that only the binding that can affect pore-lining residues, can 
impact function. In addition to anesthetic sensitivity at a site in the TMD, our study on 
GLIC suggests that anesthetic binding to the ECD may also contribute to ketamine 
inhibition. It is likely that Ketamine binding to the TMD as well as the ECD can both 
contribute to functional inhibition of the α7 nAChR 45,46,104. 
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CHAPTER 5  
MECHANISMS OF ALLOSTERIC MODULATION 
5.1. SIGNALLING PATHWAYS OF AGONIST-INDUCED ACTIVATION 
This section has been published as a full article in PLoS One. 8 (5): e64326.  
5.1.1. Background and Significance 
Vertebrate pLGICs regulate ionic conductance in nerve cells and play an important role 
in fast synaptic signal transduction 25,219. They are formed by five homologous or identical 
subunits assembled around the central channel axis. Agonist binding to the orthosteric 
site in the ECD allosterically triggers conformational changes to allow ions to pass through 
the cell membrane. How the agonist-binding signal in the ECD is propagated to a remote 
channel region in the TMD has been studied extensively on nAChRs in the past 
52,188,220,221. It remains an open subject for investigation as to whether there are common 
activation or deactivation signal pathways shared by all pLGICs. 
GLIC is a cationic homo-pLGIC 222. Crystal structures of GLIC 27,28 show a common 
scaffold with vertebrate pLGICs, such as nAChRs 1, except without an IC domain. 
Opening of the GLIC channel is triggered by extracellular protons 222, but it is unclear 
which titratable residues are responsible for GLIC activation. Similar to nAChRs 223, GLIC 
is reversibly inhibited by general anesthetics in a concentration dependent manner 
47,106,224. Recent X-ray crystallographic studies revealed anesthetic binding sites not only 
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in the upper part of the TMD within each subunit 106, but also at the interface of two 
adjacent subunits in the ECD 47. The high resolution structures and well defined 
anesthetic binding sites provide the opportunity to critically examine how perturbations on 
titratable residues of GLIC modulate the functional status of the channel and how 
anesthetic binding allosterically inhibits GLIC currents without blocking the channel.  
Introducing a Markovian process into coarse-grained models has offered 
opportunities to assess signal propagation in proteins 48,49,225-229. The PMT model 48 is 
particularly effective for probing how different parts of a macromolecular machine respond 
to signal perturbation that is either due to ligand binding or site-specific mutations. It 
characterizes the dynamic response of all residues in the protein over the time course 
from the initial perturbation to equilibrium. It can identify key signal-mediating residues 
that can be readily validated experimentally 52,188,220,221.  
In this section, we investigated signal transmission in GLIC from the EC domain to 
the TMD of GLIC upon two different stimuli. The first one is at the C loop region, where 
residues E177, D178, and R179 potentially form salt bridges with residues K148 and D91 
at the complementary site of an adjacent subunit. We performed mutations (D91N, 
E177Q, and D178N, termed the NQN mutation) to remove the potential of salt bridges. 
Perturbation to GLIC due to the NQN mutation was evidenced in our crystal structure and 
functional measurements as presented below. The second perturbation site at the ECD 
is below the C loop, where the anesthetic ketamine was found to bind to an existing inter-
subunit pocket and inhibit GLIC current in a concentration dependent manner 47. While 
the functional relevance of these perturbation sites is proven, it needs to be further 
clarified how the perturbation signal propagates from the ECD to the channel gate. Here 
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we used the PMT model to identify crucial signaling paths within a subunit and between 
adjacent subunits of GLIC. The resulting information will facilitate our understanding of 
the mechanisms of allosteric action in pLGICs. 
5.1.2. Methods 
PMT calculations 
PMT calculations were performed on the pentameric GLIC using the online server 
(http://gila-fw.bioengr.uic.edu/lab/tools/pmtmodel/). Details of the PMT model were 
provided in the previous publication 48. Briefly, the Markovian transition model 49 was used 
to investigate how a given perturbation is transmitted through a protein network over time. 
At each time step, the perturbation is transmitted from residue i to residue j with a 
probability mij, an element in the Markovian transition matrix M = {mij}NN, where N is the 
total number of residues in the protein and ∑ miji  = 1. Each residue is represented as a 
single node in the model. The mij values are computed from the atomistic (no hydrogens) 
structure according to mij = nij ∑ miji⁄ , where nij is the number of atom-atom contacts 
between residues i and j. Two atoms from different residues are considered in contact if 
the Euclidean distance between the two atoms is ≤ 4.5 Å, the cutoff that consistently 
displayed the fastest signal propagation for all tested perturbation sites 48,49. The initial 
perturbation, p(0), is defined by a set of probabilities {pi(0)}N, where pi(0) is the probability 
mass located at node i at time t = 0. The signal distribution at time t is defined by a vector 
p(t) = [p1(t), … , pN(t)]. The probability flow, which depends on both M and p(0), provides 
clues to the signal transduction within the protein under a particular stimulus. The final 
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distribution at equilibrium, p(∞), depends only on M, not on p(0). The master equation 
describing time-dependent transmission of perturbation is 
where R = M – I, and I is the identity matrix. The Krylov subspace method 230 was used 
for computing each p(t).  
The top elementary (or fundamental) signal paths of the highest probability were 
further elucidated using Yen’s algorithm 50 implemented in MATLAB®   
(http://www.mathworks.com/matlabcentral/fileexchange/32513-k-shortest-path-yens-algorithm). 
Briefly, for Yen’s algorithm, we transformed the Markov transition matrix, M, in the PMT 
model to a “cost” matrix by computing the element-wise inverse of M. Yen's algorithm 
computes the summed cost for transitions between node i and node j. The cost of each 
transition corresponds to element i,j in the cost matrix. The sequence of nodes that 
minimizes the cost between the specified starting and ending nodes was determined. The 
lower the cost is, the higher the probability of the signal path will be.  
All the data were processed using MATLAB7.10 (The MathWorkds Inc.). VMD was 
used to render protein images 86. 
The initial perturbation sites were chosen based on our crystal structures and 
functional measurements of GLIC reported previously (PDB ID: 4F8H) 47 and reported 
below. 
 
Free energy calculations for the subunit interface 
To compare the stability of the subunit interface before and after the NQN mutation in 
GLIC, we calculated free energy changes for the subunit interface in the crystal structures 
 
 ( 5.1 ) 
  
  
dp(t)
dt
= Rp(t)
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of the wild type GLIC and the NQN mutant GLIC using the PISA online server 
(http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html) 231. 
 
Protein preparation, crystallization, and structure determination  
The NQN (D91N, E177Q, and D178N) mutation to remove potential salt bridges between 
the C loop and the complementary side of the adjacent subunit was achieved using site-
directed mutagenesis on GLIC with the QuikChange Lightning Kit (Stratagene, Santa 
Clara, CA) and confirmed by DNA sequencing. The GLIC mutant was expressed in 
Rosetta(DE3)pLysS (Novagen) and purified as reported in details previously 27,28,47. The 
pentameric GLIC-NQN mutant in 0.01% (w/v) n-tetradecyl-β-D-maltoside from a final 
purification using SEC was concentrated to ~10 mg/mL and used for crystallization. 
The crystallization and cryo-protection conditions used for the GLIC-NQN mutant 
were the same as those used previously for GLIC and the GLIC-ketamine complex 47. 
The X-ray diffraction data were acquired on beamline 12-2 at the Stanford Synchrotron 
Radiation Lightsource and processed using the XDS program 232. The initial structure was 
solved by molecular replacement using the GLIC-ketamine structure (PDB ID: 4F8H) as 
the starting model. The NQN mutations were made manually on the model with COOT 
233. Phenix (version: 1.8.1) 234 was used for structure refinement. Six detergent and ten 
lipid molecules were built into well-defined extra electron densities after initial refinement 
runs. Oxalate molecules degraded from PEG reagents, acetate ions from the 
crystallization solution, and water molecules were built into the electron densities at the 
final stages of the refinement with COOT 233. Non-crystallographic symmetry (NCS) 
restraints were applied for five subunits in each asymmetric unit. The stereochemical 
quality of the model was checked with PROCHECK 140 and MolProbity 235. Crystal 
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structure analysis was performed using Phenix and CCP4 236. PyMOL 237 and VMD 86 
programs were used for structural analysis and figure preparation.  
 
Functional measurements of the NQN Mutant 
For functional measurements of the NQN mutant, the site-directed mutagenesis was 
introduced to GLIC in the pTLN vector for expression in Xenopus laevis oocytes and 
confirmed by DNA sequencing. The plasmid DNA was linearized with MluI enzyme (New 
England BioLabs, Ipswich, MA). Capped complementary RNA was transcribed with the 
mMESSAGE mMACHINE SP6 kit (Ambion, Austin, TX) and purified with the RNeasy kit 
(Qiagen, Valencia, CA). The defolliculated stage V-VI oocytes were injected with cRNA 
(10-25 ng/each) and maintained at 18°C in Modified Barth’s Solution (MBS) containing 
88 mM NaCl, 1 mM KCl, 2.4 mM NaHCO3, 15 mM HEPES, 0.3 mM Ca(NO3)2, 0.41 mM 
CaCl2, 0.82 mM MgSO4, 10 μg/mL sodium penicillin, 10 μg/mL streptomycin sulphate, 
100 μg/mL  gentamycin sulphate, pH 6.7. Two-electrode voltage clamp experiments were 
performed on oocytes expressing the NQN mutant at room temperature 16-40 hours after 
the injection, using a model OC-725C amplifier (Warner Instruments) and a 20-μl 
recording chamber (Automate Scientific). Oocytes were perfused with ND96 buffer (96 
mM NaCl, 2 mM KCl, 1.8 mM CaCl2, 1 mM MgCl2, 5 mM HEPES, pH7.4) and clamped to 
a holding potential of –40 or –60 mV. The ND96 buffer at the lower pH was prepared with 
the addition of 5 mM MES and HCl. Data were collected and processed using Clampex 
10 (Molecular Devices). The data were fit by least squares regression to the Hill Equation 
using Prism software (Graphpad). The same software was also used for statistic analysis 
using extra sum-of-squares F-test. 
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5.1.3. Two functionally relevant sites at the EC domain of GLIC 
Two functionally relevant sites at the ECD of GLIC (Figure 5.1.1a) were chosen for 
investigating how perturbation signals are transmitted from the ECD to the channel gate.  
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Figure 5.1.1. Functionally relevant sites in the EC domain of GLIC. (a) Residues for the NQN mutation 
(D91N; E177Q; D178N) and the complementary basic residues (R179 and K148) for salt bridge formation 
are highlighted in red and blue, respectively. Residues involved in the ketamine binding site (F174, L176, 
K183; N152, D153, D154) are highlighted in cyan. (b) The C loop region of the crystal structure of the NQN 
mutant (orange), showing an outward movement of the C loop in comparison with the wild type GLIC (yellow 
and gray) due to removal of salt bridges in the mutant. R179 and K148 are shown in blue and cyan sticks 
for GLIC and the NQN mutant respectively. D91N, E177Q, and D178N are shown in red and green sticks, 
before and after the mutation, respectively. The salt bridge distances in GLIC are highlighted. Note the 
enlarged gap after the mutation. No hydrogen bonds could be formed for the mutated residues. (c) Two-
electrode voltage clamp measurements on Xenopus laevis oocytes expressing the NQN mutant (solid 
square) and the wild type GLIC (open circle). The half maximal effective concentrations (EC50) for the 
mutant and GLIC are pH 4.80 ± 0.03 (n = 13) and 5.04 ± 0.02 (n = 10), respectively. The EC50 difference 
between the wild type GLIC and the NQN mutant is statistically significant (p < 0.0001). Error bars represent 
standard error from the mean. The inserts are the representative traces for GLIC and the NQN mutant. 
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One site is at the C loop region, where the inter-subunit salt bridges (E177-K148, 
D178-K148, and R179-D91) are observed in the crystal structures of the open-channel 
GLIC 27,47. In order to understand the functional role of these salt bridges, we performed 
the NQN mutation (D91N, E177Q, D178N) to eliminate the salt bridges, crystallized the 
NQN mutant, and solved its structure (PDB ID: 4IRE) to a resolution of 3.19 Å (Table 
5.1.1). The overall structures of the NQN mutant and GLIC are nearly the same (RMSD 
~ 0.5 Å) and show an open channel conformation. However, the C loop of the NQN mutant 
shows an outward movement and the interfacial gap in the C loop region, measured by 
side chain displacement of D178N, widens 3 Å (Figure 5.1.1b). The NQN mutation 
removed the salt bridges but did not generate hydrogen bonds. To compare the 
conformational stability before and after the mutation, we calculated free energies for the 
inter-subunit interface in the crystal structures of the wild type GLIC and the NQN mutant. 
The resultant free energies of –29 kcal/mol and –26 kcal/mol for GLIC and the NQN 
mutant, respectively, suggest that removing the salt bridges at the subunit interface 
destabilized the open channel conformation. Functional measurements of the wild type 
GLIC and the NQN mutant provide results consistent with the free energy calculations. 
The mutation shifted the EC50 from pH 5.0 in the wild type GLIC to pH 4.8 in the NQN 
mutant (Figure 5.1.1c). Statistical analyses confirmed that the EC50 difference between 
the wild type GLIC and the mutant was significant with p < 0.0001. Apparently, more 
protons are required for channel activation to compensate for destabilization of the open-
channel conformation due to the absence of the inter-subunit salt bridges.  
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Table 5.1.1. Data collection and refinement statistics 
Data collection and process  
Beamline SSRL BL12-2 
Wavelength (Å) 0.9795 
Space group C2 
Unit cell (Å) 182.0, 133.6, 161.4 
β (°) 102.6 
Resolution (Å) 29.86-3.19 (3.36-3.19) 
Rmerge(%)a 6.8 (70.7) 
Completeness (%)a 97.5 (92.9) 
<I/σ>a 14.0 (1.8) 
Unique reflectionsa 61417 (9335) 
Redundancya 3.8 (3.7) 
Refinement statistics  
Resolution (Å) 29.86-3.19 
No. Reflections (test set) 61291 (999) 
Rwork/Rfree 0.204/0.243 
Non-H protein (ligand) atoms 12686 (754) 
<B-factors> (Å2)  
Protein 87.3 
Detergents 107.5 
Lipids 121.0 
Solvent 93.5 
R.M.S. Deviations  
Bond lengths (Å) 0.009 
Bond angles (degrees) 1.3 
Rotamer outliers (%) 5.3 
Ramachandran outliers (%) 0.19 
Ramachandran favored (%) 97.17 
PDB ID 4IRE 
aValues in the parentheses are for highest-resolution shell.  
 
The other relevant location is the ketamine-binding site 47, which we identified 
previously in a 2.99-Å resolution X-ray structure of the GLIC-ketamine complex (PDB ID: 
4F8H). Ketamine binds to an inter-subunit cavity, which is lined by residues F174, L176 
and K183 on the principal side and N152, D153 and D154 on the complementary side. 
The ketamine binding site is partially overlapped with the homologous antagonist-binding 
site in pLGICs. The functional relevance of the ketamine site was determined by profound 
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changes in GLIC activation upon cysteine substitution of the cavity-lining residue N152. 
The functional relevance was also evidenced by changes in ketamine inhibition upon the 
subsequent chemical labeling to N152C. 
These structural and functional data highlight the functional relevance of the two 
sites and provide the experimental basis for initial perturbation in PMT calculations as 
presented below. 
5.1.4. Time-dependent transmission of perturbation initiated at the NQN mutation 
site and the ketamine-binding site 
To reveal the allosteric signaling pathway in GLIC, we placed an initial perturbation of 
uniform strength on residues shown in Figure 5.1.1a for the NQN mutation or ketamine 
binding within the PMT model. The time-dependent probability flux, defined in Equation ( 
5.1 ), was calculated for each selected scenario of initial perturbation site (Figure 5.1.2). 
The pertubation originated from the NQN mutation site was transmitted immediately to 
Y23, L103, R133, and K148. Among them, R133 and K148 form intra- and inter-subunit 
salt bridges with D178 and E177, respectively. The perturbation at the ketamine binding 
site was transmitted to a cluster of residues in β1 (Y23, I25, E26) and β6 (L130, I131, 
R133). These residues are mostly in close contact with the perturbed sites. As time 
proceeds, increasing numbers of residues in the ECD experience the positive probability 
flux (colored red in Figure 5.1.2). The positive probability flux occured in the TMD when 
most residues in the ECD experienced the negative probability flux (signal moved away, 
colored blue in Figure 5.1.2).  
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Figure 5.1.2. Trajectories of the probability flux over time for each residue upon different initial 
perturbations. (a) Initial perturbation at the NQN mutation site; (b) initial perturbation at the ketamine-
binding site. The color denotes the normalized intensity of the probability flux. See Equation ( 5.1 ) in the 
Methods section. The positive and negative signs describe the net signal flow into and out of the residue, 
respectively.  The time axis is in arbitrary unit. The initially perturbed and immediately affected residues are 
labeled in blue and red, respectively. 
 
The two initial perturbation sites share similar overall patterns of the probability flux 
in the TMD. The signals reached pre-TM1, the TM2-TM3 linker, and the C-terminus of 
TM4 before they propagated to other parts of the TMD. The residues immediately affected 
by the perturbation in the ECD were clearly identified, but specific signaling paths became 
obscured as the signal diffused through the protein. To trace the paths between the 
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initially perturbed residues and the channel gate residue I233 (also named 9’, a commonly 
presumed hydrophobic gate residue), we used Yen’s algorithm 50 that outputs the most 
likely paths based on the probabilities stored in the Markovian transmission matrix. The 
pore-lining residues other than 9’ were also tested as target residues and produced the 
same paths as observed for the target 9’. There were a total of three and six initially 
perturbed residues for the NQN mutation site and ketamine-binding site, respectively. For 
each of the perturbed residues involved in the NQN mutation site (D91, E177, D178) and 
ketamine binding site (N152, D153, D154, F174, L176, K183), 10 signal paths with the 
highest probability were determined using Yen’s algorithm 50. The signal starts at the 
perturbed residue and ends at the channel gate residue I233. For completeness, three 
scenarios following each perturbation were considered, assume all signals start in subunit 
B: (1) signal starts and ends within subunit B; (2) signal starts in subunit B and ends in 
subunit A; (3) Signal starts in subunit B and ends in subunit C. In total, 270 paths were 
obtained (9 initial perturbations, 10 paths of highest probability for each perturbation, 3 
different scenarios for the ending point). Many of the observed signal pathways are 
degenerate. However, the emerged pathways of the highest probability for signal 
transduction from the ECD to the channel pore in our analysis (Table 5.1.2) reveal the 
involvement of two critical regions. The first one is the β1-β2 loop (also named loop 2) 
that couples with the C-terminus of TM2 (Figure 5.1.3a and d). The second one is pre-
TM1 that often mediates signaling between subunits (Figure 5.1.3b, e, and f).  
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Figure 5.1.3. Paths with the highest probability to reach the channel gate (I233; 9’) under different 
initial perturbations in GLIC. (a) The path within a subunit upon perturbation to D91 of the NQN mutation; 
(b) the path between D178 of the NQN mutation site and I233 (9’) of the same subunit showing an inter-
subunit pathway; (c) the path between D91 of subunit B and I233 (9’) of subunit A; the perturbation to F174 
of the ketamine binding site shows both (d) intra- and (e) inter-subunit paths for signal starting and ending 
in subunit B; (f) the path between F174 of subunit B and I233 (9’) of subunit C.  The perturbation starting 
and ending points are shown in green and red spheres, respectively. The pathways are highlighted in purple 
spheres. Subunits A, B, and C are colored silver, yellow, and cyan, respectively. All calculations were 
performed using Yen’s algorithm 50. 
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Table 5.1.2. Highest probability paths for each residue in the NQN mutation site (D91, E177, D178) 
and ketamine binding site (N152, D153, D154, F174, L176, K183) 
 β1-β2 Loop Pre-TM1 
Subunit B to 
subunit B 
  
D91 V90, V89, D88, A87, D86, S107, A108, 
R109, T36, A34, K33, T244, E243, 
N239, I236, I233 
N/A 
D178 E177, L176, Y23, N152, V155, F156, 
P113, L114, E35, A34, K33, T244, E243, 
N239, I236, I233 
E177, L176, Y23, N152, V155, F156, T158, G159, 
Q193, Y194, F195, S196, N200, E243, N239, 
I236, I233 
E177 L176, Y23, N152, V155, F156, P113, 
L114, E35, A34, K33, T244, E243, 
N239, I236, I233 
L176, Y23, N152, V155, F156, T158, G159, Q193, 
Y194, F195, S196, N200, E243, N239, I236, I233 
N152 V155, F156, L157, L30, D31, K33, T244, 
E243, N239, I236, I233 
N/A 
D153 D154, F156, L157, L30, D31, K33, T244, 
E243, N239, I236, I233 
N/A 
D154 F156, L157, L30, D31, K33, T244, E243, 
N239, I236, I233 
N/A 
F174 N173, A172, K183, Y129, H127, L126, 
F37, T36, A34, K33, T244, E243, N239, 
I236, I233 
A175, L176, Y23, N152, V155, F156, T158, G159, 
Q193, Y194, F195, S196, N200, E243, N239, 
I236, I233 
L176 Y23, N152, V155, F156, P113, L114, 
E35, A34, K33, T244, E243, N239, I236, 
I233 
Y23, N152, V155, F156, T158, G159, Q193, 
Y194, F195, S196, N200, E243, N239, I236, I233 
K183 Y129, H127, L126, F37, T36, A34, K33, 
T244, E243, N239, I236, I233 
N/A 
Subunit B to 
subunit A 
  
D91 V90, V89, D88, A87, D86, R85, A84, 
N83, E82, Y28, S29, L30, D31, K33, 
T244, E243, N239, I236, I233 
N/A 
D178 E177, L176, Y23, L24, I25, E26, C27, 
Y28, S29, L30, D31, K33, T244, E243, 
N239, I236, I233 
N/A 
E177 L176, Y23, L24, I25, E26, C27, Y28, 
S29, L30, D31, K33, T244, E243, N239, 
I236, I233 
N/A 
N152 V155, F156, L157, L30, D31, K33, P247, 
K248, N245, T244, E243, N239, I236, 
I233 
N/A 
D153 D154, F156, L157, L30, D31, K33, P247, 
K248, N245, T244, E243, N239, I236, 
I233 
N/A 
D154 F156, L157, L30, D31, K33, P247, K248, 
N245, T244, E243, N239, I236, I233 
N/A 
F174 A175, L176, Y23, L24, I25, E26, C27, 
Y28, S29, L30, D31, K33, T244, E243, 
N239, I236, I233 
N/A 
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L176 Y23, L24, I25, E26, C27, Y28, S29,, L30, 
D31, K33, T244, E243, N239, I236, I233 
N/A 
K183 Y129, N80, V81, E82, Y28, S29, L30, 
D31, K33, T244, E243, N239, I236, I233 
N/A 
Subunit B to 
subunit C 
  
D91 V90, V89, D88, R105, V79, N80, V110, 
F37, T36, E35, A34, K33, T244, E243, 
N239, I236, I233 
N/A 
D178 E177, L176, Y23, N152, V155, F156, 
P113, L114, E35, A34, K33, T244, E243, 
N239, F238, I236, I233 
R179, R133, V132, I131, L130 Y129, H127, T125, 
Q124, S123, D122, F121, Y194, F195, S196, 
N200, E243, N239, I236, I233 
E177 L176, Y23, N152, V155, F156, P113, 
L114, E35, A34, K33, T244, E243, 
N239, F238, I236, I233 
L176, Y23, N152, V155, F156, T158, G159, Q193, 
Y194, F195, S196, N200, E243, N239, F238, 
I236, I233 
N152 V155, F156, T158, P113, L114, E35, 
A34, K33, T244, E243, N239, I236, I233 
V155, F156, T158, G159, Q193, Y194, F195, 
S196, N200, E243, N239, I236, I233 
D153 D154, F156, T158, P113, L114, E35, 
A34, K33, T244, E243, N239, I236, I233 
D154, F156, T158, G159, Q193, Y194, F195, 
S196, N200, E243, N239, I236, I233 
D154 F156, T158, P113, L114, E35, A34, K33, 
T244, E243, N239, I236, I233 
F156, T158, G159, Q193, Y194, F195, S196, 
N200, E243, N239, I236, I233 
F174 N/A N173, A172, P171, K170, V168, A167, T166, 
F165, S164, E163, I162, D161, Q193, Y194, 
F195, S196, N200, E243, N239, I236, I233 
L176 Y23, N152, V155, F156, P113, L114, 
E35, A34, K33, T244, E243, N239, 
F238, I236, I233 
Y23, N152, V155, F156, T158, G159, Q193, 
Y194, F195, S196, N200, E243, N239, F238, 
I236, I233 
K183 N/A Y129, H127, T125, Q124, S123, D122, F121, 
Y194, F195, S196, N200, E243, N239, I236, I233 
*Residues colored black, red, and green belong to subunits B, A, and C, respectively.  
*Residues in the β1-β2 loop or pre-TM1 are highlighted in bold 
 
5.1.5. The paths via the β1-β2 loop  
Paths involving the β1-β2 loop can be either within a subunit or between adjacent 
subunits. For the intra-subunit signaling path, the perturbation signals resulting from the 
NQN mutation and ketamine binding initially travel via different routes, but eventually 
emerge at the β1-β2 loop, and further propagate along the same path to the channel gate. 
For example, as shown in Figure 5.1.3a and d, the initial perturbations at D91 and F174 
have two respective paths at the beginning: (i) D91, V90, V89, D88, A87, D86, S107, 
A108, R109 T36 of the β1-β2 loop; and (ii) F174, N173, A172, K183, Y129, H127, 
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L126 F37 of the β1-β2 loop. Once the signal reached the β1-β2 loop, the rest of the 
path follows: F37, T36, A34, K33, T244, E243, N239, I236, I233(9’).  
Assuming perturbations start in subunit B, inter-subunit paths involving the β1-β2 
loop are observed for signals ending in either subunit A or subunit C. We note variations 
in the signal path when the initially perturbed residue or the ending subunit are varied 
(Table 5.1.2), but the involvement of the β1-β2 loop was observed in 66% of 270 paths 
identified by Yen’s algorithm. 
The important role of the β1-β2 loop in the channel function has been well 
documented by experimental studies. Mutagenesis in the mouse α1 subunit of nAChR 
and subsequent single channel electrophysiology measurements in the nAChR by 
Auerbach’s group showed that residues in the β1-β2 loop, homologous to GLIC D32 (α1-
E45) and K33 (α1-V46), are critical for channel gating 189,238. Sine’s group also found the 
critical role of α1-E45 and α1-V46 in the channel gating of the human nAChR 221. 
Furthermore, residues at the C-terminus of TM2 of the mouse nAChR, homologous to 
GLIC E243 (α1-V261) and T244 (α1-E262), were found in the same gating block (Φ ~ 
0.8) as the residues in the β1-β2 loop 51. They are significantly coupled to channel 
gating 51. More comparisons between our model predictions and experimental data on 
nAChR are provided in a specific section below.  
5.1.6. The paths via pre-TM1 
The paths involving pre-TM1 were not observed as frequently as those involving the β1-
β2 loop, but the significant occurrences of these paths (34% of the paths identified) make 
them worth noting. Unlike the β1-β2 loop that occurs in the signaling pathways both within 
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a subunit and between adjacent subunits, pre-TM1 occurs exclusively in pathways across 
adjacent subunits. Assuming all perturbations start in subunit B, there are at least two 
types of paths involving pre-TM1. First, the initial perturbation signal (such as L176) 
traveled across subunit B, passed the pre-TM1 in the adjacent subunit A (Y23, N152, 
V155, F156, T158, G159, Q193, Y194, F195, S196, N200), and then propagated to the 
channel gate in subunit B (E243, N239, I236, I233), such as shown in Figure 5.1.3b and 
e. Second, the initial perturbation signal traveled through pre-TM1 of subunit B (F174, 
N173, A172, P171, K170, V168, A167, T166, F165, S164, E163, I162, D161, Q193, 
Y194, F195, S196, N200) before reaching TM2 and the channel gate of subunit C (E243, 
N239, I236, I233), such as shown in Figure 5.1.3f. Additional high probability paths 
involving pre-TM1 between a perturbed residue and the channel gate are provided in 
Table 5.1.2. 
The involvement of pre-TM1 in signaling paths between the ECD and the channel 
gate is not unexpected. Pre-TM1 covalently links the EC and TM domains. The functional 
contribution of pre-TM1 has been recognized in the past. However, the contribution was 
often attributed to the coupling with other loops at the EC/TM interface185,221,239-241. 
Mutagenesis, single-channel kinetic analyses, and thermodynamic mutant cycle analyses 
on the nAChR revealed energetic coupling among residues from pre-TM1, the Cys-loop, 
and the TM2–TM3 linker 185. Specific interactions between pre-TM1 and the β1-β2 loop 
are shown in crystal structures of the mouse α1 nAChR ECD 32 and GLIC 27,28. The 
functional coupling of pre-TM1 with the loop β1-β2 has been demonstrated in several 
experimental studies185,239,241. It was proposed that the coupling of pre-TM1 to the TM2–
TM3 linker constitutes a principal transduction pathway 221,240. Our analysis here reveals 
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a novel coupling mode of pre-TM1, in which pre-TM1, in conjunction with the C-terminal 
end of TM1, can directly transduce signals to TM2 and the channel gate of the adjacent 
subunit. This newly identified coupling is more direct and probably more effective for pre-
TM1 to convey signals from the ECD to the channel gate. In addition, since the coupling 
is between adjacent subunits, it facilitates communications and cooperative action among 
subunits.  
It is worth noting that among all four TM helices, the TM2 conformation is the most 
sensitively correlated to the channel state as indicated in the crystal structures 27,211 and 
in MD simulations 62. The TM1 conformation is the second most sensitive to the channel 
state 27,211,242. The direct coupling of pre-TM1 N200 with TM2 E243 of the neighboring 
subunit may alter the TM2 tilting angles and induce a conformational change. 
5.1.7. Why only the β1-β2 loop and pre-TM1 
Four regions from the EC domain (β1-β2, 8-9, 10, and the Cys-loop) and two regions 
from the TM domain (pre-TM1 and the TM2-TM3 linker) comprise the coupling interface 
between the EC and TM domains of GLIC and other pLGICs. Previous studies on Cys-
loop receptors have shown that these regions, either individually or in combination, 
mediate the transduction of agonist binding to channel gating 52,185,188,221,239,240,243,244. 
In the context of the PMT model, paths to TM2 through either the β1-β2 loop or 
pre-TM1 have higher probabilities than paths through other loops, such as the Cys-loop 
and the TM2-TM3 linker. While these loops were not detected in the highest probability 
paths, this does not imply that such loops are not important. The PMT model has a 
limitation in that it only considers the number of atom-atom contacts for the probability of 
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passing a signal from one residue to another. Consequently, Van der Waals interactions 
are weighted more heavily than Coulombic interactions. For Cys-loop receptors, the 
importance of salt bridges at the interface of the EC and TM domains has been well-
documented 44,221,243. Thus, our results should not be interpreted to rule out the functional 
contribution of the Cys-loop and the TM2-TM3 linker. Rather, these results explicitly 
demonstrate the importance of the β1-β2 loop and pre-TM1 in the signaling pathways.   
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5.1.8. The signaling pathway within the muscle-type nAChR 
 
Figure 5.1.4. Trajectory of the probability flux and the highest probability path in nAChR (PDB ID: 
2BG9). (a) Trajectory of the probability flux over time for each residue of the α1 nAChR upon perturbation 
to the agonist-binding site (Y93, W149, Y190, and Y198). The color denotes the normalized intensity of the 
flux. Positive and negative signs describe the net signal flow into and out of the residue, respectively. (b) 
The signaling path with highest probability between Y190 of the C loop and the pore-lining residue L251 
(9’) in the α1 nAChR. Perturbation starting and ending points are shown in green and red spheres, 
respectively. Residues comprising the path are shown in purple spheres. The labeled residues were 
identified previously in the mutagenesis and functional studies for transferring energy from the extracellular 
domain to the channel gating 51,184,189,238,245,246. 
 
The results from the PMT model depend heavily on the protein structure. 
Therefore, what we observed on GLIC is expected to be applicable to the homologous 
Cys-loop receptors. To confirm this is the case, we performed the same calculations on 
the muscle-type nAChR (PDB ID: 2BG9). The advantage of using the muscle-type nAChR 
is not only the availability of the structure, but also the availability of extensive 
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experimental data 51,184,185,189,221,239,245,246. The initial perturbation was placed at the 
agonist binding site, namely residues α1-Y93, α1-W149, α1-Y190, and α1-Y198 (Figure 
5.1.4). The results from Yen’s algorithm show that these residues in the binding site are 
well coupled, as they pass signal to each other along the highest probability paths. Thus 
we examined the representative pathway between Y190 and L251 (L9’).   
Despite the inclusion of adjacent subunits in the calculations, the initial perturbation 
signal traveled only through an intra-subunit path via the β1-β2 loop to reach the channel 
gate. More interestingly, when the path was constrained between Y190 and the channel 
gate of either adjacent subunit, the signal still traveled to TM2 within the same subunit 
before ending at the channel gate residue of the adjacent subunit. This is presumably due 
to tighter TM2 helical packing in the closed-channel nAChR structure versus the open-
channel GLIC structure. The intra-subunit path for the nAChR is similar to the intra-
subunit path observed for GLIC (Figure 5.1.3a and d). Furthermore, residues along the 
pathway were previously suggested for signal propagation in experimental studies (Figure 
5.1.4b) 51,184,189,238,245,246. The observed pathway is well supported by experimental data. 
5.1.9. Conclusions 
Using the PMT model in combination with Yen’s algorithm, we revealed multiple pathways 
for signal transduction from the ECD to the channel gate. While the EC/TM interfacial 
structural elements (such as the Cys-loop, the β1-β2 loop, pre-TM1, and the TM2-TM3 
linker) are expected to play roles in the signal transduction, we only found the β1-β2 loop 
or pre-TM1 in the signal transduction pathways of the highest probability upon different 
perturbations to the ECD. Paths involving the β1-β2 loop can be either within a subunit or 
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between adjacent subunits, but paths involving pre-TM1 are exclusively between adjacent 
subunits. In the past, signaling involving pre-TM1 has been attributed to pre-TM1 coupling 
with other loops at the EC/TM interface. Our data suggest that pre-TM1 can directly 
couple with TM2 of the adjacent subunit, providing a new insight into the allosteric 
signaling mechanisms of pLGICs. 
5.2. THE RELATIONSHIP BETWEEN DYNAMICS AND ALLOSTERIC 
MODULATION 
This section of the Thesis is based on publications in Structure 21 (10): 1-8, J Phys Chem 
B 114: 7649-7655, Biochim Biophys Acta 1828 (9): 398-404, and J Biol. Chem. (2013) 
and a manuscript recently accepted for publication in Biochim Biophys Acta.  
5.2.1. Background and Significance 
The precise mechanisms of allosteric modulation within Cys-loop receptors are currently 
unknown. Our NMR study on the glycine receptor TMD showed unique dynamics at the 
EC end of the TMD that could be related to channel function 38. Other studies have also 
shown that dynamics at the EC end of TM2 is important to channel gating 57,58. Our 
structural study of the hGlyR-α1 TMD also suggested that mutations affecting anesthetic 
sensitivity more likely affected the intrinsic gating dynamics than specific anesthetic 
binding 38. In support of this theory, several past studies have shown that mutations 
affecting anesthetic modulation often concurrently affect the intrinsic gating dynamics of 
the channel 54-56. Our NMR studies on the neuronal nAChRs also provide support for the 
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involvement of dynamics in allosteric modulation and suggest that only the ligand binding 
that can affect the channel dynamics will produce the functional effect. 
In this section we explore the relationship between dynamics and allosteric 
modulation. Our study on the hGlyR-α1 TMD identified dynamics at the EC end of the 
TMD that could be related to channel gating. Further support for the role dynamics in 
allosteric modulation was observed in both our computational MD results and 
experimental NMR results. The results show significant changes to channel dynamics in 
channels affected by anesthetics. The results presented here provide compelling 
evidence for the importance of dynamics in allosteric modulation. Our findings present a 
significant achievement towards understanding the mechanism of allosteric modulation 
in Cys-loop receptors.  
5.2.2. Channel gating and dynamics in the hGlyR-α1 TMD  
Dynamic characteristics of the TM2 and TM3 helices near the TM2-TM3 linker can be 
observed both in the bundle of structures (Figure 2.2.5), and directly in the high-resolution 
NMR spectra. In the spectra, two sets of NMR peaks are identifiable for several residues 
near the TM2 C-terminus, including S268(16’), G269(17’), and S270(18’) (Figure 2.2.7a). 
The data suggest that at least two conformations coexist in this region and undergo slow 
exchange on the μs timescale. A similar minor conformation was also observed in an 
extended TM2 segment of GlyR 124 and in the TM2-TM3 construct in lipid bicelles 121. The 
NMR structures determined in the present study are associated with the major peaks. 
The structure in the minor conformation could not be determined because of insufficient 
NOESY connectivity. A considerable degree of conformational flexibility in the region of 
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the TM2 and TM3 helices near the TM2-TM3 linker is also evident in the backbone 
dynamics, as measured by the 15N relaxation parameters (R1 and R2) and 15N-{1H} 
hetNOE of the major peaks. The segment from S267 (S15’) in TM2 to K276 (K24’) in the 
TM2-TM3 linker, and residues involved in the TM3 helical kink show smaller hetNOE and 
R2 values and relatively higher R1, suggesting high flexibility in the region 38. 
The conformational dynamics near the EC end TM2 shows two conformations for 
R271(19’), with a smaller population in a more extended helix and a larger population in 
an unwound conformation. Consequently, instead of facing the pore, R19’ in some 
structures is mostly tangent to the pore, where R271(19’) experiences a more 
hydrophobic environment. Indeed, such conformational flexibility was noted previously by 
tethering a rhodamine fluorophore to R271C 126, suggesting that conformational flexibility 
at the EC end of the pore is related to channel function. Ester substitution is expected to 
weaken the backbone hydrogen bonds and increase the flexibility of the pore-lining TM2 
helix. Single-point amide-to-ester mutations at 13’, 16’, or 19’ of nAChR increased the 
receptor’s sensitivity to agonist more than tenfold 57. A more recent study using electron 
paramagnetic resonance spectroscopy also observed greater conformational changes at 
the EC end of TM2 upon agonist binding 58. 
The high flexibility of the TM2 C-terminus of hGlyR-α1 is likely coupled with the 
structural flexibility near the N-terminal helix of TM3. A helical kink (I285-A288) divides 
the TM3 domain into two α-helical segments: one from V277 to D284 and the other from 
V289 to V307 (Figure 2.2.5a and Figure 2.2.6). While the TM3 helices in the crystal 
structure of the GluCl and ivermectin complex show no kink 29, the kink may exist in the 
absence of ivermectin. When we aligned the TM structures of GluCl and hGlyR-α1, it 
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became clear that ivermectin partially overlapped with the kink observed in the NMR 
structure (Figure 2.2.7b), suggesting that ivermectin binding may have stabilized a 
straight helical conformation and that without ivermectin the flexibility would make it much 
more challenging to obtain high quality GluCl crystals for X-ray structure determination.  
S267 and A288 mark the two ends of a dynamic region of the channel in our hGlyR-
α1 TMD structures (Figure 2.2.7c). Intriguingly, mutations S267Y and A288W in the 
hGlyR-α1 TMD were found to substantially reduce general anesthetic and alcohol 
potentiation of GlyR responses 55. Mutations at S267 showed that ethanol modulation 
was correlated with the volume but not the polarity or hydropathicity of the substituting 
side chains, suggesting that S267 itself is not directly involved in alcohol binding 128. 
These functional consequences may result from the reduced conformational flexibility in 
the region due to bulky substitution at the S267 position. In fact, our previous NMR study 
demonstrated that the S267Y mutation increased the α-helix length at the TM2 C-
terminus 111. Mutation of A288 to an amino acid with a different size can also alter 
conformational flexibility in the region with functional consequences. Indeed, A288F and 
A288G have opposite functional impacts, with the former reducing and the latter 
increasing glycine-induced channel activation 54. It is unlikely that glycine binding is 
affected by the mutations because the orthosteric agonist-binding site in the ECD is 
remote from A288. The changes in conformational flexibility due to mutations alter the 
channel’s susceptibility to allosteric activation. 
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5.2.3. Effects of halothane on dynamics of α7 and α4β2 in MD simulations 
Molecular simulations have shown a link between anesthetic effects on protein dynamics 
and the ability of the drug to modulate channel function. In previous sections we showed 
that cross-correlation maps from GNM analyses revealed correlations between the Cys-
loop and the β1-β2 linker with the TM2-TM3 linker were unaffected by halothane in α7, 
but were diminished by halothane in β2 (Figure 4.1.3). Given the importance of 
interactions between these loops for propagating agonist binding signals in the ECD to 
channel gating in the TMD 138,188-192, a sensitive response of β2 and an insensitive 
response of α7 to halothane to correlated motions at the EC/TM interface is consistent 
with halothane induced functional responses of α7 and α4β2 5,6. 
Differences in halothane affects to local motion were also observed between α7 
and α4β2. To assess whether halothane affected the local motion of α7, we calculated Cα 
RMSF for the closed- and open-channel α7 in both the control and halothane systems. 
For comparison, the same RMSF analysis was also performed on the previous α4β2 
simulation data. As expected, residues in large loops and linkers, particularly at the N- 
and C-termini, show greater RMSF values than residues in helices or β sheets. Because 
of this terminal effect, residues at the N- and C-termini were excluded in our examination 
of halothane’s effect on the RMSF. For a clear illustration of RMSF changes between the 
halothane and control systems, the average ratios of the backbone RMSFs of each 
subunit type in the halothane system to the control system were calculated. As shown in 
Figure 5.2.1, the average RMSF ratios for the majority of residues have values close to 
one, indicating that the motion of these residues on the ps-ns time scale was almost 
unaffected by halothane. The elevated ratios around residues 305 to 307 were due to the 
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disconnection between TM3 and TM4. The significant changes in the RMSF ratios of the 
halothane system to the control system were observed in the A- and F-loops of the β2 
subunit, but the changes did not occur to α7 and α4. Interestingly, for most residues in 
the F-loop, their RMSF changes between the control and halothane systems are 
comparable to the changes between the open and closed channels (Table 5.2.1). Thus, 
halothane affected the RMSF of these residues in a way as if to shift an open-channel 
conformation to a closed channel conformation. It is known that the F-loop is important 
for coupling agonist binding to channel gating 188,247. Mutations in the homologous loops 
in the δ and ε subunits have been shown to cause a dramatic decrease in channel 
conductance 248. The ability of halothane to change the RMSF of the F-loop in α4β2 but 
not in α7 might be another source differentiating halothane functional impact on α4β2 
from α7.  
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Figure 5.2.1. Changes in RMSF between halothane and control systems for the open-channel α7 
and α4β2. (A) The ratio of the RMSFs in the presence and absence of halothane for the open-channel α7 
(black) and α4β2 (α4-blue and β2-red). The RMSF was calculated using the data from the last 7-ns 
simulation of each system and averaged for the same type of subunits. Ratios close to 1 indicate that the 
flexibility of residues in both control and halothane systems are nearly identical. Two significant changes in 
the present of halothane are observed in A-loop and F-loop of β2. The large variations around residues 305 
to 307 were due to the ending residues of TM3 and TM4. (B) The residues around the A-loop (magenta) 
and F-loop (also referred to as β8-9 loop) in the β2 subunit showed a large RMSF increase and decrease 
in the halothane systems, respectively. 
 
Table 5.2.1. RMSF difference values for residues in the F-loop of a β2 subunit in the open-channel 
conformation. 
Residue Halothane – Control Closed – Open 
175 -2.6 Å  N/A 
176 -2.6 Å  N/A 
177 -3.1 Å  -2.6 Å 
178 -3.9 Å -3.8 Å 
179 -3.5 Å -3.6 Å 
180 -2.9 Å -2.9 Å 
*Only the RMSF differences of a magnitude greater than 2 Å are shown 
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5.2.4. Effects of halothane and ketamine on dynamics of the α4β2 nAChR TM 
domains  
Motional characteristics of proteins are often reflected in peak intensities of residues in 
the NMR spectra 66,249. Residues at the N- and C-termini as well as exposed loops 
experience fast motions (on the ps-ns timescale) and have higher signal intensities than 
residues in helices. Residues in the TM helices have weaker intensity due to restricted 
motion or broadening due to conformational-exchange on the μs-ms timescale 250.  
Upon addition of anesthetics, changes in motion or conformational exchange for 
residues in α4β2 were evident in the NMR spectra. The most remarkable change is 
splitting of single peaks into double peaks (for example, V236 and L222 of α4; Figure 
5.2.2A). The visibly separated double peaks could result from either a decrease in the 
rate of conformational exchange or a shift in the conformational distribution 251. In the first 
scenario, a single NMR signal was detected when the exchange rate between the two 
conformations was faster than the NMR detection time scale. The single peaks became 
double peaks when anesthetics slowed down the exchange rate. The observed double 
peaks of V253 and L222 belong to this scenario. For shifting conformation equilibria by 
anesthetics, V236 of α4 gave a good example. In the second scenario, V236 had two 
populations (75% vs. 25%) with distinct resonance frequencies in the absence of 
halothane. The major peak shifted and its peak intensity dropped in an anesthetic 
concentration dependent manner. Conversely, the minor peak had less change in 
chemical shift but its intensity increased so that the two conformations became almost 
equal populated in the presence of 2 mM halothane. Thus, anesthetics have either 
decreased conformational exchange rates or shifted conformation equilibria. 
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In addition to the change in peak splitting, we observed increased and decreased 
signal intensities for some residues. When we highlight these residues in the structures 
of α4 and β2 (Figure 5.2.2), several features become clear. Most residues in the vicinity 
of anesthetic binding sites experienced dynamic changes. However, dynamic changes 
induced by anesthetics could extend beyond the binding sites, such as the case of 
dynamical changes at the upper helical region of α4 when ketamine bound to the inter-
subunit site close to the IC end of the TMD. It is also noticeable that loop residues of fast 
motion and high NMR signal intensities are not affected by anesthetics, but residues at 
junctions of helices and loops (V262 and S271 of β2 and I267, I268, S277 of α4) are 
susceptible for dynamical modulation by anesthetics. This observation is consistent with 
a previous NMR study on another membrane protein 167. 
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Figure 5.2.2. Anesthetics changed dynamics of residues in the α4β2 TM domains. (a) A representative 
expanded region of the 1H-15N TROSY-HSQC spectra for α4(β2) in the absence (black) and presence (red) 
of 2 mM halothane. Note the peak splitting for L222 and V236, indicative of slow exchange. (b) Residues 
experienced dynamics changes upon halothane binding are highlighted on the α4 (yellow) and β2 (silver) 
structures. (c) Residues experienced dynamics changes upon ketamine binding are highlighted on the α4 
(yellow) and β2 (silver) structures. Three scenarios of dynamics changes are included in both (b) and (c): 
residues exhibiting peak splitting (cyan), decreases in peak intensity (blue), and increases in peak intensity 
(purple). Halothane and ketamine are shown in ghost representation to assist viewing each binding site. 
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Conformational changes in the TM domains of the α4β2 nAChR constitute different 
functional states of the ion channel. Our NMR data show that anesthetic sites at the EC 
end of the TM domains are virtually located behind the channel gate, while the sites at 
the IC end of the TM domains are adjacent to the ion selectivity filter. Both locations are 
crucial to channel function 106,252,253. Conformational changes in these regions can affect 
transitions between different states of ion conductivity through channels.  
Anesthetic modulation on channel motion was evidenced by changes of NMR 
signal intensities upon adding anesthetics, as well as peak splitting of the α4 and β2 
residues at the EC and IC ends of the TM domains. Although changes in peak intensities 
alone could not tell whether anesthetics made conformational exchanges slower or faster, 
peak splitting unambiguously indicated a decrease in the conformational exchange rate 
on a µs-ms timescale 250. Anesthetic occupancy of the α4β2 cavities may have reduced 
the degrees of freedom of interacting side chains and the attached backbone atoms, 
consequently resulting in decrease of exchange rate. For the same reason, anesthetic 
binding stabilized the original sub-conformation, shifted the conformational equilibria, and 
changed the population distribution of different conformations. The same trend of 
decrease in conformational exchange rates caused by anesthetics was also observed on 
other proteins 93,168. The results support the notion that multiple conformers coexist 
dynamically in ion channel proteins and general anesthetics can shift the equilibrium 
among different conformation states 134. 
It is also imperative to know that dynamics changes occurred not only to residues 
adjacent to anesthetics, but also to residues remote from the anesthetic binding sites. 
The observation is in accord with the consensus of allosteric mechanisms of signal 
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transduction 254. Propagation of local anesthetic perturbation to remote sites, especially 
to the junctions of helices and loops, can lead functional consequences. Although 
ketamine does not bind near I267, I268, and S277 of α4, the observed motion changes 
in these residues are likely to affect communication between the EC and TM domains in 
the agonist-elicited channel activations 131,185.  
5.2.5. Effects of halothane and ketamine on dynamics of the α7 nAChR TMD 
Upon adding anesthetics to α7, relative amide peak intensities of some residues 
increased or decreased in the α7 NMR spectra (Figure 5.2.3), indicating changes in 
protein dynamics 36,66,249. Residues lining the binding site for halothane or ketamine 
tended to experience intensity decrease, while residues distant from the binding sites had 
intensity decrease and increase (Figure 5.2.4). Among residues whose intensity changed 
more than 25%, halothane binding decreased intensity for 7 out of 10 residues; those in 
TM2 and TM3 decreased exclusively. In contrast, 6 out of 11 residues having more than 
25% intensity changes in response to ketamine binding experienced peak intensity 
increase. Another notable difference between halothane and ketamine binding is the 
number of residues in TM4 affected by ketamine (R447, F453, S447, I458, and T461) 
and halothane (C449). The profound perturbation to TM4 is expected to introduce 
functional consequences 255-257. The role of TM4 in Cys-loop receptor-lipid interactions as 
well as in nAChR function has been established 255-258. 
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Figure 5.2.3. Anesthetics modulate backbone dynamics of the α7 nAChR TMD. Relative changes in 
peak intensity of the α7 TMD induced by (a) halothane (1.7 mM) and (b) ketamine (80 μM) versus the 
residue number. Residues significantly affected by halothane included L13, S21, L26, and C112 (peak 
intensity increased) as well as V18, I20, K37, I38, L54, T87, and I89 (peak intensity decreased). The 
ketamine binding affected the following residues: L13, G41, I89, R110, S117, and T124 (peak intensity 
increased) as well as F28, V80, L82, F116, and I121 (peak intensity decreased). To convert the numbering 
in this figure to the numbering for the full-length α7 nAChR, add 202 for residues labeled 1 to 102 and add 
337 for residues labeled 103 to 137. 
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Figure 5.2.4. Anesthetic effects on backbone dynamics of the α7 nAChR TMD. Residues, whose 
relative peak intensity increased (red) or decreased (blue) upon the addition of (a) halothane (silver surface) 
and (b) ketamine (cyan surface) binding, are highlighted in the α7 structure. (c) Representative regions of 
1H-15N TROSY-HSQC spectra in the absence (red or black) and presence (green or blue) of halothane. α7-
V229 (top, left) is equivalent to α4-V236 (bottom, left); α7-L215 (top, right) is equivalent to β2-L216 (bottom, 
right). Note the halothane-induced peak splitting in α4-V236 and β2-L216, a sign of decrease of 
conformational exchange rates by halothane. Such changes were not observed in α7. 
 
Peak splitting was observed previously in NMR spectra of the α4β2 nAChR TMD 
in the presence of anesthetics 39. The splitting likely indicates a shift of conformational 
exchange from intermediate (or fast) to slow time scale. It is noteworthy that the splitting 
observed on α4β2 did not occur on α7 (Figure 5.2.4c). Neither halothane nor ketamine 
was able to drive α7 into slow conformational exchange mode as they did on α4β2.  
The α7 nAChR, unlike the α4β2 nAChR, has distinct low functional sensitivity to 
volatile anesthetics, such as halothane 5,182. The α7 nAChR does not have a binding site 
for halothane at the EC end of the TMD as revealed previously for α4β2 39. Furthermore, 
we have disclosed an association of anesthetic modulation on channel dynamics and 
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channel function (Figure 5.2.4). Comparisons of structural, dynamics, and anesthetic 
binding information between α7 and α4β2 offer a clue for reasoning why α7 is insensitive 
to halothane and other volatile anesthetics. As discussed in chapter 3, halothane binds 
to α7, but the binding to the IC end of the TMD did not effectively modulate dynamics of 
channel residues as it did in α4β2 (Figure 5.2.4), where more profound dynamics changes 
were observed. These results suggest a plausible association between dynamics 
modulation and functional modulation by anesthetics. Anesthetic binding would not 
produce functional impact unless the binding can significantly alter channel motions 
coupled with functions.  
Comparisons of halothane sites in α7 with those in the α4β2 nAChR 39 and distinct 
dynamic responses of these receptors to halothane binding convey an important 
message, that is, effective functional modulation occurs only when the binding of 
anesthetics, or any modulators, induces dynamics or conformational changes in the 
channel pore.  
5.2.6.  Isoflurane effects on the dynamics of α7 and β2 subunits 
Peak intensities of residues in the 1H-15N HSQC spectra can reveal backbone motional 
characteristics of proteins 39,66,249. Terminal and loop residues usually experience fast 
motion on the ps-ns timescale and show relatively high peak intensities. In contrast, 
residues in the TM helices often show weaker or invisible signals due to restricted motion 
or conformational exchange on the μs-ms timescale 250. α7 and β2 exhibit similar motional 
characteristics in their respective 1H-15N HSQC spectra in the absence of isoflurane 
(Figure 5.2.5). However, they respond differently to the addition of isoflurane.  
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Figure 5.2.5. Pore-lining residues show more profound dynamics changes in β2 than in α7. (a)-(d) 
Excerpts of the 1H-15N TROSY-HSQC spectra for the 2 pore lining residues in the presence (green) and 
absence (black) of 1.3 mM isoflurane. (e)-(h) Excerpts of the 1H-15N TROSY-HSQC spectra for the α7 pore 
lining residues in the presence (red) and absence (blue) of 1.6 mM isoflurane. The presence of isoflurane 
significantly decreased peak intensities of the β2 pore-lining residues K20’, L16’ and L9’. V13’ is difficult to 
be accurately assessed because of its peak overlap with another residue. In contrast, the homologous pore-
lining residues of α7 exhibit no significant changes in the NMR spectra. 
 
Figure 5.2.6 shows percentage changes of 1H-15N HSQC spectral peak intensities 
for residues in α7 and β2 in the presence and absence of isoflurane. α7 has a significant 
number of residues gaining more than 20% signal upon addition of isoflurane, while β2 
has many more residues whose peak intensities decreased more than 20% due to 
isoflurane binding. Of particular note is the over 20% reduction of peak intensities for the 
β2 pore-lining residues (L9’, L16’, and K20’) (Figure 5.2.6). V13’ may also be affected to 
a similar degree, but the peak overlapping in the NMR spectrum limits the accuracy of its 
calculation (Figure 5.2.5). The data of relative intensity increase or decrease suggest that 
isoflurane largely facilitates the motion on α7, but slows down the motion of β2. 
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Figure 5.2.6. Different dynamics responses of β2 and α7 to isoflurane modulation. (a) β2 and (b) α7 
have distinctly different patterns in percentage changes of NMR spectral peak intensity in the absence (I0) 
and presence (I) of isoflurane. Residues lining the respective isoflurane-binding cavities in the β2 and α7 
TM domains are marked with open circles.  
 
One of the most striking differences between α7 and β2 is that upon isoflurane 
binding, α7 retained a single signal for each residue in the NMR spectra, but β2 showed 
classic examples of two-site chemical exchange 208,209 for several residues, including the 
channel gate residue L249(9’) and V262(22’) lining the isoflurane-binding pocket in β2. 
As shown in Figure 4.2.4, in the absence of isoflurane (black), each of these β2 residues 
showed a single peak in the NMR spectrum. After adding 1.3 mM isoflurane (red), an 
additional peak became observable for L248 and T265 (denoted as L248’ and T265’, 
respectively). When the isoflurane concentration was increased to 3 mM (cyan), L249 and 
V262 also showed additional peaks. The combined chemical shift change between each 
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pair of peaks (A-B or A’-B), ΔωH+N = [(ΔωH2 +ΔωN2)]1/2, is 32, 27, 37, 32 Hz for L248, L249, 
V262, and T265 of β2, respectively. Based on the consensus from many previous studies 
208-210, the occurrence of two distinct peaks for a residue indicates a slow exchange with 
kex<< 2πΔωH+N ~ 200s-1.  
Conformational exchange among β2 residues also shows some differences. For 
residues L248 and T265, peak A remained at 20 Hz line width and the same resonance 
frequency in the absence and presence of isoflurane, indicating a possibility that slow 
conformational exchange with an extremely low population for the second conformation 
(peak B) already existed in the absence of isoflurane. Isoflurane shifted the equilibria 
between the two conformations. Indeed, the population of conformation B, pB = 1-pA, 
increased from 0 to ~0.3 and more than ~0.5 when isoflurane was increased from 0 to 
1.3 and 3 mM. Overall, L248 and T265 fit well to the scheme of slow exchange between 
two conformations 208-210. In the case of L249 and V262, however, a single peak with a 
broader line width in the 1H dimension was observed in the presence of 0 mM (L249, 21 
Hz; V262, 17 Hz) and 1.3 mM isoflurane (L249, 19 Hz; V262, 16 Hz), but two narrower 
peaks (L249, 16 and 12 Hz; V262, 14 and 12 Hz) were observed in the presence of 3 mM 
isoflurane. The results suggest that L249 and V262 were likely in an intermediate 
exchange regime 208,209 before exposed to 3 mM isoflurane. In addition to slower 
exchange between A’ and B conformations, the increased isoflurane concentration also 
shifted peak A’ from peak A by 14 and 11 Hz for L249 and V262, respectively (Figure 
4.2.4). This is not unexpected, considering that multiple conformers with subtle 
differences can co-exist in a functional state 211,212. 
The sensitivity of β2 and insensitivity of α7 to the dynamics modulation by 
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isoflurane are in good agreement with their distinctly different functional responses to 
isoflurane inhibition. Differences in their structures and isoflurane-binding sites may have 
contributed to different dynamics responses of β2 and α7 to isoflurane binding. Only in 
β2 were isoflurane-induced changes in conformational populations and motion on the μs-
ms timescale observed. The combined effects from structures, anesthetic binding sites, 
and dynamics modulations may have contributed to the functional differences between 
β2 and α7. 
5.2.7. Discussion 
Computational results showed that halothane binding to α7 did not induce profound 
changes in the structure and dynamics of α7 that could be related to the channel function. 
The favorable interaction between halothane and the amphiphilic EC/TM interface of the 
β2 subunit brings about changes in dynamics at this interface. The insensitivity of α7 to 
halothane-induced dynamics changes may be the reason why α4β2 is functionally more 
sensitive to halothane than α7. 
The respective sensitivity and insensitivity of β2 and α7 to dynamics modulation 
by volatile general anesthetics was affirmed by our NMR results. What makes β2 more 
susceptible to dynamics modulation than α7. We previously discussed in Chapter 4 that 
the β2-V22’M mutation could decrease the volume of the anesthetic binding cavity to 
prevent isoflurane from binding. However, methionine may also stabilize the TM2 helix 
and make it more resilient to structural and dynamic perturbation introduced by anesthetic 
binding. Previous studies using unnatural amino acid substitutions have shown that 
residues with un-branched side chains, such as methionine and alanine, have a more 
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stabilizing effect on α helices than branched amino acids, such as valine and isoleucine 
213. Similarly, β2-S19’ and α7-A19’ could also make dynamics differences to the TM2 
helix. Alanine is a natural helix promoter 214, while serine and threonine often disrupt α-
helices due to backbone to side chain hydrogen bonds 125,215. Our study on hGlyR-α1 TM 
noted heightened conformational dynamics at the EC end of TM2, which is uniquely rich 
with serines in this region compared to other pLGICs 38. 
Our results suggest that the EC end of the TMD plays a critical role for channel 
gating in pLGICs. Increasing the rigidity of residues at the EC end of the TMD can make 
the channel less responsive to activation signals. Many previous studies support this 
notion. Increasing helical flexibility at the EC end of TM2 of the nAChR was found to 
increase the receptors’ sensitivity to agonist more than tenfold 57. Disulfide bond trapping 
experiments on the GABAA receptor 216 and EPR experiments on GLIC 58 also support 
heightened dynamics at the EC end of TM2 during channel gating. Our work on the 
glycine receptor suggested that increasing or decreasing the conformational dynamics at 
the EC end of TM2 could respectively increase or decrease the channel’s susceptibility 
to allosteric modulation 38. Thus, it is conceivable that changing dynamics of the EC end 
of the TMD, either via drug binding or point mutations, is a common mechanism to 
modulate functions of pLGICs. 
5.2.8. Conclusions 
Past studies have shown that mutations affecting anesthetic modulation often 
concurrently affect the intrinsic gating dynamics of the channel 54-56, suggesting that the 
ability of anesthetics to modulate the channel is intrinsically related to the channel gating 
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dynamics. Our NMR studies on the neuronal nAChRs suggest that only the ligand binding 
that can affect the channel dynamics will produce the functional effect. Particularly, it was 
observed that isoflurane binding at the EC end of the TMD could substantially reduce 
dynamics for nearby residues in TM2 40. Other studies have shown that dynamics at the 
EC end of TM2 is important to channel gating 57,58. The results suggest that binding to an 
intra-subunit site at the EC end of the TMD the anesthetic can limit dynamics at the EC 
end of TM2 and consequently make the channel more difficult to open. Only the binding 
that modulates dynamics of pore-lining residues, such as that at the EC end of the β2 
TMD, can impact function. Our study emphasizes the role of channel dynamics in 
allosteric modulation. 
5.3. THE IMPORTANCE OF ASYMMETRY TO ALLOSTERIC MODULATION 
This section has been published as a full article in J. Am. Chem Soc. 35 (6): 2172-2180.  
5.3.1. Background and Significance 
Structural symmetry of a protein assembly results from its functional evolution 259-262. The 
symmetry feature is often required to retain global structural stability and cooperative 
functionality 254,259,260,263. Cys-loop receptors mediate fast synaptic signal transmission. 
Each Cys-loop receptor is comprised of five homologous subunits that form a pLGIC. For 
a homo-pLGIC, a fivefold symmetry around the central pore is assumed. Each subunit 
contains an ECD, a TMD of four TM helices (TM1 to TM4) with TM2 lining the pore, and 
an ICD that links TM3 and TM4. Agonist binding to the ECD induces channel opening 
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and allows ions to move through the pore. Despite the existence of five identical agonist-
binding sites in a homo-pLGIC, occupancy of three nonconsecutive sites by agonists was 
found to induce maximal mean channel open time 59. The maximum channel-gating 
efficacy could be reached when only three potential binding sites were occupied in the 
homomeric α1 GlyRs 60 and ρ1 GABAA receptors 61. Skepticism remains as to whether 
asymmetric agonist binding induces spontaneous asymmetric conformational changes. 
In addition, it remains unclear whether ligands other than agonists also bind 
asymmetrically to these proteins to produce functional impact. Interestingly, an 
asymmetric intermediate conformation of a homo-trimeric transporter was captured 
recently in the crystal structure 264, indicating the involvement of asymmetric 
conformational change in biological function.  
At pharmacologically relevant concentrations, general anesthetics potentiate 
anion-selective GlyRs and GABAA receptors, but inhibit cation-selective nAChRs and 
serotonin receptors 153,265. Occupancy of a single binding site in the homo-pLGIC α1 GlyR 
by volatile anesthetics and alcohols was found to be sufficient to potentiate channel 
currents 266. General anesthetics 224 and alcohols 56 also modulate the function of GLIC. 
Crystal structures of GLIC in complex with propofol or desflurane 106 reveal intra-subunit 
binding sites in the TMD of all five subunits (Figure 5.3.1). The structures of the 
anesthetic-GLIC complexes are virtually identical to the apo GLIC structure 27,106. Propofol 
inhibits GLIC currents at concentrations used clinically 106,224. A higher propofol 
concentration could completely close the GLIC channel and inhibit ion conductance 
106,224. Therefore, an apparently open channel structure of GLIC under symmetric 
anesthetic occupancy in the crystal structure seems incongruent with the potent inhibition 
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observed in the functional measurements. The relevance of the identified anesthetic site 
in the structure, however, is supported by functional studies on various mutants 106. The 
question is whether inhibition of GLIC requires anesthetics to occupy all five subunits 
simultaneously or only a few subunits similar to channel activations by asymmetric 
agonist binding 59-61. 
To address this apparent disagreement between structure and function, we 
performed multiple sets of MD simulations on the crystal structures of GLIC and the 
propofol-GLIC complex. The number of propofol molecules bound to GLIC was varied in 
different simulation systems by either keeping all five propofol molecules or deleting 
propofol from some of the subunits before the simulations. Two groups with distinct 
channel hydration states and conformations emerged over the course of MD simulations. 
GLIC with symmetric propofol occupancy in all five sites and the apo GLIC acted as one 
group, while GLIC with asymmetric propofol binding belonged to another group. The study 
suggests that symmetry of ligand binding has a profound effect on conformational 
transitions. Symmetry breaking by ligand binding facilitates conformational transitions. In 
general, symmetry breaking is a prevalent process in biology and symmetry breaking 
along well-defined axes is often linked to functional diversification on every scale 267. The 
current simulation study along with previous knowledge of asymmetric agonist binding in 
activation of Cys-loop receptors 59-61,266 demand thorough characterizations of symmetry 
breaking by ligand binding in the functions of pLGICs, just as those characterized for 
many other biological systems 267.267 
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5.3.2. Methods 
Crystal structures of the open-channel apo GLIC (PDB ID: 3EAM) and the open-channel 
propofol–GLIC complex (PDB ID: 3P50) were used for MD simulations. Crystal structures 
of the locally closed GLIC (PDB IDs: 3TLS and 3TLW) were used as references for the 
closed-channel conformations observed from the simulations. Five simulation systems 
were generated by varying the propofol occupancy in GLIC: (i) no propofol bound to GLIC 
(0PFL); (ii) five propofol molecules bound to GLIC (5PFL) as shown in the X-ray structure 
of the propofol–GLIC complex 106; (iii) three propofol molecules bound to nonconsecutive 
subunits (3PFL); (iv) two propofol molecules bound to consecutive sites (2PFL); and (v) 
one propofol molecule bound to GLIC (1PFL). For each system, three parallel runs were 
performed using different seed numbers and each run lasted for 100 ns. Figure 5.3.1 
shows all five systems and the propofol binding sites. 
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Figure 5.3.1. Propofol binding sites in different GLIC systems. Top views of the transmembrane 
domains of (a) 0PFL; (b) 5PFL; (c) 3PFL; (d) 2PFL; (e) 1PFL; and (f) a side view of 5PFL. Propofol is in 
VDW representation and colored in purple. 
 
Protonation states of titratable residues in GLIC at pH = 4.6 were assigned based 
on the results reported by Bocquet et al. 27 Some modifications, including deprotonation 
of five H235 residues and two E222 residues, were made based on our recent 
calculations 268. The TM domain of GLIC was inserted into a pre-equilibrated and solvated 
POPE/POPG (3:1) binary lipid mixture. Each simulation system has a hexagonal 
boundary condition of 104.6 Å × 104.6 Å × 129.8 Å, one GLIC, 167 POPE, 54 POPG, and 
approximately 23 700 TIP3 water molecules. 
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MD simulations were performed using NAMD 2.7b1 91. CHARMM27 force field with 
CMAP corrections (version 31) was used for protein, water, and lipids 145,269. Propofol 
parametrization was done following the protocol of the CHARMM General Force Field 
(CGenFF) for drug-like molecules 270. The details for propofol parameterization can be 
found in the online supporting material of the manuscript 62. All simulation systems 
followed the same simulation protocol. Each system was energy minimized for 20 000 
steps before equilibration for 2 ns, during which the backbone constraint on GLIC was 
gradually reduced from 10 kcal·mol–1·Å–2 to zero. Each system underwent three runs up 
to 3 × 100 ns of unconstrained simulations under constant pressure (P = 1 bar) and 
temperature (T = 310 K) 271,272. 
Periodic boundary conditions, water wrapping, hydrogen atoms constrained via 
SHAKE, and evaluation of long-range electrostatic forces via the Particle Mesh Ewald 
(PME) algorithm 273 were used in the simulations. Bonded interactions and short-range, 
nonbonded interactions were calculated every time step (2 fs). Electrostatic interactions 
were calculated every two time steps (4 fs). The cutoff distance for nonbonded 
interactions was 12 Å. A smoothing function was employed for the van der Waals 
interactions at a distance of 10 Å. The pair-list of the nonbonded interaction was 
calculated every 20 time-steps with a pair-list distance of 13.5 Å. 
VMD 86 was used for visualization and most parts of data analysis. Unless 
otherwise specified, snapshots every 20 ps of the simulation trajectories (a total of 5000 
snapshots) were used for data analyses for each 100-ns simulation. The number of water 
molecules (Nwater) inside the hydrophobic gate region was obtained by counting water 
inside the pore between I233 (I9′) and I240 (I16′). The channel hydration state was 
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defined based on Nwater: fully hydrated if Nwater ≥ 10, partially dehydrated if 0 < Nwater < 10 
and fully dehydrated if Nwater = 0. Ten water molecules inside the hydrophobic gate region 
are equivalent to 65% of the bulk water density and were used previously as a threshold 
in the evaluation of the channel hydration status 274. A histogram of Nwater was calculated 
based on the data from three 100-ns parallel runs for each system. Each run was named 
according to the duration of time that the channel remained hydrated. For example, the 
channel hydration time in the 5PFL system follows the order: 5PFL-1 > 5PFL-2 > 5PFL-
3. 
Orientation of the pore-lining TM2 helix was characterized by the radial (θ) and 
lateral (φ) tilting angles of the TM2 helices relative to the membrane normal, as defined 
in previous publications 176,183. The same method as detailed previously 176 was used to 
calculate the radial and lateral tilting angles. For each system, distributions and 
histograms of the radial and lateral tilting angles were calculated for each channel 
hydration state and averaged over all five subunits in three replica simulations. 
A normalized histogram for the joint events of (θ, φ) was used to estimate 
heterogeneity of the TM2 tilting angles using MATLAB. The joint Shannon entropy S(i,j) 
was calculated by 275: 
where pij is the joint probability of the event (θi, φj) obtained from the normalized histogram 
of the tilting angles, and N is the number of bins. For each system, the radial and lateral 
tilting angles were collected over all five subunits in three replica simulations. To generate 
the histogram, a bin size of 0.1° was used to sample angles ranging from −12° to 15° for 
 
S(i,j) =∑∑p
ij
ln p
ij
N
i=1
N
j=1
 
( 5.2 ) 
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both θ and φ. Standard deviations of the entropies were estimated with the bootstrap 
method 276, using 100 sets of randomly sampled data points from the first 2600 × 3 
snapshots for each system. The analysis of variance with posthoc Tukey HSD multiple 
comparison test between groups was performed using SPSS v20. 
The anisotropic network model (ANM) 277 was used for structure-based analysis of 
GLIC dynamics. The Hessian matrix was built using all Cα atoms and a pairwise 
interaction cutoff of 15 Å. The 10 lowest frequency modes of ANM were calculated and 
visualized using ProDy 278. 
The force, resulting from VDW and electrostatic interaction of propofol with GLIC, 
was calculated in x, y, z directions using the pairInteraction module implemented in NAMD 
2.7b1 91. Residues within 5 Å of propofol were selected in the calculations. To quantify 
the primary component of the force, we performed principal component analyses (PCA) 
on the force trajectory (5000 frames over 100 ns) using MATLAB. For visualization, the 
principal component of the force is presented within the context of the GLIC structure. 
Each principal component was scaled by its eigenvalue and multiplied by the inverse of 
the eigenvector matrix. Each resultant vector was then centered on the propofol position 
and plotted. 
For statistical analyses of the channel opening probability, we categorized a 
channel as “open” if the number of water molecules inside the channel gate is equal to or 
greater than 10; otherwise, the state of the channel is labeled as “closed”. We pooled all 
3 replicated simulations for each system (snapshots every 0.5 ns of the simulation 
trajectories were used) and represented the number (X) of simulation snapshots that 
assumed an open state using a binomial distribution: X ~ Bin(N, p), where N is the total 
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number of simulation snapshots and p is the channel opening probability. The estimate 
of the channel open probability ( ), confidence interval for , the adjusted confidence 
interval for comparing two estimated channel opening probabilities, (p ̃1 – p̃2), and therein 
the p-value were derived using an R language script and the methods described by 
Agresti and Caffo 279. The open-channel probability was estimated by  = X/N, the 
confidence interval for the estimate of channel opening probability is  ± zα/2[ (1 – 
)/N]1/2, and the adjusted confidence interval for the estimated difference between two 
channel opening probabilities is  
. 
5.3.3. Asymmetric Propofol Binding Increased the Probability of Channel 
Dehydration 
The channel hydration status is strongly related to the ion conductance. Ions cannot pass 
through a dry channel even if the pore is not yet geometrically closed 280. An evolution 
from a fully hydrated to a completely dehydrated channel in simulations signifies a 
transition of the channel functional state. The GLIC crystal structures used for our 
simulations, in the absence and presence of propofol, have the same open-channel 
conformation 27,28,106. At the beginning of all simulations, the GLIC channel was fully 
hydrated. Over the course of the simulations, GLIC exhibited only a small deviation from 
the crystal structure. The Cα RMSD of the overall protein and the TM domain reached a 
plateau after 5–8 ns. The RMSDs remained under 2 Å for the TM domain thereafter. The 
duration of the fully hydrated state, however, varied by runs, particularly by systems. As 
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shown in Figure 5.3.2a, 5PFL-1 remained full hydration almost for the entire 100 ns, while 
5PFL-2 and 5PFL-3 were fully hydrated for 65 and 50 ns, respectively. The system with 
no propofol, 0PFL, showed almost the same results. In contrast, 3PFL, 2PFL, and 1PFL 
experienced much more rapid and extended channel dehydration. 
 
Figure 5.3.2. Channel hydration under different scenarios of propofol binding. (a) Time evolution of 
the number of water molecules in the hydrophobic gate region (Nwater). Three replicate runs, 5PFL-1, 5PFL-
2 and 5PFL-3, are colored in green, red and black, respectively. Histograms of Nwater were generated based 
on three replicate runs for each system, (b) 0PFL; (c) 5PFL; (d) 3PFL; (e) 2PFL; and (f) 1PFL. Snapshots 
with a 20-picosecond interval were taken from each run. A total of 15000 structures were used for each 
histogram analysis. 
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To objectively evaluate and compare the channel hydration status among different 
systems, we made histograms for each system based on the data from all three replicate 
runs. Figure 5.3.2b–f shows that the distribution of the number of water molecules inside 
the channel gate is bimodal, with one peaking near 20 waters and the other peaking at 
zero water. We hypothesize that these two peaks correspond to the “open” and “closed” 
states of the channel, respectively. On the basis of this assumption, we used the value of 
10 waters per channel—the groove between the two modes—as a threshold to categorize 
the state of the channel in each snapshot as “open” (≥10 waters per channel) or “closed” 
(otherwise). The channel open probabilities for the symmetric systems 0PFL and 5PFL 
are 68 ± 6% and 68 ± 6%, respectively. In contrast, the open probabilities for the 
asymmetric systems 3PFL, 2PFL, and 1PFL are only 42 ± 7%, 28 ± 6%, and 32 ± 6%, 
respectively. The errors represent 99.9% confidence intervals of the estimates. Using the 
same level of confidence interval for the differences between the estimated probabilities 
279, we found that the channel open probability is significantly higher in the symmetric 
systems than in the asymmetric systems with a p-value < 0.001. The results clearly 
differentiate two groups of systems that are divided based on the propofol binding 
symmetry. Asymmetric propofol binding facilitated the transition from a fully hydrated 
channel to a dehydrated channel. 
GLIC is expected to be mostly open and hydrated at pH 4.6 222. The channel in 
0PFL or 5PFL was indeed hydrated for most of the simulation time. The dehydration 
occurred and resembled the observations from several previous simulations on GLIC 
175,176,280,281. Since GLIC is a proton-gated channel, imperfect imitation of pH conditions 
within the simulations could be one of the reasons to cause dehydration. In reality, we do 
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not have a complete set of titratable residues that has been experimentally proven to be 
responsible for pH activation of GLIC. Accurately predicting pKa’s in membrane proteins 
remains challenging. Other imperfections in the simulation environment may also have 
compromised the time scale of channel hydration. However, for all of the simulated 
systems reported here, everything was identical except the number of propofol molecules. 
Any consequences induced by system imperfections are systematic and common to all 
the systems. Thus, it is reasonable to conclude that the observed propensity of changes 
in channel hydration status in Figure 5.3.2 results primarily from variation in propofol 
occupancy. 
A significantly higher probability of dehydration promoted by asymmetric propofol 
binding is consistent with the inhibitory effect of propofol on GLIC 106,224. It is known that 
propofol also inhibits cationic currents of nAChRs 6,282 and 5HT3 receptors 283. The results 
observed here on GLIC are likely relevant to the inhibitory effect of propofol on these 
receptors as well. 
The finding that asymmetric propofol occupancy facilitated the channel transition 
more effectively than 5PFL does not contradict the concentration dependence of 
anesthetic inhibition of GLIC 224. The crystal structure presents the maximum binding 
sites. In order to make propofol observable in the crystal structure, propofol was added 
to GLIC in a saturating amount for crystallization. In functional measurements, however, 
propofol inhibited GLIC in concentrations (IC50: 0.5–10 μM) several orders of magnitude 
lower than that used for crystallization 106,224. In addition, the Hill coefficient of propofol 
inhibition was 0.42 224, an indication of negative cooperative process, in which one 
propofol bound to GLIC reduces the ability of another propofol to inhibit channel. All of 
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these suggest that propofol completely inhibits GLIC at a concentration well below the 
saturated concentration and before it occupies all five sites. Once the channel falls into a 
closed state, an additional amount of anesthetics cannot resume the GLIC current (our 
own unpublished data). The crystal structure of the open channel GLIC with five propofol 
molecules bound symmetrically may only reflect a preferred conformation of GLIC at the 
crystallization conditions. The discrepancy between the functional state and the channel 
conformation captured in the crystal structures has also been observed recently on 
ELIC 105. 
5.3.4. Asymmetric Propofol Binding Facilitated the Pore-Lining TM2 toward a 
Closed-Channel Conformation 
It has long been proposed that TM2 helix tilting underlies the channel gating of pLGICs 
111. The lateral (δ) and radial (θ) tilting angles of the pore lining TM2 helices give 
quantitative measurements of pore conformational changes 176,183. Compared to the 
closed-channel ELIC (δ ≈ −7.9°; θ ≈ −3.5°), the open-channel GLIC (δ ≈ 0.7°; θ ≈ 6.5°) 
has no more than 10° difference on both angles 26,28,120,281. A combined crystallographic 
and functional study revealed the locally closed conformations of GLIC, demonstrating 
that a few degree changes in the lateral and radial tilting angles of TM2 are sufficient to 
stop GLIC current 211. 
Figure 5.3.3 shows the lateral and radial tilting angles of TM2 for each of the five 
systems simulated to 100 ns. The angles are colored in green, purple, and black to 
represent three channel states: fully hydrated, transitional, and fully dehydrated at the 
hydrophobic gate region, respectively. For comparison, the lateral and radial tilting angles 
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of TM2 in the crystal structures of the open-channel GLIC 28,281 and the locally closed-
channel GLIC 211 are also marked in Figure 5.3.3. For the fully hydrated state, the lateral 
and radial tilting angles of TM2 are highly populated near 0.7° and 6.5°, respectively, 
more or less the same as those in the open channel GLIC. Quantitative information about 
populations of tilting angles for each system is shown by histograms in Figure 5.3.4. A 
deviation by a few degrees in either the lateral or radial tilting angle could result in channel 
dehydration. The TM2 tilting angles associated with the dehydrated state are largely 
shifted toward the angles in the locally closed GLIC 211. 
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Figure 5.3.3. Distributions of lateral and radial tilting angles of TM2 for (a) 0PFL, (b) 5PFL, (c) 3PFL, 
(d) 2PFL, and (e) 1PFL. (f) Depiction of radial and lateral directions for calculating the tilting angles. (g) 
The aligned crystal structures of the open-channel GLIC (PDB ID: 3EAM; green) and the locally closed 
GLIC (PDB ID: 3TLS; gray). The colors in (a) – (e) denote the channel hydration states associated with the 
TM2 tilting angles as defined by Nwater: green for a fully hydrated channel (Nwater >10); Purple for a partially 
dehydrated channel (0< Nwater ≤10) and black for a fully dehydrated channel (Nwater =0). Each system 
summarizes a total of 15,000 structures, sampled evenly over 100 ns for each of the three replicates. For 
comparison, a blue square and a blue triangle mark the TM2 tilting angles for the crystal structures of the 
open-channel GLIC and the locally closed GLIC, respectively. Counts of each hydration state for each 
system are provided in Figure 5.3.4. 
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Figure 5.3.4. Histograms of the TM2 lateral tilting angles in (a) 0PFL; (b) 5PFL; (c) 3PFL; (d) 2PFL; 
and (e) 1PFL. Histograms of the TM2 radial tilting angles in (f) 0PFL; (g) 5PFL; (h) 3PFL; (i) 2PFL and (j) 
1PFL. Colors mark the channel hydration statuses accompanying the TM2 tilting angles that were defined 
by Nwater: green for a fully hydrated channel (Nwater ≥10); purple for partially dehydrated (0<Nwater <10) and 
black for fully dehydrated (Nwater = 0). A bin size of 0.1° was used in the analysis. The same data used for 
Figure 5.3.3 are used for the histograms presented here.  
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To evaluate conformational changes in other regions of GLIC, we also calculated 
lateral and radial tilting angles for TM1, TM3, and TM4 in all of the simulations. Consistent 
with the crystal structures of the open and locally closed GLIC channels (Figure 5.3.3g), 
these three helices, especially TM3 and TM4, showed much smaller conformational 
differences between the two channel states (Figure 5.3.5), whereas TM2 conformation 
correlates most sensitively to the channel state. Although the conformation differences 
for different channel states are also visible in other TM helices, they are less distinct than 
that observed in TM2. 
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Figure 5.3.5. Distributions of lateral and radial tilting angles of TM1 (residues 196 to 217), TM2 
(residues 221 to 246), TM3 (residues 253 to 282), and TM4 (residues 285 to 314) for (a) 0PFL, (b) 
5PFL, (c) 3PFL, (d) 2PFL, and (e) 1PFL. Depiction of radial and lateral directions for calculating the tilting 
angles is shown in Figure 5.3.3. The colors denote the channel hydration statuses as defined by Nwater: 
green for a fully hydrated channel (Nwater >10); Purple for a partially dehydrated channel (0< Nwater ≤10) and 
black for a fully dehydrated channel (Nwater =0). Each system summarizes a total of 3,000 structures, 
sampled evenly over 100 ns for each of the three replicates. For comparison, a blue square and a blue 
triangle mark the tilting angles for the crystal structures of the openchannel GLIC (PDB ID: 3EAM) and the 
locally closed GLIC (PDB IDs: 3TLS and 3TLW), respectively. As indicated in the crystal structures, the 
TM2 tilting angles are most sensitive to the channel opening state than other TM helices. 
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The symmetry of propofol binding influenced the TM2 tilting angles (Figure 5.3.3 
and Figure 5.3.4). Compared to the symmetric 0PFL and 5PFL, the asymmetric 3PFL 
and 2PFL as well as 1PFL had higher populations of TM2 whose lateral- and radial-tilting 
angles shifted more toward the locally closed-channel conformation 211. In addition, 1PFL, 
2PFL and 3PFL had broader distributions of the TM2 tilting angles than 0PFL and 5PFL, 
particularly in the lateral angles. The broadness of the distributions reflects the 
conformational heterogeneity, which can be quantified by the joint Shannon entropy 275. 
The calculation of the joint Shannon entropies of the TM2 tilting angles using Equation ( 
5.2 ) yielded the values of 7.00 ± 0.01, 6.81 ± 0.01, 6.82 ± 0.01, 6.04 ± 0.01, and 6.31 ± 
0.01 for 1PFL, 2PFL, 3PFL, 5PFL, and 0PFL, respectively. One-way ANOVA with respect 
to propofol occupancy shows significant difference of the Shannon entropies among the 
five systems (p < 0.001). Post hoc Tukey HSD comparison tests indicate that 1PFL, 2PFL, 
and 3PFL are significantly different from 0PFL and 5PFL (p < 0.001). Clearly, asymmetric 
propofol binding increased the conformational heterogeneity of TM2. 
Although the quaternary twist motion is thought to dominate channel conformation 
transitions in pLGICs 131,138,281,284, asymmetric motion has been observed to lead to 
channel opening 285 and closing 131,138. Experimental data also support the role of 
asymmetric motion in channel functions 286,287. An asymmetric and independent 
contribution of the TM2 residues to gating of nAChR was observed in a single-channel 
study 286. Thus, it is not surprising to see spontaneous asymmetric motion in our 
simulations. After carefully examining individual trajectories, we found that TM2 helices 
in different subunits experienced different degrees of tilting at a given time point. 
Moreover, inward radial tilting (or contraction) and/or lateral tilting of the TM2 helix in one 
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or two subunits was sufficient to alter the channel hydration state. The same phenomena 
were also observed in other studies on GLIC 176,280,281. We also performed ANM analysis 
on the crystal structure of GLIC. Among the 10 lowest frequency modes, which are 
coupled with the large-scale global domain motions, mode 3 is the only mode showing 
symmetric twisting motion (Figure 5.3.6). Asymmetric motions in other modes, especially 
asymmetric inward/outward motion among subunits, are expected to contribute to 
functional changes in channel conformations 131. Thus, asymmetric anesthetic binding 
does not create new modes of motion, but rather shifts the population of asymmetric 
motion. 
 
Figure 5.3.6. First ten modes identified by ANM analysis of GLIC. Note that only mode 3 shows 
symmetric motion. 
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5.3.5. Propofol Motion and Imposing Forces Affect the Channel Hydration Status 
Propofol bound asymmetrically to GLIC facilitates a population shift of TM2 toward the 
closed-channel conformation and increases conformational entropy. To further 
understand why asymmetric propofol binding facilitates the conformational transition, we 
examined the forces imposed by propofol on each subunit. 
Propofol binding imposed a force on GLIC. We calculated the force between 
propofol and residues within 5 Å of propofol and examined the time trajectory of the vector 
sum of all forces imposed on each subunit (Figure 5.3.7). The trajectories of the force for 
all simulations can be found in the online supporting material of the published 
manuscript 62. Several characteristics about the force are noteworthy. The force trajectory 
generated by each propofol over simulation times assumes the shape of an ellipsoid. On 
the basis of principal component analyses, the primary component of the force is 
tangential to the pore and substantially larger than the second component that is mostly 
radial to the pore. Both the tangential and radial forces are well balanced in 5PFL (Figure 
5.3.7), but obviously uneven in the systems of asymmetrical propofol binding. In addition 
to the force trajectories on all residues within 5 Å of propofol, we also examined the forces 
on individual residues in the binding cavity, T255 of TM3 and Y197 of TM1. Each residue 
experienced a force imposed by propofol at any given time. The force fluctuated along a 
narrow range of directions over the course of simulations. The time averaged net force 
resulted from dividing the accumulated force by the number of snapshots that were 
sampled evenly from each simulation trajectory. In most cases, the averaged net force 
became smaller when simulation time became longer. For example, the averaged net 
force on T255 of 3PFL was 1.7, 1.3, and 1.0 kcal/(mol·Å) at the 10-, 50-, and 100-ns 
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simulation, respectively. Even though the time averaged net force is not large, the 
propofol force at any given time is substantial to prevent the binding cavity from shrinking. 
Intuitively, an unevenly distributed force creates an unstable condition that could facilitate 
transitions, either to a direction leading channel closure (such as the case of anesthetic 
binding in GLIC) or to the direction of channel opening (such as the case of agonist 
binding in pLGICs). Indeed, when one of the propofol molecules in 5PFL-3 migrated out 
of the cavity after ~45 ns simulation, the channel was dehydrated soon thereafter. 
The force analysis suggests that propofol imposes a larger force along the 
tangential direction than the radial direction to the pore. Impact of the force to 
conformational transition can be substantiated once the force becomes unbalanced 
among five subunits. Although it seems uncommon to link asymmetrically distributed 
force with conformational and ultimately functional changes, there is engrained 
experimental support for the biological significance of symmetry breaking 267. For 
instance, an asymmetric protrusive force resulting from symmetry breaking in the actin 
assembly drives directional cell mobility 288,289. The fact that asymmetric agonist binding 
activates Cys-loop receptors 59-61 also speaks for the involvement of a symmetry breaking 
in the process. 
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Figure 5.3.7. Representative projections of the propofol-force trajectories, (a) 5PFL-1 and (b) 3PFL-
1. The force trajectory (cyan) over a 100-ns simulation for each subunit is centered on propofol, which is 
marked by a black dot. The shape of the overall force trajectory is ellipsoid with the longest axis tangential 
to the pore. The first (red arrows) and second (purple arrows) principal components of each force trajectory 
are scaled by their respective eigenvalues and projected onto the same plane as the force trajectory. Zoom-
in views of the propofol force on individual residues Y197 and T255 of subunit B in (a) 5PFL and (b) 3PFL 
were generated based on the force calculation separately for each residue. The force trajectory is colored 
in blue and red for the first and last 50-ns simulation, respectively. The coordinate trajectory of the propofol’s 
center of mass is shown in green and black for the first and last 50-ns simulation, respectively. The time 
averaged net force on Y197 and T255 for first 50-ns and entire 100 ns simulations are shown in orange 
and yellow arrows, respectively. Reference scales for the amplitude of the force in the overall and zoom-in 
views are shown. 
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5.3.6. Conclusions 
The most important conclusion from this study is that transient symmetry breaking by 
asymmetric ligand binding in pLGICs facilitates changes in channel conformation. The 
simulations for systems that are otherwise identical except for the number of propofol 
occupancy provide compelling evidence to support the conclusion. Binding without 
perturbing symmetry in 5PFL preserved the open-channel conformation as observed in 
0PFL. The result is consistent with the consensus that the symmetry feature retains global 
structural stability 254,259,260,263. In contrast, asymmetric propofol binding perturbed the 
symmetry and facilitated conformational changes. The distinct difference resulting from 
asymmetric ligand binding does not come as a total revelation. As Blundell and his 
colleague stated based on their examinations of several enzymes, mild perturbation from 
perfect symmetry may be essential in some systems for dynamic functions 259. It is also 
known that asymmetric agonist binding without occupying all five equivalent sites can 
produce the maximal opening of Cys-loop receptor channels 59-61. It is likely that, no 
matter channel activation or inhibition, asymmetric ligand binding works more effectively 
to induce transitions from one state to another. 
Our multiseeded, parallel simulations exceeded 1.5 μs in total. Although extending 
each set to the microsecond time scale 178,281 is desirable, such extensions for multiple 
μs simulations to cover all possible anesthetic-binding scenarios demand much more 
computational power that has not been available to us. Fortunately, the current simulation 
time scale is able to cover the transitions between different channel hydration states. Our 
statistical approaches with multiple independent runs have sufficient power to 
unequivocally differentiate the functional propensities of GLIC under different scenarios 
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of propofol binding. To generalize the functional role of asymmetric ligand binding in 
pLGICs requires further experimental investigations, which may be challenging but are 
not impossible. The most encouraging examples are the elegant experimental 
demonstrations that asymmetric agonist binding activates homo-pLGICs 59-61 and that 
anesthetic or alcohol binding to a single subunit in the homomeric α1 GlyR is sufficient to 
alter channel function 266.  
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APPENDIX A.  
STRUCTURE CALCULATION OF THE GLYCINE RECEPTOR 
A.1. MONOMER CALCULATION 
One hundred (100) random structures were generated and annealed using Cyana-
3.0 84,290. Structures were annealed using 2,000,000 steps and an annealing schedule 
modified slightly from the default annealing schedule in Cyana-3.0. Modifications to the 
annealing schedule include using a quadratic (vs. a quartic) cooling profile in the second 
annealing stage. With the large number of steps, decreasing the temperature more slowly 
in the second annealing stage improves the annealing. By default, the van der Waals 
(VDW) penalty is initially divided by four and restored to its default value at the end of the 
second annealing stage. In the modified algorithm the VDW penalty was initially divided 
by 4, then multiplied by 2 halfway through the second annealing stage, and restored to 
its default value at the end of the second annealing stage. This change was made to 
prevent structures from entering into minima with bad VDW contacts. Of the 100 
structures calculated, the 32 structures with lowest target functions were refined. 
Refinement was performed using Cyana-3.0 and the annealing schedule outlined in Table 
A-1. Radii and weights were not adjusted at any point in the refinement schedule and 
parameters not reported below are identical to those in Cyana’s default annealing 
algorithm. Two rounds of refinement were performed. The first round of refinement used 
an input temperature of 0.3 target function units per degree of freedom and 2,000,000 
steps. The second used an initial temperature of 0.03 target function units per degree of 
freedom and 1,000,000 steps. From the 32 refined structures the 15 with lowest target 
function were obtained and reported. 
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Table A-1. Cyana Refinement Annealing Schedule 
 Steps1 Starting T2 Ending T Tau3 VDW4 
Minimization 100 N/A N/A N/A N/A 
Pre-Equilibration 0.02N T T 1.0 10 
Equilibration 1 0.02N 0.9T 0.9T 1.0 10 
Equilibration 2 0.02N 0.855T 0.855T 1.0 10 
First Cooling 0.36N 0.855T 0.154T 10.0 10 
Second Cooling 0.44N 0.154T 0.0086T 10.0 5 
Final Cooling 0.16N 0.0086T 0 1.0 20 
Final MD 4000 0 0 1.0 20 
Minimization 1000 N/A N/A N/A N/A 
 
1N is total number of steps. Pre-Equilibration and Final MD are not included when adding up to N. 2T is the 
input temperature. Temperatures visited in between the starting and ending temperatures result from a 
linear interpolation between starting and ending temperatures. 3Tau is the correlation time controlling 
coupling to the temperature bath. 4VDW column shows the number of steps after which VDW forces are 
evaluated.  
A.2. PENTAMER CALCULATION 
The calculation of the pentamer structure was developed based on the symmetric 
arrangement of monomer subunits in a pentameric configuration. The intra-subunit NMR 
restraints were copied five times. We defined five groups of symmetric contacts within 
Cyana from which Cyana automatically generated 3996 angle identity restraints and 
100,000 symmetric distance restraints. From the EM images we obtain a restraint on the 
radial distance of each monomer subunit from the pore. Tilting angles for TM2 with 
respect to the channel pore were obtained from RDC measurements in low-q bicelles 121. 
The average angle between TM2 and the channel pore (13±1) is within the range of 
angle values for proteins in the same superfamily of Cys-loop receptors: the α1 nAChR 
(12) 291, the α4 nAChR (12±1 and 16±1 for α4 and α4β2 respectively) 169, and the 
GABAA receptor (15±2)166. The angles all fall in the range of 11 to 17. We considered 
the possibility that the presence of TM1 and TM4 may produce changes to the TM2 tilting 
angle and used a ±5 error term for this angle in the pentamer structure calculation (see 
section A.2.3 Rotational Error). To generate Cyana distance restraints based on the EM 
and RDC restraints, a model of the pentamer was constructed using MATLAB® (2010a, 
The MathWorks, Inc., Natick, Massachusetts). Details for the construction of the model 
and generation of Cyana restraints are described below. 
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A.2.1 Atoms in the Model 
 Residues present in the model coming from TM2 correspond to the residues in TM2 
over which the RDC data was reported (residues 253 to 265) 121. Residues in TM1 (226 
to 241), TM3 (290 to 302) and TM4 (402 to 414) were added to the model. The RMSD for 
backbone atoms listed was less than 0.5 Å. Coordinates for backbone atoms of the listed 
residues were extracted from the structure bearing the minimum RMSD to all other 
structures in the bundle and imported into MatLab. The imported coordinates and 
corresponding atoms define the monomer subunit used in construction of the pentamer 
model. 
A.2.2 Pentamer Construction 
 The pentamer model was constructed by creating vertices for a pentagon inscribed 
on a unit circle lying in the membrane plane and centered at (0, 0, 0). The pentagon 
coordinates were multiplied by the radius obtained from the EM data. The radius was the 
distance from the center of the EM image to the peak in electron density after circular 
averaging of the EM images. Hydrogen and nitrogen coordinates for residues in TM2 
were oriented according to the RDC constraints. The monomer was centered according 
to its center of density, moved to one of the vertices, and TM2 was oriented to face the 
pore. The center of density was calculated for the bundle of 15 monomer structures using 
the VolMap tool in VMD. The pentamer was created by moving subunits to each 
remaining vertex and applying a 72 rotation for each consecutive movement around the 
pentagon.  
A.2.3 Rotational Error 
 The error reported in the RDC experiments was 1 for rotations about the 1st and 2nd 
principle axes and 10 around the 3rd principle axis. The 1st and 2nd principle axes 
correspond to tilting within the membrane while the 3rd principle axis corresponds to a 
rotation about the monomer’s principle axis. In this model a 5 rotational variance was 
allowed about each of the monomer axes. The 5 rotational variance was accounted for 
by applying rotations ranging from -5 to 5 about each axis with a step size of 1. 
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Coordinates resulting from these rotations were stored for each atom. The result is a 
cluster of 1331 (11x11x11) atom positions.  
A.2.4 Atoms Restrained 
 For each TM domain restraints were created for atoms closest to the monomer 
center as well as farthest along the channel axis in both directions from the center of each 
TM domain were chosen to restrain. Atoms were also chosen at the midpoints along the 
channel axis, resulting in 5 atoms per TM domain for which restraints were imposed.   
A.2.5 Upper and Lower Bound Limits 
 Self restraints were defined as restraints between identical atoms in different 
subunits. For example in TM1, restraints were calculated for the following combinations: 
  A1B1 B1C1 C1D1 D1E1 
  A1C1 B1D1 C1E1 
  A1D1 B1E1 
  A1E1 
 
Where A1B1 = TM1 of chain A paired with TM1 of chain B, B1C1 = TM1 of chain B paired 
with TM1 of chain C, and so forth. These pairings were repeated for TM2, TM3, and TM4.   
 To determine the distance restraint to use in the Cyana calculation, pairwise 
distances were calculated between each atom position in each cluster. Where the cluster 
referred to is described under Rotational Error. The upper bound limit was the maximum 
distance calculated plus a 1 Å error term accounting for EM resolution. The lower bound 
limit was the minimum distance calculated minus 1 Å. For example, the distance restraint 
for atom (i) in the pair A1B1 is calculated as follows: The distance between atom (i) in 
TM1 of chain A and atom (i) in TM1 of chain B is calculated for each of the 1331 positions 
of atom (i) in the generated cluster. This results in a total of 1331 distances. The one to 
one correspondence of the number of atom positions stored in each cluster and the 
number of distances results from a symmetry assumption implicit in the model. Five-fold 
symmetry around the channel axis requires that any rotation applied to one subunit must 
necessarily be applied to all subunits. Therefore we only compute distances between 
points having the same applied rotations for each subunit. The upper bound limit was 
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calculated by taking the maximum value of the 1331 distances plus 1 Å, while the lower 
bound limit was calculated by taking the minimum value of the 1331 distances minus 1 Å.  
 
Restraints were also calculated between TM1 and TM3 in a similar fashion. 
 
That is the restraints were as follows: 
A1B3 B1C3 C1D3 D1E3  A3B1 B3C1 C3D1 D3E1 
A1C3 B1D3 C1E3  & A3C1 B3D1 C3E1 
A1D3 B1E3    A3D1 B3E1 
A1E3     A3E1 
 
In this case, atoms in TM3 were necessarily different from atoms in TM1. However, the 
relative position of the atoms along the channel axis was fixed. In other words, the atom 
closest to the center in TM3 was paired with the atom closest to the center in TM1. 
A.2.6 Calculation 
Similar to the monomer calculation 100 random structures were generated and 
annealed using Cyana-3.0.  Structures were annealed in 500,000 steps using the 
modified Cyana annealing schedule as described for the monomer calculation. An input 
temperature of 8.5 target function units per degree of freedom, rather than the default of 
8.0 target function units per degree of freedom, was also used for the pentamer 
calculation. Of the 100 structures calculated, thirty-two were refined using the refinement 
schedule described in Table A-1. Two rounds of refinement were also performed for the 
pentamer calculation. The first round of refinement used 500,000 steps and a temperature 
of 0.3 target function units per degree of freedom and the second round of refinement 
used 250,000 steps and a temperature 0.03 target function units per degree of freedom. 
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